US20090004262A1 - Nanoparticulate formulations and methods for the making and use therof - Google Patents

Nanoparticulate formulations and methods for the making and use therof Download PDF

Info

Publication number
US20090004262A1
US20090004262A1 US11/998,362 US99836207A US2009004262A1 US 20090004262 A1 US20090004262 A1 US 20090004262A1 US 99836207 A US99836207 A US 99836207A US 2009004262 A1 US2009004262 A1 US 2009004262A1
Authority
US
United States
Prior art keywords
drug
particles
salt
formulation
size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/998,362
Other languages
English (en)
Inventor
Kenneth Shaw
Mingbao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marinus Pharmaceuticals Inc
Original Assignee
Marinus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinus Pharmaceuticals Inc filed Critical Marinus Pharmaceuticals Inc
Priority to US11/998,362 priority Critical patent/US20090004262A1/en
Publication of US20090004262A1 publication Critical patent/US20090004262A1/en
Assigned to MARINUS PHARMACEUTICALS reassignment MARINUS PHARMACEUTICALS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHAW, KENNETH, ZHANG, MINGBAO
Priority to US12/777,920 priority patent/US8455002B2/en
Priority to US13/887,673 priority patent/US9017728B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Definitions

  • nanoparticulate formulations of drugs having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4 which provide enhanced stability, physical and chemical properties and can provide enhanced pharmacokinetic properties to achieve an optimal balance between pharmacodynamic and side effect profiles in mammals, and dosage forms containing the same, as well as methods of making nanoparticulate drug formulations and their use in the treatment of various disorders.
  • Nanoparticle liquid formulation e.g., nanosuspension.
  • nanosuspension the less water soluble and more lipophilic the drug, the more difficult it is to obtain a stable small particle “nanosuspension” in polar solvents like water. Particle growth (Otswald Ripening) and aggregation must be minimized in nanoparticulate compositions if the benefit of small particle formulations is to be realized.
  • the milling is a high energy process, to avoid contamination from abraded materials (milling chamber and grinding balls), the shortest milling time possible with the lowest energy is the most preferred process.
  • oral nanoparticulate formulations are formed generally to increase dissolution rates in the gastrointestinal tract, maintaining a constant particle size until the compound is absorbed is the key parameter to monitor.
  • small particle pharmaceutical compositions (effective particle size (D50) of less than 500 nm) have been described since 1988 (H. Steffen B T Gattefosse No. 81, 1988 pp. 45-53; U.S. Pat. No. 4,540,602 (Motoyama, et al.); and U.S. Pat. No. 5,145,684 (Liversidge, et al.)).
  • These submicron (nanoparticulate) compositions all describe using non-crosslinked excipients associated with the surface of the small particle to stabilize the composition from significant particle size growth and/or agglomeration.
  • non-ionic stabilizers also called steric stabilizers or modifiers
  • ionic stabilizers The most common non-ionic stabilizers are excipients which are contained in classes known as binders, fillers, surfactants and wetting agents. Limited examples of non-ionic surface stabilizers are hydroxypropylmethyl cellulose, polyvinylpyrrolidone, Plasdone, polyvinyl alcohol, Pluronics, Tweens and Polyethyleneglycols (PEGs). A subset of surface stabilizers commonly used is ionic in nature. These ionic surface stabilizers tend to fall into the class of excipients which are typically used as surfactants and wetting agents.
  • Ionic stabilizers used in the prior art are typically organic molecules bearing an ionic bond such that the molecule is essentially fully charged in the formulation.
  • the two most described ionic surface stabilizers are the long chain sulfonic acid salts sodium lauryl sulfate and dioctyl sodium sulfosuccinate (DOSS). Broad ranges for all surface stabilizers have been claimed in U.S. Pat. No. 5,145,684 (the '684 patent) ranging from 0.1% to 90% by weight of the composition.
  • milling suspensions with drug concentrations of 5-30% are typically milled with a hard grinding media in a ball mill to obtain particles with a D50 in the 100-500 nm size range.
  • the literature teaches that particle size reduction using milling is conducted at a sufficient speed and time to obtain a desired particle size.
  • the surface stabilizers are present or added to keep the particle size constant over a variety of stability indicating measurements as compared to the particle size (D50) obtained at the end of milling.
  • One of the major issues in wet ball milling is potential residual metals in the composition due to extended milling or energy needed to obtain the desired particle size (Jia, L. Current Nanoscience, 1, pp 237-243 (2005)).
  • Enhancing stability has been the focus of much research. Stability is a broad reference and in the pharmaceutical industry is generally recognized as testing needed to determine storage stability (the stability of the formulation under storage over time), purity stability (the purity profile of the formulation over storage conditions), release or dispersion stability (the stability of release or disintegration characteristics for the formulation in water and physiological media).
  • the physiological media for dispersion stability is dependent on the route of administration (simulated gastric and/or intestinal fluid for oral products, saliva for buccal and sub-lingual products, etc). In general any parameter important to the performance or tolerability of a formulation must be monitored for stability.
  • the drugs that would benefit from this approach are limited to those that can form a cyclodextrin complex.
  • Stable drug particles described herein comprise a complex of drug and a complexing agent. Additional factors that affect stability and particle size are described herein.
  • the present invention is directed to drug complexed particles having a volume weighted median diameter (D50) from about 50 nm to about 500 nm, each of the particles comprising in association (i) a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4, (ii) a surface stabilizer, and (iii) a complexing agent capable of forming a cyclodextrin inclusion complex when the particles are cured for at least about 3 days.
  • D50 volume weighted median diameter
  • the complexing agent may be included in an amount effective to cause an initial increase in the size of the particles, wherein the volume weighted median diameter (D50) of the particles before the initial growth is from about 100 to about 400 nm and the D50 at the end of the curing time is 20% to 300% larger than the D50 measured before the curing period.
  • the complexing agent is included in an amount from about 0.1% to about 8%, w/w of the size-stabilized drug particles
  • the volume weighted diameter (D50) of the complexed particles does not change by more than 10% after a time in consecutive measurements separated by about 72 hours.
  • the complexed particles increase in effective particle size from about 0% to about 200% upon dispersion in simulated gastric or intestinal fluid as compared to dispersion in water under the same conditions.
  • the present invention provides for a pharmaceutical composition comprising the drug complexed particles described above together with at least one pharmaceutically acceptable excipient.
  • the pharmaceutical composition may be in the form of a solid dosage form.
  • the pharmaceutical composition may be in the form of a liquid dosage form, e.g., suspension.
  • the amount of drug complexed particles may range from about 1% to about 99%, based on the weight of the entire composition and the amount of pharmaceutically acceptable excipient may range from about 1 to about 99% based on the weight of the total composition.
  • the present invention is directed to size-stabilized drug complexed particles comprising a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4 in association with effective amounts of a surface stabilizer and a complexing agent capable of forming a cyclodextrin inclusion complex, the size-stabilized drug complexed particles having a volume weighted median diameter (D50) from about 50 nm to about 500 nm; the drug complexed particles exhibiting an increase in volume weighted median diameter (D50) of from 0% to not more than about 200% when the formulation is dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg drug/mL and placed in a heated bath at 36° to 38° C. for 1 hour using a Type I or II dissolution apparatus and a stirring rate of 75 RPM, as compared to the D50 of the drug particles
  • the present invention is directed to a solid pharmaceutical formulation, comprising a plurality of inert beads spray layered with a coating comprising (a) drug complexed particles having a volume weighted median diameter (D50) from about 50 nm to about 500 nm, each of the particles comprising in association (i) a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4, (ii) a surface stabilizer, (iii) a complexing agent capable of forming a cyclodextrin inclusion complex; together with effective amounts of (b) a water soluble spacer and (c) an ionic dispersion modulator.
  • D50 volume weighted median diameter
  • the present invention is directed to an orally ingestible tablet, comprising a compressed mixture of (a) drug complexed particles having a volume weighted median diameter (D50) from about 50 nm to about 500 nm, each of the particles comprising in association (i) a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4, (ii) a surface stabilizer, (iii) a complexing agent capable of forming a cyclodextrin inclusion complex; together with effective amounts of (b) a water soluble spacer and (c) an ionic dispersion modulator; an inert diluent; and a tableting lubricant.
  • D50 volume weighted median diameter
  • the present invention is directed to a size-stabilized nanoparticulate liquid composition
  • a size-stabilized nanoparticulate liquid composition comprising a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4 in association with effective amounts of a surface stabilizer and a complexing agent capable of forming a cyclodextrin inclusion complex, wherein the volume weighted median diameter (D50) of the size-stabilized particles is from about 50 nm to about 500 nm after curing.
  • D50 volume weighted median diameter
  • the nanoparticulate liquid compositions may further contain at least one additional pharmaceutically acceptable excipient selected from the group consisting of a hydrophilic polymer, a wetting agent, an ionic dispersion modulator, a water soluble spacer, and any combinations or mixture thereof.
  • the nanoparticulate liquid composition is converted to a solid nanoparticulate composition by removal of solvent (e.g., via spray drying, spray granulation, spray layering onto inert cores).
  • the present invention is directed to a method for preparing stabilized drug particles, comprising: a) reducing the size of drug particles capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4 into a size range of about 50 nm to about 200 nm; b) adding an effective amount of a surface stabilizer to the drug particles before, during or after reducing the size of the drug particles to form particles comprising the drug and the surface stabilizer; and c) further stabilizing the particles of step b) by adding an effective amount of a complexing agent capable of forming a cyclodextrin inclusion complex to provide particles that attain a stabilized size such that the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
  • D50 volume weighted median diameter
  • the size stabilized particles are prepared by contacting drug particles with a complexing agent such that the size of the particles exhibits an increase in volume weighted median diameter of from about 20% to about 300% and an endpoint is reached such that the particles are size-stabilized.
  • the endpoint can be, e.g., from about 1 to about 20 days.
  • the present invention is directed to a suspension of size-stabilized drug complexed particles comprising a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4 in association with effective amounts of a surface stabilizer and a complexing agent capable of forming a cyclodextrin inclusion complex, the size-stabilized drug complexed particles having a volume weighted median diameter (D50) from about 50 nm to about 500 nm; the drug complexed particles exhibiting an increase in volume weighted median diameter (D50) of from 0% to not more than about 200% when the formulation is dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg drug/mL and placed in a vial and heated in a bath at 36° to 38° C. for 1-3 hours as compared to the D50 of the drug particles in suspension before dispersion into SGF
  • the size-stabilized drug particles comprise from about 30 to about 95% drug, from about 3 to about 70% surface stabilizer, based on the weight of the size-stabilized drug particles, and from about 0.1% to about 8% complexing agent, based on the weight of the size-stabilized drug particles.
  • the particles further comprise from about 0 to about 40% ionic dispersion modulator and from about 0% to about 60% water soluble spacer, based on the weight of the size-stabilized drug particles.
  • the amount of ionic dispersion modulator may range from about 0.1% to 40%. The % weights are not meant to be limiting.
  • the present invention is further directed to methods of preparing the compositions disclosed herein, including but not limited to, drug particles, liquid formulations, and solid dosage forms (e.g., immediate release, sustained release, delayed release and pulsatile release).
  • the present invention is also directed to methods of treating subjects comprising administering to a subject any of the compositions disclosed herein, including, but not limited to, drug particles, liquid formulations, and oral solid dosage forms (e.g., immediate release, sustained release, delayed release and pulsatile release).
  • any of the compositions disclosed herein including, but not limited to, drug particles, liquid formulations, and oral solid dosage forms (e.g., immediate release, sustained release, delayed release and pulsatile release).
  • the invention is directed to a solid composition
  • a solid composition comprising particles comprising a complexed drug; and an effective amount of an ionic dispersion modulator to reduce agglomeration and particle size growth of the particles (e.g. upon storage, dispersion in physiological fluids and water), wherein the volume weighted median diameter (D50) of the particles is from about 100 nm to about 500 nm.
  • D50 volume weighted median diameter
  • the invention is directed to a solid composition
  • a solid composition comprising particles comprising a complexed nanoparticulate drug; and an ionic dispersion modulator in an amount of from about 1% to about 50%, w/w, based on the weight of the size stabilized particles, wherein the volume weighted median diameter (D50) of the particles (dispersed in water and/or physiological fluids) is from about 100 nm to about 500 nm.
  • D50 volume weighted median diameter
  • the excipient comprises a water soluble spacer.
  • the water soluble spacer can be a saccharide or an ammonium salt, a polyethylene glycol or urea that is a solid at temperatures of 50° C. or more.
  • the saccharide can be selected from the group consisting of fructose, sucrose, glucose, lactose, mannitol and mixtures thereof.
  • the polyethylene glycol can be selected from PEG 3350, PEG 4000 or PEG 6000.
  • the invention is directed to pharmaceutical particles comprising drug or a pharmaceutically acceptable salt thereof, the complexed particles being stable (suitable curing time) such that the volume weighted median diameter (D50) of the particles does not increase by more than about 50% after 28 days storage at room temperature, the volume weighted median diameter (D50) of the particles prior to storage being from about 50 nm to about 500 nm; the particles milled for a sufficient time to achieve the stability.
  • the complexed particles being stable (suitable curing time) such that the volume weighted median diameter (D50) of the particles does not increase by more than about 50% after 28 days storage at room temperature, the volume weighted median diameter (D50) of the particles prior to storage being from about 50 nm to about 500 nm; the particles milled for a sufficient time to achieve the stability.
  • the volume weighted median diameter (D50) of the particles does not change by more than about 25% after 28 days storage at room temperature (25° C.) conditions, does not change by more than about 15% after 28 days storage at room temperature, does not change by more than about 10% after 28 days storage at room temperature (25° C.) and or does not change by more than about 10% after 4 months storage at 25° C./60% relative humidity and 40° C./75% relative humidity.
  • the present invention is directed to a formulation of solid size-stabilized drug complexed particles comprising a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4 comprising (a) drug complexed particles having a volume weighted median diameter (D50) from about 50 nm to about 500 nm, each of the particles comprising in association (i) a drug capable of forming a cyclodextrin inclusion complex and having an aqueous solubility of less than 1 mg/ml in a pH of about 7.4, (ii) a surface stabilizer, (iii) a complexing agent capable of forming a cyclodextrin inclusion complex, the drug complexed particles exhibiting an increase in volume weighted median diameter (D50) of from 0% to not more than about 200% when the formulation is dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF)
  • the invention is directed to a solid composition (e.g., a powder, immediate release dosage form, or controlled release dosage form) comprising size-stabilized drug particles and at least one pharmaceutically acceptable excipient, the size-stabilized drug particles exhibiting an increase in volume weighted median diameter (D50) of from 0% to not more than about 200%, not more than about 150%, not more than about 100% or not more than about 50%, when the formulation is dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg drug/mL (in any suitable volume, e.g., 15 mL to 1000 mL) and placed in a heated bath at 360 to 38° C.
  • SGF gastric fluid
  • SIF simulated intestinal fluid
  • the volume weighted median diameter (D50) of the drug particles dispersed in distilled water is from about 50 nm to about 1000 nm, from about 100 nm to about 500 nm, or from about 100 nm to about 350 nm.
  • the volume weighted median diameter (D50) of the coated beads prior to dispersion can be, e.g., from about 0.1 mm to about 5.0 mm.
  • the solid formulation can be, for example, a powder, a tablet, a capsule, etc.
  • the present invention is directed to liquid pharmaceutical compositions containing size stabilized drug particles comprising a drug complex exhibiting a D50 after dispersion in SGF or SIF at 36 to 38° C. for 1-3 hours of not greater than about 500 nm, and in certain embodiments having a ratio to D50 after such dispersion in SGF or SIF to the D50 prior to dispersion of less than about 3:1.
  • Particle size measurement is generally described and well known to those skilled in the art.
  • the volume weighted median diameter or D50 is a commonly accepted measure of particle size.
  • Loose aggregates can generally be broken up via sonication. The formation of loose aggregates could impact the pharmacokinetic performance (variability, systemic levels and bioavailability) of a nanoparticulate formulation.
  • nanoparticulate formulation which is formed for a water soluble compound that is being protected from storage degradation might actually benefit from aggregates (longer absorption time due to larger effective particle size).
  • Significant tight aggregation (unreversible) and particle size growth are obviously undesirable as this would effectively loose the advantageous increased kinetic dissolution of the drug.
  • Hydroxypropylmethyl cellulose e.g., HPMC-15 and sodium lauryl sulfate, have also been described as surface stabilizers of drug nanoparticles in water (H. Steffen B T Gattefosse No. 81, 1988 pp. 45-53).
  • Preservatives are also sometimes added to nanosuspensions to protect the formulation from contamination.
  • Megace ES Suspension® (Parr) is preserved with benzoic acid (as sodium benzoate buffered to pH 4.0 with citric acid and sodium citrate).
  • this enhanced stability was achieved via the preparation of particles comprising ganaxolone and a complexing agent, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
  • the complexing agent was disclosed as, for example, a paraben, benzoic acid and mixtures thereof.
  • the term “drug” means any therapeutically active agent capable of forming a cyclodextrin inclusion complex in aqueous based solutions/suspensions.
  • such drugs (not as a cyclodextrin inclusion complex) have an aqueous solubility of less than 1 mg/ml at a pH of about 7.4.
  • Bioavailability refers to the degree to which a drug becomes available at the site(s) of action after administration.
  • bioavailability of a drug formulation refers to the percentage of the weight of drug dosed that is delivered into the general circulation of the animal or human being studied. The total exposure (AUC (0- ⁇ ) ) of a drug when administered intravenously is usually defined as 100% bioavailable (F %).
  • Oral bioavailability refers to the extent to which drug is absorbed into the general circulation when the pharmaceutical composition is taken orally as compared to intravenous injection. The degree and timing in which an active agent becomes available to the target site(s) after administration is determined by many factors, including the dosage form and various properties, e.g., solubility and dissolution rate of the drug.
  • measurable plasma concentrations are typically measured in ng/ml or ⁇ g/ml.
  • the plasma concentration of a drug may vary significantly between subjects, due to variability with respect to metabolism and/or possible interactions with other therapeutic agents.
  • the blood plasma concentration of drug may vary from subject to subject.
  • values such as measured concentration of the active agent in the plasma at the point of maximum concentration (C max ) or time to reach maximum plasma concentration (T max ), or total area under the plasma concentration time curve (AUC (0- ⁇ ) ) may vary from subject to subject.
  • AUC (0- ⁇ ) or “exposure or bioavailability” is the area under the curve of a graph of the concentration of the active agent (typically plasma concentration) vs. time ( ⁇ ), measured from time 0 to ⁇ . AUC (0- ⁇ ) is also used to define the exposure to the drug over a defined period of time. Due to variability, the amount necessary to constitute “a therapeutically effective amount” of drug may vary from subject to subject.
  • Carrier materials include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility with drug and the release profile properties of the desired dosage form.
  • curing means treating the drug (either before, during or after particle size reduction) with a complexing agent under suitable conditions to obtain a size stabilized drug product.
  • a measurement of stability can be via the comparison of the particle size (e.g., D50) of the uncomplexed drug versus the complexed drug.
  • curing time means a sufficient time until an endpoint is reached such that the properties of the (complexed) drug are stabilized.
  • the curing time can be measured as the time until a size stabilized particle size is reached under a specified test condition.
  • a suitable curing time may be such a time wherein the D50 of the (complexed) drug particles do not change or substantially change after time in consecutive measurements separated by approximately 72 hours, e.g., by more than the accuracy of the measuring instrument ⁇ 5%. in 72 hours after the curing period.
  • Preferred curing times are 1-20 days, 2-15 days or 3-10 days.
  • a suitable curing time may be such a time wherein the D50 of the (complexed) drug particles do not change or substantially change after time in consecutive measurements over 3 hours at 37° C. in simulated gastric and/or simulated intestinal fluid.
  • complexed or “complexed nanoparticulate drug” indicates an association of molecules and/or a particle including drug, a complexing agent and other components which results in better particle size stability of drug particles or some other desirable effect.
  • complexing agents initially increase particle size (D50) before imparting stability or other beneficial attributes to the formulation.
  • complexed drug or complexed nanoparticulate drug made by adding complexing agents requires a curing time.
  • Complexing agents are small molecular weight molecules which can form a cyclodextrin inclusion complex and after suitable curing time impart additional stability to the drug.
  • Complexing agents include small compounds under MW 550.
  • Complexing agents include but are not limited to the group consisting of phenol, parabens, ascorbic acid, methyl anthranilate, salicylic acid, acetosalicyclic acid, tocopherol, organic acids, carboxylic acids, aromatic acids, aromatic esters, acid salts of amino acids, benzaldehyde, cinnimaldehyde, imidazole, menthol, thiophenol, m-aminobenzoic acid, anthranilic acid, picolinic acids and alkyl esters thereof, toluidides, sodium benzoate, methylparaben, sodium methylparaben, para-aminobenzoic acid and esters, sorbic and benzoic acids, 2,6-di-t-butyl-alpha-di
  • Controlled release or “modified release”, consistent with its use herein, means a dosage form for which the drug release characteristics versus time and/or conditions at the site of dissolution are chosen to accomplish therapeutic or convenience objectives not offered by conventional immediate release dosage forms.
  • Controlled release dosage forms include sustained release, prolonged release, pulsatile release and delayed release forms.
  • Controlled release dosage forms can provide therapeutically effective levels of drug for an extended period of time and therefore provide a longer therapeutic period relative to immediate release forms. Addition of a complexing agent can also impart additional suspension stability during freeze/thaw cycles and boiling if sterilization is needed.
  • “Delayed release”, consistent with its use herein, means a dosage form that releases a portion or all drug at any time other than immediately after administration and/or at any other location in the gastrointestinal tract more distal to that which would have been accomplished by an immediate release dosage form.
  • disintegrate is the dispersion of the dosage form when contacted with gastrointestinal fluid.
  • disintegration agents or disintegrants facilitate the breakup or disintegration of a formulation.
  • disintegration agents include a starch, e.g., a natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®, a cellulose such as a wood product, microcrystalline cellulose, e.g., Avicel®, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® P100, Emcocel®, Vivacel®, Ming Tia®, and Solka-Floc®, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Sol®), cross-linked carboxymethylcellulose, or cross-linked croscar
  • Drug absorption typically refers to the process of movement of drug from site of administration of a drug across a barrier into a blood vessel or the site of action, e.g., a drug moving from the gastrointestinal tract into the portal vein or lymphatic system.
  • Effective particle size and “particle size” is interchangeably used with “D50”.
  • D50 it is meant that 50% of the particles are below and 50% of the particles are above a defined measurement.
  • D50 can be used to describe different parameters (volume, length, number, area . . . etc).
  • Effective particle size or D50 as used herein indicates the volume-weighted median diameter as measured by a laser/light scattering method or equivalent, wherein 50% of the particles, by volume, have a smaller diameter, while 50% by volume have a larger diameter.
  • the volume weighted D50 also relates to the percentage of weight of the particle under a certain size.
  • a D50 of 500 nm means that 50% of the particulate mass is less than 500 nm in diameter and 50% of the particulate mass is greater than 500 nm in diameter.
  • the effective particle size is measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering (e.g., with a Microtrac UPA 150), laser diffraction and disc centrifugation.
  • effective particle size is the volume-weighted median diameter as determined using laser/light scattering instruments and methods, e.g. a Horiba LA-910, or Horiba LA-950.
  • D90 is the volume-weighted diameter, wherein 90% of the particles, by volume, have a smaller diameter, while 10% by volume have a larger diameter
  • D10 is the volume-weighted diameter, wherein 10% of the particles, by volume, have a smaller diameter, while 90% by volume have a larger diameter. It is sometimes useful to express the D50 value after sonication for 1 minute or less using about 40 watts of sonicating power at room temperature (25° C.).
  • an “enteric coating” is a substance that remains substantially intact in the stomach but dissolves and releases the drug in the small intestine and/or colon.
  • the enteric coating comprises a polymeric material that prevents release in the low pH environment of the stomach but that ionizes or solubilizes at a higher pH, typically a pH of 5 to 7, but at least above 3.0, more or above 5, or even more specifically at a pH of about 5.5 to about 7, and thus dissolves sufficiently in the small intestine and/or colon to release the active agent therein.
  • the enteric coatings release greater than 50% of the drug that is coated in the small intestine.
  • the enteric coating provides the release of a substantial portion (greater than 40%) of the coated drug in the mid-small intestine, e.g., the jejunum.
  • enteric coatings may comprise a semi-permeable membrane which releases drug slowly in a non pH-dependent manner.
  • grinding media refers to the material used in milling to physically reduce the particle size of a composition.
  • preferred grinding media are spherical balls of yttrium stabilized zirconium oxide, glass or a plastic resin.
  • stomach fluid is the fluid of the gastrointestinal tract of a subject or the saliva of a subject or the equivalent thereof.
  • An “equivalent” of stomach or gastric secretion” is an in vitro fluid having similar content and/or pH as stomach secretions such as simulated gastric fluid (SGF) prepared using USP guidance of about 0.1N HCl solution in water containing about 0.03M NaCl at a pH of around 1.2.
  • an “equivalent” of intestinal secretion” is an in vitro fluid having similar content and/or pH as intestinal secretions such as simulated intestinal fluid (SIF) prepared using USP guidance is an aqueous phosphate buffer system at pH of 6.7-6.9.
  • “Immediate Release” means a dosage form that releases at least 80% of drug within 2 hours of administration, more specifically, within 1 hour of addition to a commonly accepted simulated gastric fluid. Typically an immediate release composition is tested in dissolution apparatus (Type I or II most common) in an amount considered to be therapeutic in patients and a volume of SGF of 500-1000 mL.
  • Ionic Dispersion Modulator is defined as a salt (not a sulfonic acid), which when added to a complexed small particle composition will reduce the amount of certain ingredient(s) needed to stabilize solid dosage forms or blends when dispersed in water, SGF and SIF.
  • Milling residence time is the time that a particle is present in the milling chamber over the total time of milling to obtain desired particles.
  • milling slurry refers to a suspension containing the drug for particle size reduction and other ingredients to facilitate the milling process.
  • the composition of the milling slurry is usually not the final formulation composition.
  • milling media refers to the components of the milling slurry minus the active pharmaceutical ingredient(s).
  • milled slurry refers the milling slurry after it had been reduced to a small particle suspension by milling.
  • the most preferred milling slurries for a liquid dispersion are those that meet particle size and compositions that can be diluted with water and appropriate ingredients to obtain the final formulation.
  • preferred milled slurries are those that can be utilized with minimal manipulation to yield the final solid dosage form.
  • “Pharmacodynamics” refers to the factors which determine the biologic response observed relative to the concentration of drug at a site of action.
  • “Pharmacokinetics” refers to the factors which determine the attainment and maintenance of the appropriate concentration of drug at a site of action.
  • Preservatives are compounds which inhibit microbial growth and are typically added to dispersions to prevent microbes from growing.
  • a “pulsatile release” dosage form is a dosage form capable of providing more than one peak blood plasma concentration following a single administration.
  • a “pulsatile release” formulation can contain a combination of immediate release, sustained release, and/or delayed release formulations in the same dosage form.
  • Pharmacokinetic parameters are parameters which describe the in vivo characteristics of the drug over time, including, for example plasma concentration of the drug. Pharmacokinetic parameters include C max , T max , and AUC 0- ⁇ (each discussed above).
  • Solubilizers include compounds such as triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium doccusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cyclodextrins, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200 to 600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide, miglyol, glycerin, glycerol, and the like.
  • Spray Drying is a process by which a solvent is removed from a composition yielding a dried form of the ingredients in that composition. Drying is effected by spraying the composition through a nozzle into a heated environment containing a vacuum or a flow of air or inert gas. Spray drying can produce amorphous or crystalline powders of drugs or granulations, both which can be converted into a solid dosage form by those skilled in the art.
  • Spray Layering is a procedure where a solution or suspension containing ingredients are sprayed through a nozzle into a fluidized bed containing particles which are coated with a film containing the composition of the solution or suspension as the solvent is removed by the flow of a heated gas.
  • Spray layering typically involves coating an inert core usually comprised of a sugar and starch or cellulosics or combinations thereof. Such cores are typically 20 to 35 mesh in size.
  • Spray Layering is used extensively for applying coatings (finish or enteric) to solid dosage formulations as well as spherical beads containing a drug for use in a capsule or tablet formulation.
  • Size-stabilized means the D50 does not substantially change (greater than 50%) after an initial time is defined (e.g., after an appropriate curing time) and up to 4 months storage at room temperature (25° C.).
  • the size stabilized drug particles described herein in an aqueous dosage form will not show an increase in effective particle size of greater than 50% over a four month storage period, and preferably no increase in effective particle size of greater than 50% over a two year storage period.
  • the size-stabilized drug particles described herein in a liquid or solid form will show an increase in effective particle size of about 0% to about 200% upon dispersion in simulated gastric or intestinal fluid as compared to dispersion in water under the same conditions.
  • the formulations described herein does not produce any significant amount of unidentified drug degradation impurities up to 4 months storage at room temperature (25° C.) at individual levels of about greater than 0.1% by weight as compared to the impurity levels at the initial time designation.
  • “Stabilizers” include agents which maintain a desirable attribute of the formulation over a time interval including but not limited to mechanical, chemical and temperature stressing that can be tested in a laboratory setting. Such attributes include stable particle size or homogeneity resulting in concentrations consistent with the labeled potency and maintaining purity. Some but not all of the attributes are listed above.
  • Step state is when the amount of drug administered is equal to the amount of drug eliminated within one dosing interval resulting in a plateau or constant plasma drug exposure.
  • Subject as used herein is any mammal. Subjects include individuals in need of drug treatment (patients) and individuals not in need of drug treatment (e.g. normal healthy volunteers. Humans are preferred subjects and patients.
  • “Delayed Release”, consistent with its use herein, means a dosage form that allows at least a one dose reduction in dosing frequency per day as compared to the drug in conventional form, such as a suspension or an immediate release solid dosage form.
  • a “therapeutically effective amount” or “effective amount” is that amount of a pharmaceutical agent to achieve a pharmacological effect.
  • the term “therapeutically effective amount” includes, for example, a prophylactically effective amount.
  • An “effective amount” of drug is an amount needed to achieve a desired pharmacologic effect or therapeutic improvement without undue adverse side effects.
  • the effective amount of a drug will be selected by those skilled in the art depending on the particular patient and the disease. It is understood that “an effective amount” or “a therapeutically effective amount” can vary from subject to subject, due to variation in metabolism of drug, age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.
  • Treatment refers to any treatment of a disorder or disease, such as preventing the disorder or disease from occurring in a subject which may be predisposed to the disorder or disease, but has not yet been diagnosed as having the disorder or disease; inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or reducing the symptoms of the disease or disorder.
  • FIG. 1 is a graph showing the curing curve of sonicated and unsonicated complexed ganaxolone particles at room temperature (25° C.).
  • FIG. 1 a shows the curing curve of ganaxolone particles complexed with sodium benzoate at pH 4.0.
  • FIG. 1 b shows the curing curve of ganaxolone particles complexed with parabens.
  • FIG. 2 is a graph showing the D50 vs. Time of paraben complexed and sodium benzoate complexed (at pH 4.0) ganaxolone particles at room temperature (25° C.).
  • FIG. 3 is a graph showing stability plots (D50 vs. Time) of uncomplexed ganaxolone particles with varying milled residence times.
  • FIG. 4 is a graph showing measured D50 values for uncomplexed ganaxolone particles as a function of milling residence time for a typical milling run using a Dyno-Mill KDL equipped with four 64 Mm polyurethane agitator discs.
  • FIG. 5 is a graph showing particle size distribution (after 1 minute low power sonication) of re-suspended solid dosage forms containing sodium chloride (with and without methylparaben as the complexing agent).
  • the drug formulations described herein can be administered to a subject by conventional administration routes.
  • Drug oral solid dosage forms and oral aqueous suspensions are included herein. Immediate, modified, controlled, and pulsatile release drug dosages forms are provided herein.
  • the drug formulations described herein can comprise drug particles having a D50 of less than about 500 nm.
  • the starting drug composition can be predominantly crystalline, predominantly amorphous, or a mixture thereof.
  • These drug particles can be made by using any method known in the art for achieving particle sizes of less than 500 nm including, for example, milling, homogenization, supercritical fluid fracture or precipitation techniques. Exemplary methods are described in U.S. Pat. Nos. 4,540,602 and 5,145,684, each of which is specifically incorporated by reference.
  • compositions comprising nanoparticles are also described in U.S. Pat. Nos. 5,518,187; 5,718,388; 5,862,999; 5,665,331; 5,662,883; 5,560,932; 5,543,133; 5,534,270; 5,510,118; 5,470,583 and U.S. Pub. Appl. 2004/0067251, each of which is specifically incorporated by reference.
  • the drug is milled in order to obtain submicron particles.
  • the milling process can be a dry process, e.g., a dry roller milling process, or a wet process, i.e., wet-grinding.
  • this invention is practiced in accordance with the wet-grinding process described in U.S. Pat. Nos. 4,540,602, 5,145,684, 6,976,647 and EPO 498,482, the disclosures of which are hereby incorporated by reference.
  • the wet grinding process can be practiced in conjunction with a liquid dispersion medium and dispersing or wetting agents such as described in these publications.
  • Useful liquid dispersion media include water, safflower oil, aqueous salt solutions, ethanol, n-butanol, hexane, glycol and the like.
  • the dispersing, and/or wetting agents can be selected from known organic and inorganic pharmaceutical excipients such as described in U.S. Pat. Nos. 4,540,602 and 5,145,684, and can be present in an amount of 2.0-70%, preferably 3-50%, and more preferably 5-25% by weight based on the total weight of the drug in the formulation.
  • the grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in shape, e.g., beads. However, grinding media in the form of other non-spherical shapes are expected to be useful in the practice of this invention.
  • the grinding media preferably can have a mean particle size up to about 500 microns.
  • the grinding media particles have a mean particle size preferably less than about 500 microns, less than about 100 microns, less than about 75 microns, less than about 50 microns, less than about 25 microns, less than about 5 microns, less than about 3 mm, less than about 2 mm, less than about 1 mm, less than about 0.25 mm, or less than about 0.05 mm.
  • the grinding media particles preferably are from about 0.05 to about 0.6 mm, more preferably, about 0.1 to about 0.4 mm in size. Smaller size grinding media will result in smaller size drug particles as compared to the same conditions using larger sized grinding media.
  • grinding media with higher density e.g., glass (2.6 g/cm 3 ), zirconium silicate (3.7 g/cm 3 ), and zirconium oxide (5.4 g/cm 3 ) and 95% zirconium oxide stabilized with yttrium, are generally preferred for more efficient milling.
  • Zirconium oxide such as 95% Zirconium oxide stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of therapeutic or diagnostic compositions.
  • other media such as stainless steel, titania, agate, glass and alumina, are believed to be useful.
  • polymeric media having a density typically from about 1 to about 2 g/cm 3 are also expected to be useful.
  • the grinding media can comprise particles consisting essentially of the polymeric resin.
  • the grinding media can comprise particles comprising a core having a coating of the polymeric resin adhered thereon.
  • the polymeric resin preferably has a density from 0.8 to 3.0 g/cm 3 . Higher density resins are preferred inasmuch as it is believed that these provide more efficient particle size reduction.
  • polymeric resins suitable for use herein are chemically and physically inert, substantially free of metals, solvent and monomers, and of sufficient hardness and friability to enable them to avoid being chipped or crushed during grinding.
  • Suitable polymeric resins include but are not limited to crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene, styrene copolymers, polycarbonates, polyacetals, such as DelrinTM, vinyl chloride polymers and copolymers, polyurethanes, polyamides, poly(tetrafluoroethylenes), e.g., TeflonTM, and other fluoropolymers, high density polyethylenes, polypropylenes, cellulose ethers and esters such as cellulose acetate, polyhydroxymethacrylate, polyhydroxyethyl acrylate, silicone containing polymers such as polysiloxanes, and the like.
  • the polymeric polymer can be biodegradable.
  • biodegradable polymers include poly(lactides), poly(glycolide) copolymers of lactides and glycolide, polyanhydrides, poly(hydroxyethyl methacylate), poly(imino carbonates), poly(N-acylhydroxyproline)esters, poly(N-palmitoyl hydroxyproline) esters, ethylene-vinyl acetate copolymers, poly(orthoesters), poly(caprolactones), and poly(phosphazenes).
  • contamination from the media itself advantageously can metabolize in vivo into biologically acceptable products which can be eliminated from the body.
  • the core material preferably can be selected from materials known to be useful as grinding media when fabricated as spheres or particles.
  • Suitable core materials include but are not limited to zirconium oxides (such as 95% zirconium oxide stabilized with magnesia or yttrium), zirconium silicate, glass, stainless steel, titania, alumina, ferrite, and the like.
  • Preferred core materials have a density greater than about 2.5 g/cm 3 . The selection of high density core materials is believed to facilitate efficient particle size reduction.
  • Useful thicknesses of the polymeric coating on the core are believed to range from about 1 to about 500 microns, although other thicknesses outside this range may be useful in some applications.
  • the thickness of the polymer coating preferably is less than the diameter of the core.
  • the cores can be coated with the polymeric resin by techniques known in the art. Suitable techniques include spray coating, fluidized bed coating, and melt coating. Adhesion promoting or tie layers can optionally be provided to improve the adhesion between the core material and the resin coating. The adhesion of the polymer coating to the core material can be enhanced by treating the core material to adhesion promoting procedures, such as roughening of the core surface, corona discharge treatment, and the like.
  • Suitable mills include an airjet mill, a roller mill, a ball mill, an attritor mill, a vibratory mill, a planetary mill, a sand mill and a bead mill.
  • a high energy media mill is preferred when small particles are desired.
  • the mill can contain a rotating shaft.
  • the preferred proportions of the grinding media, drug, the optional liquid dispersion medium, and dispersing, wetting or other particle stabilizing agents present in the grinding vessel can vary within wide limits and depend on, for example, the size and density of the grinding media, the type of mill selected, the time of milling, etc.
  • the process can be carried out in a continuous, batch or semi-batch mode. In high energy media mills, it can be desirable to fill 80-95% of the volume of the grinding chamber with grinding media. On the other hand, in roller mills, it frequently is desirable to leave the grinding vessel up to half filled with air, the remaining volume comprising the grinding media and the liquid dispersion media, if present. This permits a cascading effect within the vessel on the rollers which permits efficient grinding. However, when foaming is a problem during wet grinding, the vessel can be completely filled with the liquid dispersion medium or an anti-foaming agent may be added to the liquid dispersion.
  • the attrition time can vary widely and depends primarily upon the particular drug substance or imaging agent, mechanical means and residence conditions selected, the initial and desired final particle size and so forth. For roller mills, processing times from several days to weeks may be required. On the other hand, milling residence times of less than about 2 hours are generally required using high energy media mills.
  • the grinding media is separated from the milled drug particulate product (in either a dry or liquid dispersion form) using conventional separation techniques, such as by filtration, sieving through a mesh screen, and the like.
  • the grinding media comprises beads having a size ranging from 0.05-4 mm, preferably 0.1-0.4 mm.
  • high energy milling of drug with 0.1 mm zirconium oxide balls for a milling residence time of 2 hours in batch mode the milling temperature should not exceed 50° C. as the viscosity of the suspension may change dramatically. Elevated temperatures also may result in precipitation of certain polymers in the milling slurry and will increase wear on the mill seals.
  • this process will require recycling the material to a cooled holding tank and re-milling of the material until the desired particle (D50) size and appropriate properties are achieved in continuous mode and the mill is also jacketed with cooling.
  • the mill can be jacketed to help control internal temperatures in both continuous or batch mode.
  • this weight percentage is based on total weight of the milling slurry.
  • the milling concentration is from about 10% to about 30% drug by weight vs. the milling slurry weight.
  • the milling media is defined as the weight of the slurry that is milled minus the weight of the drug in that slurry. In one embodiment, the concentration is 25% drug by weight vs. the milling media (weight).
  • the milling media contains at least one wetting and/or dispersing agent (alternatively referred to herein and in the prior art as “surface stabilizers”) to coat the initial drug suspension so a uniform feed rate may be applied in continuous milling mode.
  • surface stabilizers wetting and/or dispersing agent
  • batch milling mode is utilized with a milling media containing at least one agent to adjust viscosity and/or provide a wetting effect so that the drug is well dispersed amongst the grinding media.
  • Drug particles can also be prepared by homogeneous nucleation and precipitation in the presence of a wetting agent or dispersing agent as described in U.S. Pat. No. 5,560,932 and U.S. Pat. No. 5,665,331, which are specifically incorporated by reference. Such drug particles are storage stable and do not show an appreciable increase in effective particle size over time. This is a method of preparing stable dispersions of drug in the presence of one or more dispersing or wetting agents (alternatively referred to herein and in the prior art as “surface stabilizers”) and one or more colloid stability enhancing surface active agents.
  • surface stabilizers alternatively referred to herein and in the prior art as “surface stabilizers”
  • Such a method comprises, for example: (1) dispersing drug in a suitable liquid media; (2) adding the mixture from step (1) to a mixture comprising at least on dispersing agent or wetting agent such that at the appropriate temperature, the drug is dissolved; and (3) precipitating the formulation from step (2) using an appropriate anti-solvent (e.g., water).
  • an appropriate anti-solvent e.g., water
  • the method can be followed by removal of any formed salt, if present, by dialysis or filtration and concentration of the dispersion by conventional means.
  • the drug particles are present in an essentially pure form and dispersed in a suitable liquid dispersion media.
  • a preferred liquid dispersion medium is water.
  • liquid media can be used including, for example, aqueous salt solutions, oils (e.g., safflower, olive or cremephor), and solvents such as ethanol, t-butanol, hexane, and glycol.
  • aqueous salt solutions oils (e.g., safflower, olive or cremephor), and solvents such as ethanol, t-butanol, hexane, and glycol.
  • the pH of the aqueous dispersion media can be adjusted by techniques known in the art.
  • the drug particles comprise a discrete phase having been admixed with a dispersing agent or wetting agent.
  • Useful dispersing agents or wetting agents are experimentally determined, but effectively minimize the difference in lipophilicity of drug and the dispersion media by inducing a non-covalent ordered complex between the media, the wetting agent, and drug.
  • the drug particles described herein are produced by high pressure homogenization (see generally U.S. Pat. No. 5,510,118).
  • a method comprises dispersing drug particles in a liquid dispersion medium, followed by subjecting the dispersion to repeated homogenization to reduce the particle size of the drug to the desired effective average particle size.
  • the drug particles can be reduced in size in the presence of at least one or more dispersing agents or wetting agents.
  • the drug particles can be contacted with one or more dispersing agents or wetting agents either before or after attrition.
  • Other compounds, such as a diluent can be added to the drug/dispersing agent composition before, during, or after the size reduction process.
  • unprocessed drug can then be added to a liquid medium in which it is essentially insoluble to form a premix.
  • concentration of the drug in the liquid medium can vary from about 0.1-60% w/w, and preferably is from 5-30% (w/w). It is preferred, but not essential, that the dispersing agents or wetting agents be present in the premix.
  • concentration of the dispersing agents or wetting agents can vary from about 0.1 to 90%, and preferably is 1-75%, more preferably 20-60%, by weight based on the total combined weight of the drug and dispersing agents or wetting agents.
  • the apparent viscosity of the premix suspension is preferably less than about 1000 centipoise.
  • the premix then can be transferred to the microfluidizer and circulated continuously first at low pressures, then at maximum capacity having a fluid pressure of from about 3,000 to 30,000 psi until the desired particle size reduction is achieved.
  • the particles must be reduced in size at a temperature which does not significantly degrade the drug substance or cause significant particle size growth through solubilization.
  • one of two methods can be used to collect the slurry and re-pass it in a microfluidizer.
  • the “discreet pass” method collects every pass through the microfluidizer until all of the slurry has been passed through before re-introducing it again to the microfluidizer. This guarantees that every substance or particle has “seen” the interaction chamber the same amount of times.
  • the second method re-circulates the slurry by collecting it in a receiving tank and allowing the entire mixture to randomly mix and pass through the interaction chamber.
  • dispersing agents and/or wetting agents are not present in the premix, they can be added to the dispersion after attrition in an amount as described for the premix above. Thereafter, the dispersion can be mixed, e.g., shaken or stirred.
  • the relative amount of drug and dispersing agents and/or wetting agents can vary widely.
  • the dispersing agents and/or wetting agents preferably are present in an amount of about 0.1-10 mg per square meter surface area of drug.
  • the dispersing agents or wetting agents can be present in an amount of 0.1-90%, preferably 5-50% by weight based on the total weight of the dry drug particles during the particle size reduction.
  • the resulting drug dispersion is storage stable and consists of the liquid dispersion medium and the above-described particles.
  • the dispersion of drug particles can be spray coated onto sugar spheres or beads or onto a pharmaceutical excipient in a fluid-bed spray coater by techniques well known in the art.
  • the drug particles generated by any of the methods described herein can be utilized in solid or aqueous liquid dosage formulations, such as controlled release formulations, pulsatile dosage forms, multiparticulate dosage forms, solid dose fast melt formulations, lyophilized formulations, tablets, capsules, aqueous dispersions, or aerosol formulations.
  • solid or aqueous liquid dosage formulations such as controlled release formulations, pulsatile dosage forms, multiparticulate dosage forms, solid dose fast melt formulations, lyophilized formulations, tablets, capsules, aqueous dispersions, or aerosol formulations.
  • the drug particles are prepared with the use of one or more materials known in the art as surface stabilizers or modulators (previously or alternatively referred to herein or in the art as wetting and/or dispersing agents) which are, e.g., adsorbed on the surface of the drug compound.
  • the surface stabilizer(s) can be contacted with the drug compound either before, during or after size reduction of the compound.
  • surface stabilizers fall into two categories: non-ionic (also called steric stabilizers or modifiers) and ionic stabilizers.
  • non-ionic stabilizers also called steric stabilizers or modifiers
  • ionic stabilizers ionic stabilizers.
  • the most common non-ionic stabilizers are excipients which are contained in classes known as binders, fillers, surfactants and wetting agents.
  • non-ionic surface stabilizers are hydroxypropylmethylcellulose, polyvinylpyrrolidone, Plasdone, polyvinyl alcohol, Pluronics, Tweens and polyethylene glycols (PEGs).
  • a subset of surface stabilizers commonly used is ionic in nature. These ionic surface stabilizers tend to fall into the class of excipients which are typically used as surfactants and wetting agents. Ionic stabilizers used in the prior art are typically organic molecules bearing an ionic bond such that the molecule is charged in the formulation.
  • the two most described ionic surface stabilizers are the long chain sulfonic acid salts sodium lauryl sulfate and dioctyl sodium sulfosuccinate (DOSS). Broad ranges for all surface stabilizers have been claimed in U.S. Pat. No. 5,145,684 (the '684 patent) ranging from 0.1% to 90% by weight of the composition. Typically, one adds 20%-150% (wt % of drug) of a nonionic surface stabilizer and 0.2%-5% of an ionic surface stabilizer (wt % of drug) to achieve maximal particle size stabilization from these surface stabilizers.
  • DOSS dioctyl sodium sulfosuccinate
  • Conversion of a nanoparticulate composition containing surface stabilizers is most commonly described via a spray drying, spray granulation or spray layering process. These procedures are well known in those skilled in the art. It is also common to add additional excipients prior to removal of solvent in the nanoparticulate suspension to aid in the dispersion of the solid composition in medium in which the solid composition will be exposed (e.g. gastrointestinal fluids) to further prevent agglomeration and/or particle size growth of the small drug particles.
  • An example of such an additional excipient is a water soluble spacer (also referred to as a redispersing agent) which has been described is sucrose (U.S. Patent Application Publication No. 2004/0214746, the disclosure of which is hereby incorporated by reference).
  • Other examples of water soluble spacers include sugars, polyethylene glycols, urea and quarternary ammonium salts.
  • a concern with the preparation of any small particle suspension is the stability of the size-reduced (e.g., milled) particles.
  • the particles after a period of time e.g., four weeks
  • D50 not greater than about 500 nm most compositions never stabilize and continue to grow until large particles (1-30 microns) are realized.
  • the rate at which these particles grow depends on the composition and the residence time of e.g., milling.
  • the art around producing small particle compositions of organic molecules has focused on various methods and compositions to suppress particle growth or aggregation.
  • one aspect of the invention is directed to the use of complexing agent(s) which stabilize the size of the particles.
  • complexing agent(s) which stabilize the size of the particles.
  • the addition of such complexing agent(s) initially provide a rapid particle size growth over a curing period, and then results in size-stabilized particles which have more desirable attributes than the uncomplexed particles.
  • the resultant size-stabilized particles have a D50 value of not greater than about 500 nm (the meaning of size-stabilized is defined herein at paragraph [0073]).
  • such complexing agents When combined with particles comprising drugs useful in the present invention (preferably with effective amounts of a surface stabilizer(s), such complexing agents provide added stability and superior physical properties such as storage stability, freeze/thaw stability, heat stability and stability in the physiological medium (e.g., simulated gastrointestinal fluids) that the formulation will be exposed to.
  • This enhanced stability allows the small particle compositions to be exposed to a variety of conditions as mentioned in the previous sentence and/or to be redispersed while maintaining a D50 not greater than about 500 nm.
  • Complexing agents also can minimize the milling time needed to manufacture a stable nanoparticulate formulation and increase the concentration of drug content in various formulations.
  • complexing agents include but are not limited to aryl or heteroaryl (N, O, S) aromatic acids and esters and salts thereof. Complexing agents can be substances containing a phenol moiety, an aromatic ester moiety or an aromatic acid moiety.
  • complexing agents include but are not limited to phenol, parabens (e.g., methylparaben, propylparaben, potassium methylparaben, sodium methylparaben), BHT, sorbic acid, ascorbic acid, methyl anthranilate, salicylic acid, acetosalicyclic acid, tocopherol, organic acids, carboxylic acids, aromatic acids, aromatic esters, acid salts of amino acids, benzaldehyde, cinnimaldehyde, imidazole, menthol, thiophenol, m-aminobenzoic acid, anthranilic acid, picolinic acids and alkyl esters thereof, toluidides, sodium benzoate, benzoic acid, para-aminobenzoic acid and esters, sorbic and benzoic acids, 2,6-di-t-butyl-alpha-dimethylamino-p-cresol, t-butylhydroquinone, di-t-
  • the final storage stable particle size of a nanoparticulate suspension as measured by volume-weighted-median (D50) is dependent upon the concentration of the complexing agents and/or milling residence time.
  • concentration of complexing agents was kept constant, the post-milling growth of particles correlates closely with residence time. Therefore, certain aspects of the present invention are directed to the unexpected observation that the residence time that the active agent particles (e.g., drug particles) are subjected to during the milling process, has an impact on the variability of the subsequent growth in particles size after milling.
  • the milling residence time is defined by the following equation:
  • Milling Residence Time (milling chamber void volume/milling slurry volume) ⁇ milling time (Equation 1).
  • the void chamber volume is the void space in the mill chamber that can be occupied by the milling slurry. It is calculated by estimating the bead void space in the beads (for 0.4 mm yttrium-stabilized zirconium oxide beads, the bead void space is approximately 36-40% of the beads volume) and void chamber volume is the volume of the milling chamber ⁇ the volume of the beads+the bead void space (all in the same volume units).
  • the disclosed residence times are obtained using flow rates varying from 1 ⁇ 4 of the estimated void volume/minute to 3 times (3 ⁇ ) the estimated void chamber volume/minute. Ideally flow rates of 0.5 ⁇ void chamber volume per minute to 1.5 ⁇ void volume per minute are used.
  • the curing time is the time needed for the complex to become a size-stabilized particle.
  • the effect of the milling residence time may affect the variability of size growth due to that prolonged milling produces more particles with smoother surfaces that have less area for contact and are less prone to aggregation.
  • a preferred embodiment is shorter and lower energy milling by which a size stabilized nanoparticulate composition can be formed by adding a complexing agent. Additional preferred embodiments include nanoparticulate compositions in which addition of a complexing agent allows for more concentrated drug compositions.
  • certain embodiments of the present invention provide pharmaceutical particles comprising complexed drug thereof which exhibit a stable growth profile over time, i.e., the particles provide a D50 ratio of 1.5:1 or less as compared to D50 after 4 months storage (25° C.) with the D50 after a suitable curing period.
  • the novel nature of adding a small molecule complexing agent is seen in some embodiments where one can reproducibly increase the particle size by about 20% to 300% within 1-4 weeks curing. After this curing period the particle size is stable for many months.
  • the invention is directed to a composition
  • a composition comprising particles comprising a drug (preferably with a surface modifier(s) and an effective amount of a complexing agent (added during or within 24-48 hours after particle size reduction) to stabilize the particle growth after an initial particle growth and endpoint is reached (curing time), wherein the volume weighted median diameter (D50) of the particles before the initial growth is from about 50 to about 200 nm and the D50 at the end of the curing time is 20% to 300% larger than the D50 measured before the curing period.
  • D50 volume weighted median diameter
  • the particles have a ratio of D50 values four months storage (25° C.) after curing to of about 1.25:1 or less; or about 1.15:1 or less.
  • the particles In order for the milled drug particles of the present invention to provide a growth stable profile with drug particles in the 100-500 nm range (D50), the particles have a preferred milling residence time of at least 25 minutes if a complexing agent is added. However, these times are not meant to be limiting. The residence time necessary for obtaining a growth stable formulation can be ascertained by one of skill in the art, given the guidance provided by the present disclosure.
  • the resultant particles of the milling process disclosed herein can have a D50 of less than 500 nm, less than 400 nm, less than 300 nm, less than 200 nm or less than 100 nm.
  • the resultant particles can also have a D90 of less than 1 micron, less than 500 nm, less than 400 nm, less than 300 nm, less than 200 nm.
  • the end product of the milling processes to obtain growth stable particles can comprise the active agent particles suspended in water (i.e., a suspension).
  • a complexing agent during or preferably post-milling was found to improve the physical stability (storage and dispersed in simulated gastrointestinal fluids) of drug particles formulations (e.g. liquid suspension and solid formulations).
  • the improvement in physical stability is believed to be the result of the formation of complex's of drug particles and the complexing agent which causes an increase in drug particle size.
  • the increase in drug particle size in complexing agent containing formulations is achieved through a particle complex forming process.
  • the complexing agent(s) can act as an aggregating for drug particles to form drug-aggregates associated with the complexing agent and possibly other ingredients in the suspension.
  • the initial target size for the drug particles considered desirable by the inventors was in the range of about 100-200 nm.
  • milling one gets a non-linear curve. Initially a large decrease in particle size is obtained per unit milling time which then decreases so that very little particle size change with additional milling occurs. Longer milling times are generally associated with an increase in residual materials (from the milling chamber lining and balls) in the suspension.
  • the inventors have found that when adding a preservative to a suspension of drug particles (necessary to preserve the suspension), e.g., ganaxolone in size range of 100-200 nm manufactured using a surface stabilizer(s), it was noticed that the drug particles exhibited a rapid rise in particle size that kept on growing.
  • a preservative e.g., ganaxolone in size range of 100-200 nm manufactured using a surface stabilizer(s
  • size-stabilized drug particles can also be accomplished using a wide range of drugs (as defined herein) and complexing agents other than the parabens.
  • drugs as defined herein
  • complexing agents other than the parabens For example, nanoparticles of phenyloin (5,5-diphenylhydantoin) have been complexed with methyl anthranilate to provide initial rapid particle size growth followed by similarly size-stabilized particles.
  • a common property of all complexing agents and drugs which are capable of forming a complexed, size-stabilized particulate composition is the ability of these complexing agents and drugs to form a cyclodextrin inclusion complex.
  • a complexing agent as the term is used in the present application, may be defined as a low molecular weight organic molecule (MW ⁇ 550) capable of forming a cyclodextrin inclusion complex.
  • FIG. 2 shows the particle size growth plots for both methylparaben and propylparaben and sodium benzoate (adjusted to pH 4.0) with drug 100 to 200 nm particles. Both formulations contain 5% drug, 5% HPMC, 1% PVA, 0.1 to 0.2% SLS.
  • the parabens formulation contained 0.1% methylparaben, 0.02% propylparaben and 0.1% simethicone while the sodium benzoate formulation contained 0.17% sodium benzoate, 0.13% citric acid and 0.01% sodium citrate (pH 4.0). It has recently been found that the addition of methyl anthranilate can form a complex which does not change after sonication after 1 day. In the case of methyl anthranilate, approximately 0.05% was added to a non-complexed drug particle suspension at 180 nm and a D50 of 390 nm was seen 72 hours later.
  • the cured drug-particles appear to have much better physical stability than drug particles that do not contain the complexing agent. Once the drug particle complexes are formed, no further substantial increase in drug particle size is observed. Drug particles of ganaxolone that were milled for less than 2 hours milling residence time and do not contain complexing agents continue to increase gradually in size over a number of months ( FIG. 3 .).
  • Parabens are esters of para-hydroxybenzoic acid.
  • Parabens which can be utilized in the present invention include methylparaben, ethylparaben, propylparaben, and butylparaben.
  • Other parabens which can be utilized in the present invention include isobutylparaben, isopropylparaben, benzylparaben.
  • Pharmaceutically acceptable salts e.g., sodium and potassium salts, can also be utilized in the present invention.
  • Especially preferred parabens for use in the present invention include methylparaben and propylparaben and their sodium salts. If the sodium salts of parabens are utilized an equimolar amount of an organic acid, e.g., citric acid should be added.
  • milled drug particle suspensions are converted into a solid dosage form.
  • Governmental drug regulatory agencies such as the FDA, requires justification of all ingredients and their levels in a formulation. Therefore, it is quite uncommon for a preservative to be included in a solid dosage form.
  • commercialized solid dosage forms prepared from a nanosuspension e.g., TriCor®), Emmend®) and Rapamune®
  • complexing agents impart significant stability qualities into solid dosage forms.
  • the complexing agent can be present in any suitable amount, e.g., from about 0.001% to about 5%, from about 0.01% to about 2.5%, from about 0.015% to about 1%, from about 0.1% to about 0.5% or from about 0.02% to about 0.1%, based on the weight of the milled slurry.
  • Certain embodiments of the invention are directed to minimizing aggregation and/or particle size growth due to the association of the drug particles and the complexing agent when dispersed in simulated gastrointestinal fluids. These embodiments are directed to pharmaceutical particles comprising drug thereof associated with a complexing agent, the particles exhibiting a ratio of D50 after dispersion in SGF or SIF at 36-38° C. for 1-3 hours to D50 prior to dispersion in SGF or SIF of less than about 3:1; less than about 2.7:1, less than about 2.5:1, less than about 2:1, or less than about 1.5:1.
  • the invention is directed to pharmaceutical particles comprising drug thereof stabilized with a complexing agent, the complexed particles exhibiting a ratio of D50 after dispersion in SGF or SIF for 1-3 hours to D50 prior to dispersion of from about 1.5:1 to about 3:1; from about 1.8:1 to about 2.7:1 or about 2:1 to about 1.5:1.
  • Certain embodiments of the invention are directed to the “cured” complexes which exhibit size-stabilized particles. These embodiments are directed to pharmaceutical particles comprising drug thereof complexed with a complexing agent, the particles cured for a sufficient time until an endpoint is reached such that the D50 does not change by more than about 5% as measured over 3 days after curing. In other embodiments, the particles are cured for a sufficient time until an endpoint is reached such that the D50 does not change by more than about 12%, more than about 10%, more than about 8% or more than 5% over 1 month after the curing period.
  • the particles are cured for a sufficient time until an endpoint is reached such that the D50 does not change by more than about 5% (over the instrument's variability at the measure particle size) after 20 days after curing, 40 days after curing, 60 days after curing, or 80 days after curing storage conditions of 5° C. to 25° C.
  • Cured drug particulate complexes are more desirable as these compositions will provide a more uniform result due to a decreased change in particle size over time, better thermal stability and less aggregation in the gastrointestinal tract.
  • the endpoint needed to reach size stabilized particles can be ascertained by one skilled in the art.
  • the endpoint can be reached in about 5 days to about 25 days; in about 5 days to about 7 days, in about 7 days to about 14 days, in about 14 days to about 21 days, or about 10 days to about 15 days.
  • the particles have a D50 prior to storage of less than 350 nm, less than 250 nm or less than 150 nm. In other embodiments, the particles have a D50 prior to storage of from about 50 nm to about 350 nm, from about 75 nm to about 250 nm or from about 100 nm to about 150 nm.
  • the benefits of having a complexed nanosuspension include but are not limited to the following: (1) very stable particle size once cured (e.g., no significant change in particle size after about 2 years); (2) the non-complexed drug suspensions of similar composition are generally less stable in simulated gastric and intestinal fluids, e.g., when incubated at 37° C.
  • milling time can be decreased via the use of a complexing agent to get a storage stable particle size as opposed to obtaining a storage stable particle size by increasing milling time (also less contamination).
  • Milling time is also called residence time and is the time a particle is in the mill when being recirculated through the mill into a large tank.
  • milling residence time to obtain a storage stable drug particle suspension may be, e.g., from about 30 to about 35 minutes versus about 1.5 to 2 hours (which translates to a 3-4 time increase in productivity).
  • Complexed drug suspensions comprising drug (e.g., Ganaxolone), HPMC, SLS, methylparaben, propylparaben, and PVA were found to provide desirable pharmacokinetic results in animal studies versus uncomplexed Ganaxolone formulations with D50 values 1 ⁇ 3 that of the complexed material. Surprisingly, the total exposure (AUC) was slightly higher with the complexed and higher D50 composition.
  • AUC total exposure
  • the smaller uncomplexed formulation gave higher Cmax values as one would expect with increased dissolution but not higher bioavailability. Higher Cmax levels without an increase in bioavailability is an undesirable attribute for some compounds as higher side effects will be seen without any additional benefit.
  • Formulations containing drug complexes as described above may provide a more desirable pharmacokinetic performance (e.g., improved bioavailability, reduction in variability, etc.).
  • Foaming during the nanosizing of pharmaceutical products can present formulation issues and can have negative consequences for particle size reduction.
  • high levels of foam or air bubbles in the mill can cause a drastic increase in viscosity rendering the milling process inoperable.
  • Even a very low level of air presence can dramatically reduce milling efficiency causing the desired particle size unachievable. This may be due to the resultant air in the mill cushioning the milling balls and limiting grinding efficiency.
  • the air also can form a microemulsion with the milled ingredients which presents many issues with respect to the delivery of an accurate dose and palatability.
  • Addition of a small amount of simethicone is a very effective anti-foaming agent which minimizes milling variability or special handling techniques to avoid the introduction of air into the milling process.
  • Suitable drugs which can form a cyclodextrin inclusion complex for use in the present invention include, but are not limited to, antineoplastics (anticancer/antitumor agents), sedatives, antiinflammatory steroids (glucocorticoids such as actometasone, betamethasone, beclomethasone, fluocinonide, flunisolide, dexamethasone, cortisone, hydrocortisone, methylprednisolone, mometasone, prednisolone, prednisone, fluticasone, budesonide, and triamcinolone), tranquilizers, anticonvulsants, antivirals, antihistaminics (fexofenadine), vitamins/nutritional factors, emetics (apomorphine), anticoagulants (dicumarol or coumadin), cardiotonics (including the cardiac glycosides such as digoxin or digitoxin), diuretics, carbonic anhydrase inhibitors, non
  • Suitable neurosteroids may include, but are not limited to, beta-hydroxy-delta 5-compounds, such as pregnenolone (PREG) and dehydroepiandrosterone (DHEA), their sulfates, and reduced metabolites such as the tetrahydroderivative of progesterone 3 alpha-hydroxy-5 alpha-pregnane-20-one (3 alpha,5 alpha-THPROG).
  • PREG pregnenolone
  • DHEA dehydroepiandrosterone
  • ganaxolone can indeed form a cyclodextrin inclusion complex, that drug has been described previously in our U.S. patent application Ser. Nos. 11/606,222 and 11/605,700, both filed on Nov. 28, 2006, the disclosures of which are hereby incorporated by reference in their entirety. However, ganaxolone is therefore excluded from the claims of the present application.
  • Suitable antineoplastics for use in the present invention include, but are not limited to chlorambucil, lomustine, melphalan, methotrexate, hexamethylmelamine, teniposide, etoposide, semustine (methyl CCNU), camrabine (Ara-AC), mercaptopurine, tubulazole, carmofur, carmustine, amsacrine, doxorubicin, bruceantin, diaziquone, dideminin B, echinomycin and PCNU.
  • Suitable antiinflammatory steroids for use in the present invention include, but are not limited to actometasone, betamethasone, beclomethasone, fluocinonide, flunisolide, fludrocortisone, dexamethasone, cortisone, hydrocortisone, methylprednisolone, mometasone, prednisolone, prednisone, fluticasone, budesonide, triamcinolone and any pharmaceutically acceptable salts thereof.
  • the glucocorticosteroid is triamcinolone acetonide.
  • Suitable estrogens for use in the present invention include, but are not limited to, 17 ⁇ -estradiol, 17 ⁇ -ethynylestradiol (ethinylestradiol), ethynylestradiol 3-methyl ether, estrone, mestranol and estriol.
  • the estrogen is a synthetic estrogens such as diethylstilbestrol, benzestrol, dienestrol, hexestrol and the like.
  • Suitable progestins for use in the present invention include, but are not limited to, dimethisterone, norethindrone, norethindrone acetate, norgestrel, norethynodrel, ethisterone, medroxyprogesterone acetate and progesterone.
  • Suitable immunosuppressive agents for use in the present invention include, but are not limited to, cyclosporine (also known as cyclosporin A).
  • Suitable anticonvulsants for use in the present invention include, but are not limited to, phenyloin (5,5-diphenylhydantoin) and carbamazepine.
  • Suitable barbiturates for use in the present invention include, but are not limited to, pentobarbital, phenobarbital and secobarbital, which are variously useful as hypnotics, anticonvulsants and sedatives as well.
  • Suitable antivirals for use in the present invention include, but are not limited to, acyclovir, trifluridine, zidovudine, vidarabine and virazole (also known as ribavirin).
  • Suitable vitamins/nutritional for use in the present invention include, but are not limited to, factors such as retinol (vitamin A), vitamin A-acetate, cholecalciferol, retinal, retinoic acid (also known as tretinoin or Retin-ATM), isotretinoin, etretinate, acitretin and ⁇ -carotene, collectively referred to herein as retinoids, as well as other fat-soluble vitamins such as the E, D and K vitamins.
  • factors such as retinol (vitamin A), vitamin A-acetate, cholecalciferol, retinal, retinoic acid (also known as tretinoin or Retin-ATM), isotretinoin, etretinate, acitretin and ⁇ -carotene, collectively referred to herein as retinoids, as well as other fat-soluble vitamins such as the E, D and K vitamins.
  • Beta-blockers suitable for use in the present invention include, but are not limited to, timolol, atenolol, propranolol, nadolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, metoprolol, penbutolol, pindolol and sotalol.
  • Diuretics suitable for use in the present invention include, but are not limited to, chlorthalidone, furosemide, spironolactone, and other sulfonamide-type and/or aldosterone antagonist-type diuretics.
  • Angiotensin converting enzyme inhibitors suitable for use in the present invention, include but are not limited to, enalaprilic acid (the diacid, sometimes called ‘enalaprilate’), the ethyl ester of enalaprilic acid (sometimes called enalapril), captopril, lisinopril and SCH-33861.
  • Suitable non-steroidal analgesics and/or anti-inflammatory agents for use in the present invention include, but are not limited to, aspirin, ibuprofen, indomethacin, piroxicam, sulindac and flurbiprofen.
  • Antibacterials/antibiotics, anti-infectives and/or antifungal/antiprotozoal agents suitable for use in the present invention include, but are not limited to, ampicillin, penicillin G; tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, doxycycline, minocycline, erythromycin, josamycin, rosamycin, tylosin, troleandomycin and spiramycin, benzalkonium chloride, cetylpyridinium chloride, chlorhexidine, econazole, clotrimazole, oxiconazole, bifonazole, metronidazole (metronidazole benzoate), fenticonazole, miconazole, sulconazole, tioconazole, isoconazole, butoconazole, ketoconazole, doconazole, parconazole, orconazole, valconazole
  • Suitable vasodilators include, but are not limited, to coronary vasodilators such as nitroglycerin, flunarizine, lidoflazine and mioflazine.
  • Carbonic anhydrase inhibitors suitable for use in the present invention include, but are not limited to, acetazolamide, chlorzolamide, ethoxzolamine, methazolamide, L-671,152 and MK-927.
  • H 2 -antagonists suitable for use in the present invention include, but are not limited to, famotidine, burimamide, metiamide, cimetidine and oxmetidine.
  • Antihistaminics suitable for use in the present invention include, but are not limited to, astemizole, levocabastine, flunarizine, oxatomide and cinnarizine.
  • Anthelmintic agents suitable for use in the present invention include, but are not limited to, thiabendazole, oxibendazole, cambendazole, fenbendazole, flubendazole, albendazole and oxfendazole.
  • Serotonin antagonists suitable for use in the present invention include, but are not limited to, ketanserin, ritanserin, altanserin, and mianserin.
  • Benzodiazepines suitable for use in the present invention include but are not limited to, chlordiazepoxide, diazepam, medazepam, oxazepam, lorazepam, flunitrazepam, estazolam, flurazepam, loprazolam, lormetazepam, nitrazepam, quazepam, temazepam and triazolam.
  • the drug formulations comprise a non-amorphous form of drug comprising drug particles having an effective particle size by weight of less than about 500 nm.
  • the drug particles have an effective particle size by weight of less than about 400 nm, an effective particle size by weight of less than about 300 nm, an effective particle size by weight of less than about 200 nm, or an effective particle size by weight of less than about 100 nm when measured by the above techniques.
  • the drug particles have a particle size distribution wherein the drug particles have an effective particle size by weight of less than about 400 nm and wherein the standard deviation of the particle size distribution is less than about 100 nm.
  • the drug particles by weight have a particle size 500 nm, i.e., less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm with less than at least 20%, at least about 15% or at least about 10% of the total particles having a particle size greater than 1 micron.
  • the drug particles have a particle size of around 300 nm with a distribution wherein 90% of the particles by weight have an effective particle size by weight between about 100 nm and 800 nm. In another embodiment, the drug particles have a particle size or around 100 nm and a distribution wherein 90% of the particles by weight have an effective particle size by weight between about 50 nm and 250 nm.
  • the drug compositions described herein comprise size stabilized drug particles having a particle size by weight of less than 500 nm formulated with drug particles having a particle size by weight of greater than 500 nm.
  • the formulations have a particle size distribution wherein about 10% to about 100% of the drug particles by weight are between about 100 nm and about 300 nm, about 0% to about 90% of the drug particles by weight are between about 300 nm and about 600 nm, and about 0% to about 30% of the drug particles by weight are greater than about 600 nm.
  • the formulation has a particle size distribution wherein about 20% of the drug particles by weight are between about 100 nm and about 300 nm, about 40% of the drug particles by weight are between about 300 nm and about 600 nm, and about 30% of the drug particles by weight are greater than about 600 nm. In still another embodiment, the formulation has a particle size distribution wherein about 30% of the drug particles by weight are between about 100 nm and about 300 nm, about 40% of the drug particles by weight are between about 300 nm and about 600 nm, and about 30% of the drug particles by weight are greater than about 600 nm.
  • the formulation has a particle size distribution wherein about 50% of the drug particles by weight are between about 100 nm and about 300 nm, about 40% of the drug particles by weight are between about 300 nm and about 800 nm, and about 10% of the drug particles by weight are greater than about 800 nm.
  • the drug particles generated by the methods described herein can be utilized in solid or aqueous liquid dosage formulations, such as controlled release formulations, solid dose fast melt formulations, lyophilized formulations, tablets, capsules, aqueous dispersions, or aerosol formulations.
  • compositions described herein can be formulated for administration to a subject via any conventional means including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, or intramuscular), buccal, intranasal or transdermal administration routes.
  • parenteral e.g., intravenous, subcutaneous, or intramuscular
  • buccal e.g., buccal, intranasal or transdermal administration routes.
  • the pharmaceutical drug compositions described herein can be formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, aqueous oral suspensions, solid dosage forms including oral solid dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, self-emulsifying dispersions, solid solutions, liposomal dispersions, lyophilized formulations, tablets, capsules, pills, powders, delayed release formulations, immediate release formulations, modified release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
  • aqueous oral dispersions aqueous oral suspensions
  • solid dosage forms including oral solid dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, self-emulsifying dispersions, solid solutions, liposomal dispersions, lyophilized formulations, tablets, capsules, pills, powders, delayed release formulations, immediate release formulations, modified
  • drug formulations provide a therapeutically effective amount of drug over an interval of about 30 minutes to about 8 hours after administration, enabling, for example, once-a-day, twice-a-day (b.i.d.), or three times a day (t.i.d.) administration if desired.
  • the drug particles are formulated into a controlled release or pulsatile solid dosage form for b.i.d. administration.
  • the drug particles are dispersed in an aqueous dispersion for b.i.d. administration.
  • the stabilized drug particle suspensions are converting to a solid form.
  • spray drying spray layering onto a core (fluidized bed); spray granulation (fluidized bed); or adding more excipients and performing a spheronization extrusion.
  • the inventors have found that several issues may arise when removing water from the stabilized drug particle suspension in order to prepare a solid dosage form. For example, there can be particle aggregation in the solid state or particle aggregation (increase in particle size) may occur when the solidified drug particles are re-dispersed into a biological medium.
  • the cores e.g., inert beads
  • the cores are sprayed with droplets of the drug particle suspension, e.g., in a Wurster column.
  • the entire particle should preferably be coated evenly.
  • the water in the suspension has to evaporate before the beads circulated through the Wurster column again.
  • uncomplexed drug particles can be spray layered but are generally not stable in SGF and SIF.
  • the complexed (cured particles with a complexing agent) are generally more stable; nevertheless, additional agents are typically added to make spray layering (coating) work give optimal results.
  • Spray drying manufacture allows the drug concentration to approach 80% or higher.
  • spray layering manufacture it has been typical to add a lot of sucrose into the drug particle dispersion, which is believed to act as a water soluble spacer separating the drug particles from agglomeration during spraying and re-dispersion.
  • the inventors have found that spray layered ganaxolone drug-complex beads prepared by spray layering without sucrose had good water redispersion, but aggregated more substantially in SGF and SIF.
  • the inventors then determined that adding a small amount of a salt such as sodium chloride dramatically reduced the amount of sucrose needed to help redisperse solid nanoparticulate composition with good particle size and stability. For example, a 1.5 weight % (as compared to drug) addition of NaCl reduced the amount of sucrose (water soluble spacer 20-fold (from 100% weight of drug to 5% weight of drug) to achieve minimal aggregation when dispersed in SGF. This dramatic effect has been able to provide a greater concentration of drug, thereby allowing more drug to be delivered in one capsule unit. As the stability effects are seen primarily in SGF and SIF, the salt is referred to as an “ionic dispersion modulator” as it seems to have its best effects when redispersing into an ionic medium.
  • a salt such as sodium chloride
  • the excipient comprises an ionic dispersion modulator.
  • the ionic dispersion modulator can be a salt such as an organic or inorganic salt.
  • the ionic dispersion modulator is an inorganic salt.
  • suitable inorganic salts include, but are not limited to a magnesium salt, a calcium salt, a lithium salt, a potassium salt, a sodium salt and mixtures thereof.
  • the inorganic salt is sodium chloride.
  • the salt is an organic salt.
  • Suitable organic salts include, but are not limited to a citrate salt, a succinate salt, a fumarate salt, a malate salt, maleate salt, a tartrate salt, a glutarate salt, a lactate salt and mixtures thereof.
  • the ionic dispersion modulator includes one or more of both an inorganic and organic salt.
  • the amount of ionic dispersion modulator included in a spray-layering process should be an amount effective to provide a satisfactory redispersibility of the beads with acceptable particle size and stability, without causing the mixture to become a semi-solid. Such an amount typically may comprise from about 0.2% to about 5% as compared to weight of drug in the formulation.
  • the solid dosage forms of the present invention may be in the form of a tablet (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder (including a sterile packaged powder, a dispensable powder, or an effervescent powder), a capsule (including both soft or hard capsules, e.g., capsules made from animal-derived gelatin or plant-derived HPMC, or “sprinkle capsules”), solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms, multiparticulate dosage forms, pellets, granules, or an aerosol.
  • a tablet including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet
  • a pill including a sterile
  • the pharmaceutical formulation is in the form of a powder. In still other embodiments, the pharmaceutical formulation is in the form of a tablet, including but not limited to, a fast-melt tablet. Additionally, pharmaceutical formulations of the present invention may be administered as a single capsule or in multiple capsule dosage form. In some embodiments, the pharmaceutical formulation is administered in two, or three, or four, capsules or tablets.
  • solid dosage forms e.g., tablets, effervescent tablets, and capsules
  • solid dosage forms are prepared by mixing drug particles with one or more pharmaceutical excipients to form a bulk blend composition.
  • these bulk blend compositions as homogeneous, it is meant that the drug particles are dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules.
  • the individual unit dosages may also comprise film coatings, which disintegrate upon oral ingestion or upon contact with diluents.
  • These drug formulations can be manufactured by conventional pharmaceutical techniques.
  • the solid formulation is in the form of a tablet or capsule containing the size stabilized complexed drug particles and at least one surface stabilizer, the size stable drug particles exhibiting an increase in volume weighted median diameter (D50) of from 0% to not more than about 200%, not more than about 150%, not more than about 100%, or not more than about 50%, when the tablets or capsules are dispersed in SGF or SIF (in any suitable volume, e.g., 15 mL to 1000 mL) at a concentration of 0.5 to 1 mg drug/mL at 36° to 38° C.
  • D50 volume weighted median diameter
  • the volume weighted median diameter (D50) of the drug particles when the tablets or capsules are dispersed in distilled water is from about 50 nm to about 1000 nm, from about 100 nm to about 500 nm, or from about 100 nm to about 350 nm.
  • the invention is directed to a solid formulation (e.g., a powder, immediate release dosage form, or controlled release dosage form) comprising size stabilized drug particles and at least one pharmaceutically acceptable excipient, the size stabilized drug particles exhibiting a volume weighted median diameter (D50) of less than about 500 nm when the formulation is dispersed in simulated gastric fluid (SGF) for one hour followed by simulated intestinal fluid (SIF) for three additional hours, at a concentration of 0.5 to 1 mg drug/mL (in any suitable volume, e.g., 15 mL to 1000 mL) at a temperature of 36° to 38° C.
  • a solid formulation e.g., a powder, immediate release dosage form, or controlled release dosage form
  • D50 volume weighted median diameter
  • SGF gastric fluid
  • SIF simulated intestinal fluid
  • the solid formulation is a tablet or capsule containing the stabilized drug particles and at least one excipient, the stable drug particles exhibiting a volume weighted median diameter (D50) of less than about 500 nm when the tablets or capsules are dispersed in simulated gastric fluid (SGF) for one hour followed by simulated intestinal fluid (SIF) for three additional hours, at a concentration of 0.5 to 1 mg drug/mL (in any suitable volume, e.g., 15 mL to 1000 mL) at a temperature of 36° to 38° C. using a Type I or II dissolution apparatus and a stirring rate of 75 RPM.
  • SGF gastric fluid
  • SIF simulated intestinal fluid
  • Conventional pharmaceutical techniques for preparation of solid dosage forms include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. See, e.g., Lachman et al., The Theory and Practice of Industrial Pharmacy (1986).
  • Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
  • the pharmaceutical solid dosage forms described herein can comprise the drug compositions described herein and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, complexing agent, ionic dispersion modulator, filling agent, suspending agent, flavoring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer, moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one or more combination thereof.
  • a film coating is provided around the drug formulation. In one embodiment, some or all of the drug particles are coated.
  • some or all of the drug particles are microencapsulated. In yet another embodiment, some or all of the drug is amorphous material coated and/or microencapsulated with inert excipients. In still another embodiment, the drug particles not microencapsulated and are uncoated.
  • Suitable carriers for use in the solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sugars such as sucrose, microcrystalline cellulose, lactose, mannitol, polyvinylpyrrolidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphotidylcholine, cellulose and cellulose conjugates, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride,
  • Suitable filling agents for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose (e.g., Avicel®, Avicel® PH101, Avicel®PH102, Avicel® PH1105, etc.), cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
  • lactose calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose (e.g., Avicel®, Avicel® PH101, Avicel®PH
  • “Diluents” increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling.
  • Such compounds include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose-based diluents, confectioner's sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin;
  • Non water-soluble diluents are compounds typically used in the formulation of pharmaceuticals, such as calcium phosphate, calcium sulfate, starches, modified starches and microcrystalline cellulose, and microcellulose (e.g., having a density of about 0.45 g/cm 3 , e.g. Avicel, powdered cellulose), and talc. Combinations of one or more diluents can also be used.
  • Plasticizers are compounds used to soften the microencapsulation material, film coatings or pharmaceutical blends for compression to make them less brittle. Suitable plasticizers include, e.g., polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethyl cellulose and triacetin. In some embodiments, plasticizers can also function as dispersing agents or wetting agents.
  • “Surfactants or Wetting agents” also referred to as surface stabilizers include compounds such as sodium lauryl sulfate, sodium doccusate, triacetin, vitamin E TPGS, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween® 20, 60 and 80 (ICI Speciality Chemicals)); polyethylene glycols (e.g.
  • surfactants are commercially available or can be prepared by techniques known in the art. Many are described in detail in the Handbook of Pharmaceutical Excipients , published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference.
  • Wetting agents include surfactants.
  • Antifoaming agents reduce foaming during processing which can result in coagulation of aqueous dispersions, bubbles in the finished form, or generally impair processing.
  • Exemplary anti-foaming agents include silicon emulsions or sorbitan sesquoleate.
  • Antioxidants include, e.g., butylated hydroxytoluene (BHT), butylhydroxyanisole (BHA), ascorbic acid, sodium ascorbate, and tocopherol. Combinations of one or more antioxidants can also be used.
  • BHT butylated hydroxytoluene
  • BHA butylhydroxyanisole
  • ascorbic acid sodium ascorbate
  • tocopherol tocopherol
  • the drugs utilized in certain embodiments of the present invention have low solubility, they exhibit a strong correlation between the rate of dissolution and bioavailability. Thus, it is important to optimize the rate of dissolution in biological matrices in order to enhance in vivo drug absorption.
  • disintegrants are often used in the formulation, especially when the dosage forms are compressed with binder. Disintegrants help rupturing the dosage form matrix by swelling or capillary action when moisture is absorbed into the dosage form.
  • the solid dosage drug formulation has greater than about 1 w % of a disintegrant.
  • the solid dose drug formulations have between about 1 w % to about 11 w % or between about 2 wt % to about 8 wt % disintegrant. In yet other embodiments, the drug formulations have greater than about 2 wt % disintegrant. In some embodiments, combinations of disintegrants provide superior dispersion characteristics compared to single disintegrant at a similar total weight percentage.
  • Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijel®, or a sodium starch glycolate such as Promogel® or Explotab®, a cellulose such as a wood product, microcrystalline cellulose, e.g., Avicel®, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® P100, Emcocel®, Vivacel®, Ming Tia®, and Solka-Floc®, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Sol®), cross-linked carboxymethylcellulose, or cross-linked croscarmellose, a cross-linked starch such as sodium starch glycolate, a cross-linked polymer such as crosspovidone, a cross-linked polyvinylpyr
  • Ac-Di-Sol is the disintegrant.
  • the amount of Ac-Di-Sol used in direct compression tableting may vary with typical usage levels between 1 and 3 percent. When added to granulations, generally the same percent is used as with a direct compression formulation. It is often added to both the wet and dried granulations and blends.
  • the amount of Ac-Di-Sol used in capsule formulations generally ranges from 3-6 percent. Reduced interparticle contact within a capsule facilitates the need for elevated levels of disintegrant.
  • Binders impart cohesiveness to solid oral dosage form formulations: for powder filled capsule formulation, they aid in plug formation that can be filled into soft or hard shell capsules and in tablet formulation, binders ensure that the tablet remains intact after compression and help assure blend uniformity prior to a compression or fill step.
  • Materials suitable for use as binders in the solid dosage forms described herein include, but are not limited to, carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose (e.g.
  • Hypromellose USP Pharmacoat-603 hydroxypropylmethylcellulose acetate stearate (Aqoate HS-LF and HS), hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®), microcrystalline dextrose, amylose, magnesium aluminum silicate, polysaccharide acids, bentonites, gelatin, polyvinylpyrrolidone/vinyl acetate copolymer, crosspovidone, povidone, starch, pregelatinized starch, tragacanth, dextrin, a sugar, such as sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., Xylitab®), lactose, a natural or synthetic gum such as aca
  • binder levels of 20-70% are used in powder-filled gelatin capsule formulations.
  • Binder usage level in tablet formulations is a function of whether direct compression, wet granulation, roller compaction, or usage of other excipients such as fillers which itself can act as moderate binder are used.
  • Formulators skilled in art can determine the binder level for the formulations, but binder usage level of up to 70% in tablet formulations is common.
  • Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumarate, alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, magnesium stearate, zinc stearate, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol such as CarbowaxTM, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, mineral oil, hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex®), higher
  • Suitable suspending agents for use in the solid dosage forms described here include, but are not limited to, polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 18000, vinyl pyrrolidone/vinyl acetate copolymer (S630), sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e.g., sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorb
  • Suitable antioxidants for use in the solid dosage forms described herein include, for example, e.g., butylated hydroxytoluene (BHT), butylhydroxyanisole (BHA), sodium ascorbate, Vitamin E TPGS, ascorbic acid, sorbic acid and tocopherol.
  • BHT butylated hydroxytoluene
  • BHA butylhydroxyanisole
  • Vitamin E TPGS Vitamin E TPGS
  • ascorbic acid ascorbic acid
  • sorbic acid tocopherol
  • Erosion facilitators include materials that control the erosion of a particular material in gastrointestinal fluid. Erosion facilitators are generally known to those of ordinary skill in the art. Exemplary erosion facilitators include, e.g., hydrophilic polymers, electrolytes, proteins, peptides, and amino acids. Combinations of one or more erosion facilitator with one or more diffusion facilitator can also be used in the present invention.
  • additives used in the solid dosage forms described herein should be taken as merely exemplary, and not limiting, of the types of additives that can be included in solid dosage forms of the present invention.
  • the amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired.
  • the substrates can be, e.g., inert beads, or can be selected from the group consisting of lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol and mixtures thereof.
  • lactose calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol and mixtures thereof.
  • the dosage form can be a granulation comprising the drug particles and the controlled release material, (e.g., hydrophobic polymer or pH dependent material), the granulation compressed into a tablet or filled into a capsule.
  • the controlled release material e.g., hydrophobic polymer or pH dependent material
  • the dosage form can be a plurality of pharmaceutically acceptable beads coated with the drug particles and overcoated with the controlled release material, (e.g., hydrophobic polymer or pH dependent material), the overcoated beads compressed into a tablet or filled into a capsule.
  • the controlled release material e.g., hydrophobic polymer or pH dependent material
  • one or more layers of the pharmaceutical formulation are plasticized.
  • a plasticizer is generally a high boiling point solid or liquid. Suitable plasticizers can be added from about 0.01% to about 50% by weight (w/w) of the coating composition.
  • Plasticizers include, but are not limited to, diethyl phthalate, citrate esters, polyethylene glycol, glycerol, acetylated glycerides, triacetin, polypropylene glycol, polyethylene glycol, triethyl citrate, dibutyl sebacate, stearic acid, stearol, stearate, and castor oil.
  • Compressed tablets are solid dosage forms prepared by compacting the bulk blend drug formulations described above.
  • compressed tablets which are designed to dissolve in the mouth will comprise one or more flavoring agents.
  • the compressed tablets will comprise a film surrounding the final compressed tablet.
  • the film coating can provide a delayed release of the drug formulation.
  • the film coating aids in patient compliance (e.g., Opadry® coatings or sugar coating). Film coatings comprising Opadry® typically range from about 1% to about 3% of the tablet weight. Film coatings for delayed release usually comprise 2-6% of a tablet weight or 7-15% of a spray-layered bead weight.
  • the compressed tablets comprise one or more excipients.
  • a capsule may be prepared, e.g., by placing the bulk blend drug formulation, described above, inside of a capsule.
  • the drug formulations non-aqueous suspensions and solutions
  • the drug formulations are placed in a soft gelatin capsule.
  • the drug formulations are placed in standard gelatin capsules or non-gelatin capsules such as capsules comprising HPMC.
  • the drug formulations are placed in a sprinkle capsule, wherein the capsule may be swallowed whole or the capsule may be opened and the contents sprinkled on food prior to eating.
  • the therapeutic dose is split into multiple (e.g., two, three, or four) capsules.
  • the entire dose of the drug formulation is delivered in a capsule form.
  • the capsule may comprise e.g., from 0.01 mg to about 5 grams or any dose known to one skilled in the art, such as between about 100 mg to about 600 mg of drug. In some embodiments, the capsule may comprise between about 100 to about 500 mg of drug. In other embodiments, capsule may comprise about 300 mg to about 400 mg of drug.
  • Another useful capsule has a shell comprising the material of the rate-limiting membrane, including any of the coating materials previously discussed, and filled with drug particles.
  • a particular advantage of this configuration is that the capsule may be prepared independently of the drug particles, thus process conditions that would adversely affect the drug can be used to prepare the capsule.
  • a preferred embodiment is a capsule having a shell made of a porous or a pH-sensitive polymer made by a thermal forming process.
  • An especially preferred embodiment is a capsule shell in the form of an asymmetric membrane; i.e., a membrane that has a thin skin on one surface and most of whose thickness is constituted of a highly permeable porous material.
  • a preferred process for preparation of asymmetric membrane capsules comprises a solvent exchange phase inversion, wherein a solution of polymer, coated on a capsule-shaped mold, is induced to phase-separate by exchanging the solvent with a miscible non-solvent.
  • asymmetric membranes are disclosed in the European Patent Specification 0 357 369 B1.
  • a “swelling plug device” can be used.
  • Drug particles can be incorporated into a non-dissolving capsule-half of the device, which is sealed at one end by a hydrogel plug.
  • This hydrogel plug swells in an aqueous environment, and, after swelling for a predetermined time, exits the capsule thus opening a port through which the drug can leave the capsule and be delivered to the aqueous environment.
  • Preferred hydrogel-plugged capsules are those which exhibit substantially no release of drug from the dosage form until the dosage form has exited the stomach and has resided in the small intestine for about 15 minutes or greater, preferably about 30 minutes or greater, thus assuring that minimal drug is released in the stomach.
  • a drug swelling plug device may be prepared by loading drug into a non-dissolving half-capsule shell which may be formed from a wide variety of materials, including but not limited to polyethylene, polypropylene, poly(methylmethacrylate), polyvinylchloride, polystyrene, polyurethanes, polytetrafluoroethylene, nylons, polyformaldehydes, polyesters, cellulose acetate, and nitrocellulose.
  • the open end of the capsule shell is then “plugged” with a cylindrical plug formed from a hydrogel-forming material, including but not limited to, a homo- or co-poly(alkylene oxide) cross linked by reaction with isocyanate or unsaturated cyclic ether groups, as described in PCT Application WO 90/09168.
  • a hydrogel-forming material including but not limited to, a homo- or co-poly(alkylene oxide) cross linked by reaction with isocyanate or unsaturated cyclic ether groups, as described in PCT Application WO 90/09168.
  • the composition and length of the hydrogel “plug” is selected to minimize release of drug to the stomach, to decrease the incidence and/or severity of gastrointestinal side effects.
  • the plugged capsule-half is finally sealed with a water-soluble, e.g., gelatin, capsule-half placed over the hydrogel-plugged end of the drug-containing non-dissolving capsule-half.
  • the sealed device is coated with a pH-sensitive enteric polymer or polymer mixture, for example cellulose acetate phthalate or copolymers of methacrylic acid and methylmethacrylate.
  • the weight of the enteric polymer coat will generally be from 2 to 20 wt %, preferably from 4 to 15 wt % of the weight of the uncoated sealed capsule.
  • the enteric coat dissolves quickly, e.g., within about 15 minutes, in the duodenum, triggering swelling of the hydrogel plug, exiting of the hydrogel plug, and release of the incorporated drug into the gastrointestinal tract at a time greater than about 15 minutes after, and preferably greater than about 30 minutes after, the dosage form has passed from the stomach into the duodenum.
  • Prototype unfilled “swelling plug devices” may be obtained from Scherer DDS Limited, Clydebank, Scotland, under the designation PulsincapTM.
  • a drug complex formulation comprising a dried drug complex granulation can be filled in a capsule.
  • Drug complex particle suspension comprising 10 to 30 wt % drug, 1 to 10 wt % hydroxypropylmethyl cellulose (Pharmacoat 603), 0.05 to 0.5 wt % sodium lauryl sulfate, 0.015 to 0.2 wt % paraben such as methylparaben, 0.001 to 0.05 wt % simethicone emulsion (30% in water) 0.5 to 5% sucrose and 0.1 to 2% NaCl in water is pumped into a spray granulator using standard parameters known by those skilled in the art.
  • Each wt % of the drug complex particle suspension is based on the total weight of the suspension.
  • the water is evaporated under vacuum at a temperature of 70° C. to 90° C.
  • the resulting drug complex granulation comprises about 50-80 wt % of drug based on the total weight of the solid.
  • Additional excipients such as magnesium stearate, Mannitol and a disintegrant can be added for flow and re-dispersion properties.
  • the dispersed solid in SGF or SIF
  • the capsule is a swelling plug device.
  • the swelling plug device is further coated with cellulose acetate phthalate or copolymers of methacrylic acid and methylmethacrylate.
  • spray layered drug particles or spray layered drug complex particles are filled in a capsule.
  • An exemplary process for manufacturing the spray layered drug or drug complex particles is the fluidized bed spraying process. Drug suspensions or drug complex suspensions described above are sprayed onto sugar or microcrystalline cellulose (MCC) beads (20-35 mesh) with Wurster column insert at an inlet temperature of 50 to 60° C. and air temp of 30 to 50° C.
  • MCC microcrystalline cellulose
  • the resulting spray layered drug particles or drug complex particles comprise about 30 to 70 wt % of drug based on the total weight of the particles.
  • the capsule is a size 0 soft gelatin capsule
  • the capsule is a swelling plug device.
  • the swelling plug device is further coated with cellulose acetate phthalate or copolymers of methacrylic acid and methylmethacrylate.
  • the capsule includes at least 250 mg (or at least 300 mg or at least 400 mg) drug and has a total weight of less than 800 mg (or less that 700 mg).
  • the capsule may contain a plurality of drug-containing beads, for example spray layered beads.
  • the beads are 12-25% drug by weight.
  • some or all of the drug containing beads are coated with a coating comprising 6 to 15% (or 8 to 12%) of the total bead weight. Optimization work typically involves lower loading levels and the beads constitute 30 to 60% of the finished bead weight.
  • the capsule may contain a granulated drug composition, wherein the granulated composition comprises drug, or drug, and an ionic dispersion modulator.
  • compositions additionally comprise a complexing agent and an inorganic or organic salt.
  • granulated composition in some embodiments is comprised of 0.3 to 20% (or 1 to 10% or 1 to 5%) by weight inorganic or organic salt.
  • These granulations also typically contain 5% to 30% of a binding agent, 2% to 25% of a water soluble spacing agent and a wetting agent (0.5% to 2%) of the total composition.
  • the capsule may be pulsatile release drug oral dosage form, comprising: (a) a first dosage unit comprising a first drug dose that is released substantially immediately following oral administration of the dosage form to a patient; (b) a second dosage unit comprising a second drug dose that is released approximately 3 to 7 hours following administration of the dosage form to a patient.
  • a first dosage unit comprising a first drug dose that is released substantially immediately following oral administration of the dosage form to a patient
  • a second dosage unit comprising a second drug dose that is released approximately 3 to 7 hours following administration of the dosage form to a patient.
  • the coating is a coating that is insoluble at pH 1 to 2 and soluble at pH greater than 5.5.
  • the pulsatile release capsule comprises by weight 30 to 50% of the first drug dose and 50 to 70% of the second drug dose.
  • This pulsatile release capsule may contain a plurality of beads in which some beads are immediate release beads and other beads are formulated, for example with the use of a coating, for modified release, typically 3 to 10 hours after administration.
  • the pulsatile release capsule contains a plurality of beads formulated for modified release and drug powder, for example spray granulated drug, for immediate release.
  • the particles disclosed above can be prepared according to any of the methods disclosed herein or by the methods described in U.S. Pat. Nos. 6,375,986; 6,428,814; 6,432,381; 6,592,903; 6,908,626; or 6,969,529; the disclosures of which are hereby incorporated by reference.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising particles comprising (i) drug thereof, (ii) a polymer selected from the group consisting of polyvinylpyrrolidone, polysaccharides, copolymers of vinyl acetate and vinyl pyrrolidone, polyvinyl alcohol, copolymers of vinyl acetate and vinyl alcohol, carboxyalkylcelluloses, cellulosic polymers and mixtures thereof, and (iii) a material selected from the group consisting of sodium lauryl sulfate and dioctyl sodium sulfosuccinate (DOSS) and (iv) an ionic dispersion modulator and (v) a water soluble spacer, wherein the D50 of the particles by weight have an effective particle size of less than about 500 nm (or any effective particle size, range, or any other characteristic as disclosed herein), wherein the composition comprises (a) an immediate release component comprising a first portion of the particles and providing an immediate release of the
  • the spray layered drug particles or spray layered drug complex particles present in drug formulations is coated.
  • Drug particles can be with a modified release coating, such as an enteric coating using cellulose acetate phthalate or copolymers of methacrylic acid and methylmethacrylate.
  • the enteric coating may be present in an amount of about 0.5 to 15 wt %, more specifically, about 8 to 12 wt %, based on the weight of the spray layered particles.
  • the spray layered drug particles or spray layered drug complex particles coated with the enteric coatings can be filled in a modified release capsule in which both enteric coated and immediate release drug beads are filled into a soft gelatin capsule. Additional suitable excipients may also be filled with the coated particles in the capsule.
  • mixtures of spray layered drug particles or spray layered drug complex particles coated with the enteric coatings and those without the enteric coatings at appropriate ratios may be encapsulated in a suitable immediate release capsule.
  • the uncoated particles release drug immediately upon administration while the coated particles do not release drug until these particles reach intestine.
  • desirable pulsatile release profiles may be obtained.
  • the ratios between the uncoated and the coated particles are 20/80, or 30/70, or 40/60, or 50/50, w/w to obtain desirable release.
  • the spray dried drug complex particles or spray layered drug complex particles described above can be compressed into tablets with commonly used pharmaceutical excipients.
  • Any appropriate apparatus for forming the coating can be used to make the enteric coated tablets, e.g., fluidized bed coating using a wurster column, powder layering in coating pans or rotary coaters; dry coating by double compression technique; tablet coating by film coating technique, and the like. See, e.g., U.S. Pat. No. 5,322,655 ; Remington's Pharmaceutical Sciences Handbook : Chapter 90 “Coating of Pharmaceutical Dosage Forms”, 1990.
  • the spray dried drug complex particles or spray layered drug complex particles described above and one or more excipients are dry blended and compressed into a mass, such as a tablet, having a hardness sufficient to provide a pharmaceutical composition that substantially disintegrates within less than about 30 minutes, less than about 35 minutes, less than about 40 minutes, less than about 45 minutes, less than about 50 minutes, less than about 55 minutes, or less than about 60 minutes, after oral administration, thereby releasing the drug formulation into the gastrointestinal fluid.
  • the spray dried drug complex particles or spray layered drug complex particles with enteric coatings described above and one or more excipients are dry blended and compressed into a mass, such as a tablet.
  • the enteric coated particles in the tablet substantially avoids release of drug, for example less than 15 wt %, in the stomach but releases substantially all drug (enterically coated), for example, greater than 80 wt %, in the intestine.
  • a pulsatile release drug formulation comprises a first dosage unit comprising a formulation made from drug containing granules made from a spray drying or spray granulated procedure or a formulation made from drug complex containing granules made from a spray drying or spray granulated procedure without enteric coatings and a second dosage unit comprising spray dried drug complex particles or spray layered drug complex particles with enteric coatings.
  • the first dosage unit and the second dosage unit are wet or dry blended and compressed into a mass to make a pulsatile release tablet.
  • the weight ratio between the uncoated particles and the coated particles is about ⁇ 1:4 to 4:1.
  • binding, lubricating and disintegrating agents are blended (wet or dry) to the spray dried drug complex or drug complex spray layered beads to make a compressible blend.
  • the first and the second dosage units are compressed separately and then compressed together to form a bilayer tablet.
  • the first dosage unit is in the form of an overcoat and completely covers the second dosage unit.
  • dosage forms may include microencapsulated drug formulations.
  • one or more other compatible materials are present in the microencapsulation material.
  • Exemplary materials include, but are not limited to, complexing agents, ionic dispersion modulators, pH modifiers, erosion facilitators, anti-foaming agents, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
  • Materials useful for the microencapsulation described herein include materials compatible with drug which sufficiently isolate drug from other non-compatible excipients.
  • Materials compatible with drug of the present invention are those that delay the release of the drug in vivo.
  • Exemplary microencapsulation materials useful for delaying the release of the formulations comprising drug include, but are not limited to, hydroxypropyl cellulose ethers (HPC) such as Klucel® or Nisso HPC, low-substituted hydroxypropyl cellulose ethers (L-HPC), hydroxypropyl methyl cellulose ethers (HPMC) such as Seppifilm-LC, Pharmacoat®, Metolose SR, Methocel®-E, Opadry YS, PrimaFlo, Benecel MP824, and Benecel MP843, methylcellulose polymers such as Methocel®-A, hydroxypropylmethylcellulose acetate stearate Aqoat (HF-LS, HF-LG, HF-MS) and Metolose®, Ethylcelluloses (EC) and mixtures thereof such as E461, Ethocel®, Aqualon®-EC, Surelease®, Polyvinyl alcohol (PVA) such as Opadry AMB, hydroxyeth
  • plasticizers such as polyethylene glycols, e.g., PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, and triacetin are incorporated into the microencapsulation material.
  • the microencapsulating material useful for delaying the release of the pharmaceutical compositions is from the USP or the National Formulary (NF).
  • the microencapsulation material is Klucel.
  • the microencapsulation material is methocel.
  • Microencapsulated drug may be formulated by methods known by one of ordinary skill in the art. Such known methods include, e.g., spray drying processes, spinning disk-solvent processes, hot melt processes, spray chilling methods, spray granulation via fluidized bed, electrostatic deposition, centrifugal extrusion, rotational suspension separation, polymerization at liquid-gas or solid-gas interface, pressure extrusion, or spraying solvent extraction bath.
  • spray drying processes spinning disk-solvent processes
  • hot melt processes hot melt processes
  • spray chilling methods spray granulation via fluidized bed
  • electrostatic deposition centrifugal extrusion
  • rotational suspension separation polymerization at liquid-gas or solid-gas interface
  • pressure extrusion or spraying solvent extraction bath.
  • several chemical techniques e.g., complex coacervation, solvent evaporation, polymer-polymer incompatibility, interfacial polymerization in liquid media, in situ polymerization, in-liquid drying, and desolvation in liquid media could also be used.
  • other methods
  • the spinning disk method allows for: 1) an increased production rate due to higher feed rates and use of higher solids loading in feed solution, 2) the production of more spherical particles, 3) the production of a more even coating, and 4) limited clogging of the spray nozzle during the process.
  • Spray granulation via a fluid bed is often more readily available for scale-up.
  • the material used in the spray-granulation encapsulation process is emulsified or dispersed into the core material in a concentrated form, e.g., 10-60% solids.
  • the microencapsulation material is, in one embodiment, emulsified until about 1 to 3 ⁇ m droplets are obtained.
  • the emulsion is fed as droplets into the heated chamber of the spray granulator.
  • the droplets are sprayed into the chamber or spun off a rotating disk.
  • the microspheres are then dried in the heated chamber and fall to the bottom of the chamber where they are harvested.
  • Roller compaction which involves dry granulation of single powder or a blended mixture of powders by the use of pressure to form dense compacts (the compacts are subsequently milled to a desired particle size), provides another alternative. It is a simple process that is readily available for use, and does not involve the use of solvents for granulation. Thus, roller compaction eliminates the exposure of sensitive active pharmaceutical ingredients to moisture and drying. Roller compaction can also provide some enhanced stability and taste-masking characteristics to active pharmaceutical by diluting and isolating such components in a granulated matrix of compatible ingredients. Roller compaction also imparts increased density and flow to the powder.
  • Extrusion/spheronization is another method that involves wet massing of active pharmaceutical ingredients, followed by the extrusion of the wet mass through a perforated plate to produce short cylindrical rods. These rods are subsequently placed into a rapidly rotating spheronizer to shape the cylindrical rods into uniform spheres. The spheres are subsequently dried using a fluid bed drier and then coated with a functional coating using a fluid bed equipped with a Wurster insert and spray nozzle.
  • Coacervation involves microencapsulation of materials such as active pharmaceutical ingredients and involves a three part process of particle or droplet formation, coacerate wall formation, and capsule isolation. This method can produce very small particle size microcapsules (10-70 microns).
  • the drug particles are microencapsulated prior to being formulated into one of the above forms.
  • some or most of the drug particles are coated prior to being further formulated by using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000).
  • the solid dosage drug formulations are plasticized (coated) with one or more layers.
  • a plasticizer is generally a high boiling point solid or liquid. Suitable plasticizers can be added from about 0.01% to about 50% by weight (w/w) of the coating composition.
  • Plasticizers include, but are not limited to, diethyl phthalate, citrate esters, polyethylene glycol, glycerol, acetylated glycerides, triacetin, polypropylene glycol, polyethylene glycol, triethyl citrate, dibutyl sebacate, stearic acid, stearol, stearate, and castor oil.
  • a powder comprising the drug formulations described herein may be formulated to comprise one or more pharmaceutical excipients and flavors.
  • Such a powder may be prepared, for example, by mixing the drug formulation and optional pharmaceutical excipients to form a bulk blend composition. Additional embodiments also comprise a suspending agent and/or a wetting agent.
  • This bulk blend is uniformly subdivided into unit dosage packaging or multi-dosage packaging units.
  • the term “uniform” means the homogeneity of the bulk blend is substantially maintained during the packaging process.
  • at least about 75% to about 85% of the drug has an effective particle size by weight of less than 500 nm to about 100 nm.
  • the drug comprises at least 90% drug particles having an effective particle size by weight of less than 500 nm to about 100 nm.
  • effervescent powders are also prepared in accordance with the present invention.
  • Effervescent salts have been used to disperse medicines in water for oral administration.
  • Effervescent salts are granules or coarse powders containing a medicinal agent in a dry mixture, usually composed of sodium bicarbonate, citric acid and/or tartaric acid.
  • the acids and the base react to liberate carbon dioxide gas, thereby causing “effervescence.”
  • Examples of effervescent salts include, e.g: sodium bicarbonate or a mixture of sodium bicarbonate and sodium carbonate, citric acid and/or tartaric acid. Any acid-base combination that results in the liberation of carbon dioxide can be used in place of the combination of sodium bicarbonate and citric and tartaric acids, as long as the ingredients were suitable for pharmaceutical use and result in a pH of about 6.0 or higher.
  • the method of preparation of the effervescent granules of the present invention employs three basic processes: wet granulation, dry granulation and fusion.
  • the fusion method is used for the preparation of most commercial effervescent powders. It should be noted that, although these methods are intended for the preparation of granules, the formulations of effervescent salts of the present invention could also be prepared as tablets, according to known technology for tablet preparation.
  • wet granulation is one of the oldest methods of granule preparation.
  • the individual steps in the wet granulation process of tablet preparation include milling and sieving of the ingredients, dry powder mixing, wet massing, granulation, drying and final grinding.
  • the drug composition is added to the other excipients of the pharmaceutical formulation after they have been wet granulated.
  • Dry granulation involves compressing a powder mixture into a rough tablet or “slug” on a heavy-duty rotary tablet press. The slugs are then broken up into granular particles by a grinding operation, usually by passage through an oscillation granulator. The individual steps include mixing of the powders, compressing (slugging) and grinding (slug reduction or granulation). No wet binder or moisture is involved in any of the steps.
  • the drug formulation is dry granulated with other excipients in the pharmaceutical formulation. In other embodiments, the drug formulation is added to other excipients of the pharmaceutical formulation after they have been dry granulated.
  • the drug formulations described herein are solid dispersions. Methods of producing such solid dispersions are known in the art and include, but are not limited to, for example, U.S. Pat. Nos. 4,343,789, 5,340,591, 5,456,923, 5,700,485, 5,723,269, and U.S. Pub. Appl 2004/0013734, each of which is specifically incorporated by reference.
  • the solid dispersions of the invention comprise both amorphous and non-amorphous drug and can have enhanced bioavailability as compared to conventional drug formulations.
  • the drug formulations described herein are solid solutions.
  • Solid solutions incorporate a substance together with the active agent and other excipients such that heating the mixture results in dissolution of the drug and the resulting composition is then cooled to provide a solid blend which can be further formulated or directly added to a capsule or compressed into a tablet.
  • Methods of producing such solid solutions are known in the art and include, but are not limited to, for example, U.S. Pat. Nos. 4,151,273, 5,281,420, and 6,083,518, each of which is specifically incorporated by reference.
  • the pharmaceutical solid oral dosage forms comprising the drug formulations described herein can be immediate release, or can be further formulated to provide a modified or controlled release of drug.
  • the controlled release component provides a release selected from the group consisting of sustained release or delayed release.
  • the controlled release component comprises a coating comprising a hydrophobic material, coated on the second portion of particles.
  • the controlled release component comprises a matrix comprising the second portion of particles dispersed in a hydrophobic material.
  • the immediate release component and the controlled release component are independently selected from the group consisting of a tablet, a pill, multiparticulates, a powder, a capsule, a solid dispersion, a solid solution, a pellet, or a granule.
  • the hydrophobic material is selected from the group consisting of an acrylic polymer, a cellulosic polymer, shellac, zein, fatty alcohols, hydrogenated fats, fatty acid esters, fatty acid glycerides, hydrocarbons, waxes, stearic acid, stearyl alcohol, and mixtures thereof.
  • the hydrophobic material is an enteric polymer.
  • the enteric polymer is selected from the group consisting of shellac, acrylic polymers, cellulose derivatives, polyvinyl acetate phthalate and mixtures thereof.
  • the delayed release component provides a dose of the drug or pharmaceutically acceptable salt thereof delayed by from about 2 hours to about 12 hours after administration.
  • the delayed release component provides a dose of the drug or pharmaceutically acceptable salt thereof delayed by from about 2 hours to about 8 hours after administration.
  • the delayed component provides a dose of the drug or pharmaceutically acceptable salt thereof delayed by from about 3 hours to about 7 hours after administration.
  • the controlled release component provides a sustained release of the drug or pharmaceutically acceptable salt thereof for about 2 hours to about 6 hours after administration.
  • the controlled release component provides a sustained release of the drug or pharmaceutically acceptable salt thereof for about 3 hours to about 10 hours after administration.
  • the coating further comprises a plasticizer, a colorant, a detackifier, a surfactant, an anti-foaming agent, a lubricant or a mixture thereof.
  • the immediate release component and the controlled release component independently comprise one or more pharmaceutically acceptable additives from the group consisting of carriers, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combinations thereof.
  • pharmaceutically acceptable additives from the group consisting of carriers, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combinations thereof.
  • the pharmaceutical dosage forms disclosed herein having an immediate release component and a controlled release component in this section (XIII) can provide any pharmacokinetic profile as disclosed herein.
  • the solid dosage forms described herein can be formulated as a delay release dosage form such as enteric coated delayed release oral dosage forms, i.e., as an oral dosage form of a pharmaceutical composition as described herein which utilizes an enteric coating to affect release in the small intestine of the gastrointestinal tract.
  • enteric coated dosage form may be a compressed or molded or extruded tablet/mold (coated or uncoated) containing granules, powder, pellets, beads or particles of the active ingredient and/or other composition components, which are themselves coated or uncoated.
  • the enteric coated oral dosage form may also be a capsule (coated or uncoated) containing pellets, beads or granules of the solid carrier or the composition, which are themselves coated or uncoated. Enteric coatings may also be used to prepare other controlled release dosage forms including extended release and pulsatile release dosage forms.
  • an “enterically coated” formulation of drug is intended to mean that some or most of the drug has been enterically coated to ensure that at least some of the drug is released after entering the small intestine, rather than the acidic environment of the stomach. In some embodiments, about 40% to about 60% of the coated drug particles are released in the middle region of the small intestine to minimize interaction with bile acids and minimize food effects. In some embodiments, the enterically coated formulations provide the release of greater than 80% of drug in the small intestine.
  • the enteric coating material should be non-toxic and is predominantly soluble in the intestinal fluid, but substantially insoluble in the gastric fluids.
  • examples include polyvinyl acetate phthalate (PVAP), commercially available under trade names of Opadry® Enteric or Acryl-eze MP from Colorcon®, hydroxypropylmethylcellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), methacrylic acid copolymer, hydroxypropylmethylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, hydroxypropylmethylcellulose hexahydrophthalate, hydroxypropylmethylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate trimellitate, cellulose acetate butyrate, cellulose acetate propionate, methacrylic acid/methacrylate polymer, methacrylic acid-methyl methacrylate copolymer, ethyl me
  • enteric polymers include synthetic resin bearing carboxyl groups.
  • the methacrylic acid: acrylic acid ethyl ester copolymers are commercially available under the trade names of “Eudragit® L”, such as Eudragit® L 30-D55 from Degussa.
  • Enteric coatings should be applied to a sufficient thickness such that the entire coating does not appreciably dissolve in the gastrointestinal fluids at pH below about 5 after 1 hour, but does dissolve at pH about 5 and above. It is expected that any anionic polymer exhibiting a pH-dependent solubility profile can be used as an enteric coating in the practice of the present invention to achieve delivery to the lower gastrointestinal tract.
  • the polymers for use in the present invention are anionic carboxylic polymers.
  • the polymers and compatible mixtures thereof, and some of their properties include, but are not limited to: Shellac—also called purified shellac, a refined product obtained from the resinous secretion of an insect.
  • Acrylic polymers The performance of acrylic polymers (primarily their solubility in biological fluids) can vary based on the degree and type of substitution. Examples of suitable acrylic polymers include methacrylic acid copolymers and ammonia methacrylate copolymers.
  • the Eudragit series E, L, S, RL, RS and NE are available as solubilized in organic solvent, aqueous dispersion, or dry powders.
  • the Eudragit series RL, NE, and RS are insoluble in the gastrointestinal tract but are permeable and are used primarily for colonic targeting.
  • the Eudragit series E dissolve in the stomach.
  • the Eudragit series L, L-30D and S are insoluble in stomach and dissolve in the intestine; Opadry Enteric are also insoluble in stomach and dissolve in the intestine;
  • Cellulose Derivatives Examples of suitable cellulose derivatives are: ethyl cellulose; reaction mixtures of partial acetate esters of cellulose with phthalic anhydride. The performance can vary based on the degree and type of substitution.
  • Cellulose acetate phthalate (CAP) dissolves in pH>6.
  • Aquateric (FMC) is an aqueous based system and is a spray dried CAP psuedolatex with particles ⁇ 1 ⁇ m.
  • Aquateric can include pluronics, Tweens, and acetylated monoglycerides.
  • suitable cellulose derivatives include: cellulose acetate trimellitate (Eastman); methylcellulose (Pharmacoat, Methocel); hydroxypropylmethyl cellulose phthalate (HPMCP); hydroxypropylmethyl cellulose succinate (HPMCS); and hydroxypropylmethylcellulose acetate succinate (e.g., AQOAT (Shin Etsu)).
  • HPMCP such as, HP-50, HP-55, HP-55S, HP-55F grades are suitable.
  • the performance can vary based on the degree and type of substitution.
  • suitable grades of hydroxypropylmethylcellulose acetate succinate include, but are not limited to, AS-LG (LF), which dissolves at pH 5, AS-MG (MF), which dissolves at pH 5.5, and AS-HG (HF), which dissolves at higher pH.
  • AS-LG LF
  • AS-MG MF
  • AS-HG HF
  • PVAP PolyVinyl Acetate Phthalate
  • the coating can, and usually does, contain a plasticizer and possibly other coating excipients such as colorants, talc, and/or magnesium stearate, which are well known in the art.
  • Suitable plasticizers include triethyl citrate (Citroflex 2), triacetin (glyceryl triacetate), acetyl triethyl citrate (Citroflec A2), Carbowax 400 (polyethylene glycol 400), diethyl phthalate, tributyl citrate, acetylated monoglycerides, glycerol, fatty acid esters, propylene glycol, and dibutyl phthalate.
  • anionic carboxylic acrylic polymers usually will contain 10-25% by weight of a plasticizer, especially dibutyl phthalate, polyethylene glycol, triethyl citrate and triacetin.
  • a plasticizer especially dibutyl phthalate, polyethylene glycol, triethyl citrate and triacetin.
  • Conventional coating techniques such as spray or pan coating are employed to apply coatings. The coating thickness must be sufficient to ensure that the oral dosage form remains intact until the desired site of topical delivery in the intestinal tract is reached.
  • the drug formulations described herein are delivered using a pulsatile dosage form.
  • a first dose of the drug is released followed by a second dose of the drug released approximately 3 to 7 hours following administration of the dosage form.
  • such pulsatile dosage forms may comprise: (a) a first dosage unit comprising a first dose of drug that is released substantially immediately following oral administration of the dosage form to a patient; (b) a second dosage unit comprising a second dose of drug that is released approximately 3 to 7 hours following administration of the dosage form to a patient.
  • Pulsatile dosage forms comprising the drug formulations described herein may be administered using a variety of formulations known in the art.
  • the controlled release dosage form is pulsatile release solid oral dosage form comprising at least two groups of particles, each containing the drug formulation described herein. The first group of particles provides a substantially immediate dose of drug upon ingestion by a subject.
  • the first group of particles can be either uncoated or comprise a coating and/or sealant.
  • the second group of particles comprises coated particles, which comprise from about 2% to about 75%, preferably from about 2.5% to about 70%, and more preferably from about 40% to about 70%, by weight of the total dose of the drug in said formulation, in admixture with one or more binders.
  • the coating comprises a pharmaceutically acceptable ingredient in an amount sufficient to provide a delay of from about 2 hours to about 7 hours following ingestion before release of the second dose.
  • Suitable coatings include one or more differentially degradable coatings such as, by way of example only, pH sensitive coatings (enteric coatings) such as acrylic resins (e.g., Eudragit® EPO, Eudragit® L30D-55, Eudragit® FS 30D Eudragit® L100-55, Eudragit® L100, Eudragit® S100, Eudragit® RD100, Eudragit® E100, Eudragit® L12.5, Eudragit® S12.5, and Eudragit® NE30D, Eudragit® NE 40D®) either alone or blended with cellulose derivatives, e.g., ethylcellulose, or non-enteric coatings having variable thickness to provide differential release of the drug formulation.
  • enteric coatings such as acrylic resins (e.g., Eudragit® EPO, Eudragit® L30D-55, Eudragit® FS 30D Eudragit® L100-55, Eudragit® L100, Eudragit® S100, Eudragit®
  • controlled release systems include, e.g., polymer-based systems, such as polylactic and polyglycolic acid, polyanhydrides and polycaprolactone; porous matrices, nonpolymer-based systems that are lipids, including sterols, such as cholesterol, cholesterol esters and fatty acids, or neutral fats, such as mono-, di- and triglycerides; hydrogel release systems; silastic systems; peptide-based systems; wax coatings, bioerodible dosage forms, compressed tablets using conventional binders and the like.
  • polymer-based systems such as polylactic and polyglycolic acid, polyanhydrides and polycaprolactone
  • porous matrices nonpolymer-based systems that are lipids, including sterols, such as cholesterol, cholesterol esters and fatty acids, or neutral fats, such as mono-, di- and triglycerides
  • hydrogel release systems silastic systems
  • peptide-based systems wax coatings, bioerodible dosage forms, compressed
  • a modified release dosage formulation may comprise a combination of: (a) a compressed tablet core comprising complexed drug particles, a surface stabilizer, an ionic dispersion modifier, a water soluble spacer, a pharmaceutically acceptable water swellable polymer, and an osmotic agent; and (b) an outer coating layer which completely covers the tablet core and comprises a pH sensitive coating.
  • An optional sealing coat may be applied to the compressed tablet core and an optional coating layer comprising an enteric coating agent may be applied under the outer coating layer as an inner coating or as an overcoat over the outer coating layer.
  • the tablet core may be compressed using a smooth faced tablet die.
  • the active agent is drug.
  • the osmotic agent in this dosage form is any non-toxic pharmaceutically acceptable water soluble compound which will dissolve sufficiently in water and increase the osmotic pressure inside the tablet core.
  • Suitable osmotic agents include simple sugars and salts such as sodium chloride, potassium chloride, magnesium sulfate, magnesium sulfate, magnesium chloride, sodium sulfate, lithium sulfate, urea, inositol, sucrose, lactose, glucose, sorbitol, fructose, mannitol, dextrose, magnesium succinate, potassium acid phosphate and the like.
  • the preferred osmotic agent for the tablet core is a simple sugar such as anhydrous lactose in the range of 0-50% by weight, based on the weight of the compressed, uncoated tablet.
  • the water swellable polymer may be any pharmaceutically acceptable polymer which swells and expands in the presence of water to slowly release drug. These polymers include polyethylene oxide, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and the like.
  • the water swellable polymer will be polyethylene oxide (obtained from Union Carbide Corporation under the trade name Polyox WSR Coagulant or Polyox WSR N 80). These materials form a viscous gel in water or other solvent system at a sufficient concentration to control the release of the drug. This will generally require a concentration of the pharmaceutically acceptable, water swellable polymer of about 0-50% by weight of the compressed, uncoated tablet.
  • the outer coating comprises a pH sensitive coating which functions as an enteric polymer in that it does not begin to dissolve until pH conditions in excess of the pH of the stomach region are encountered.
  • the pH sensitive coating is the same type of material that is described above.
  • the pH sensitive coating may be present in an amount of about 0.5-15 wt %, more specifically, about 8-12 wt %, based on the weight of the coated tablet core.
  • Certain controlled release formulation may release less than about 20 wt % of drug in the formulation within the first three hours after administration and more than about 60 percent of drug between 3 and 10 hours.
  • Other controlled release drug formulation may release less than about 50 percent within the first three hours after administration and about 50 percent of drug between 3 and 10 hours.
  • Colorants, detackifiers, surfactants, antifoaming agents, lubricants may be added to the coatings besides plasticizers to solubilize or disperse the coating material, and to improve coating performance and the coated product.
  • a particularly suitable methacrylic copolymer is Eudragit L®, particularly L-30D® and Eudragit 100-55®, manufactured by Rohm Pharma, Germany.
  • Eudragit L-30D® the ratio of free carboxyl groups to ester groups is approximately 1:1.
  • the copolymer is known to be insoluble in gastrointestinal fluids having pH below 5.5, generally 1.5-5.5, i.e., the pH generally present in the fluid of the upper gastrointestinal tract, but readily soluble or partially soluble at pH above 5.5, i.e., the pH values present in the small intestine.
  • materials include shellac, acrylic polymers, cellulosic derivatives, polyvinyl acetate phthalate, and mixtures thereof.
  • materials include Eudragit® series E, L, RL, RS, NE, L, L300, S, 100-55, cellulose acetate phthalate, Aquateric, cellulose acetate trimellitate, ethyl cellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, and Cotteric.
  • the invention is directed to an oral solid dosage form comprising (i) a controlled release component comprising a first portion of particles comprising drug; and a controlled release material, and (ii) an immediate release component comprising a second portion of particles comprising drug, the first and second portion of drug particles having a volume weighted median diameter (D50) of from about 50 nm to about 1000 nm, from about 100 nm to about 450 nm, or from about 100 nm to about 350 nm.
  • D50 volume weighted median diameter
  • the ratio of drug in controlled release to immediate release can be, e.g., from about 4:1 to about 1:4, from about 3:2 to about 2:3, or about 1:1.
  • the controlled release component can be in any form, including but not limited to (i) a plurality of pharmaceutically acceptable beads coated with the first portion of drug particles and overcoated with the controlled release material (optionally a film coat comprising a material such as hydroxypropylmethylcellulose or polyvinyl alcohol can be included on the beads prior to coating with the drug particles), (ii) a plurality of matrices comprising the first portion of drug particles dispersed in the controlled release material, (iii) a tablet comprising the first portion of drug particles dispersed in the controlled release material, or (iv) a granulation comprising the first portion of drug particles and the controlled release material.
  • the immediate release component can be in any form, including but not limited to (i) plurality of pharmaceutically acceptable beads coated with the second portion of drug particles, (ii) a plurality of matrices comprising the second portion of drug particles dispersed in an excipient, (iii) a tablet comprising the second portion of drug particles dispersed in excipient, or (v) a granulation comprising the second portion of drug particles and excipient.
  • the immediate release component can be included in the dosage form in powder form.
  • the controlled release component and the immediate release component are contained in a capsule.
  • the controlled release component is a tablet and the immediate release component is coated onto the tablet.
  • controlled release component and the immediate release component are in a bi-layer tablet.
  • the controlled release component comprises a plurality of pharmaceutically acceptable beads coated with the first portion of drug particles and overcoated with the controlled release material and the immediate release component comprises a plurality of pharmaceutically acceptable beads coated with the second portion of drug particles, the controlled release component and immediate release component contained in a capsule.
  • the controlled release component comprises a plurality of pharmaceutically acceptable beads coated with the first portion of drug particles and overcoated with the controlled release material and the immediate release component comprises a tablet comprising the second portion of drug particles dispersed in an excipient, the controlled release component and immediate release component contained in a capsule.
  • controlled release component comprises a plurality of pharmaceutically acceptable beads coated with the first portion of drug particles and overcoated with the controlled release material and the immediate release component comprises a granulation comprising the second portion of drug particles and an excipient, the controlled release component and immediate release component contained in a capsule.
  • the controlled release component comprises a plurality of pharmaceutically acceptable beads coated with the first portion of drug particles and overcoated with the controlled release material
  • the immediate release component comprises a granulation comprising the second portion of drug particles and an excipient, the controlled release component dispersed in the immediate release component in the form of a compressed tablet.
  • the controlled release component comprises a compressed tablet and the immediate release component is compression coated over the controlled release tablet.
  • controlled release material can be coated onto the drug layered bead in an amount, e.g., from about 3% to about 25%, or from about 10% to about 20%, based on the total weight of the component.
  • the dosage forms of the present invention provide pulsatile release of two or more doses of drug.
  • the dosage form can provide an immediate release dose after administration and at least one additional dose at a time after administration selected from the group consisting of 3-8 hours, 6-10 hours, 10-14 hours, 14-18 hours, 16-20 hours and 22-24 hours.
  • the invention is directed to an oral solid dosage form comprising drug particles and a controlled release material, the drug particles having a volume weighted median diameter (D50) of from about 50 nm to about 1000 nm, the dosage form providing a controlled release of the drug to provide a therapeutic effect for about 8 to about 24 hours after administration.
  • D50 volume weighted median diameter
  • the invention is directed to an oral solid dosage form comprising particles comprising drug; and a pH dependent polymer, the drug particles having a volume weighted median diameter (D50) from about 50 nm to about 1000 nm, the dosage form providing a delayed release of the drug for a time period from about 2 to about 12 hours after administration.
  • D50 volume weighted median diameter
  • the dosage forms can be prepared according to any of the methods disclosed herein or by the methods described in U.S. Pat. Nos. 5,209,746; 5,213,808; 5,221,278; 5,260,068; 5,260,069; 5,308,348; 5,312,390; 5,318,588; 5,340,590; 5,391,381; 5,456,679; 5,472,708; 5,508,040; 5,840,329; 5,980,508; 6,214,379; 6,228,398; 6,248,363; 6,514,518; 6,569,463; 6,607,751; 6,627,223; 6,730,325; 6,793,936; 6,902,742 and 6,923,988, the disclosures of which are hereby incorporated by reference.
  • pharmaceutical drug formulations comprising the drug particles described herein and at least one dispersing agent or suspending agent for oral administration to a subject.
  • the drug formulation may be a powder and/or granules for suspension, and upon admixture with water, a substantially uniform suspension is obtained.
  • the aqueous dispersion can comprise amorphous and non-amorphous drug particles of consisting of multiple effective particle sizes such that drug particles having a smaller effective particle size are absorbed more quickly and drug particles having a larger effective particle size are absorbed more slowly.
  • the aqueous dispersion or suspension is an immediate release formulation.
  • an aqueous dispersion comprising amorphous drug particles is formulated such that about 50% of the drug particles are absorbed within about 3 hours after administration and about 90% of the drug particles are absorbed within about 10 hours after administration.
  • addition of a complexing agent to the aqueous dispersion results in a larger span of drug containing particles to extend the drug absorption phase such that 50-80% of the particles are absorbed in the first 3 hours and about 90% are absorbed by about 10 hours.
  • a suspension is “substantially uniform” when it is mostly homogenous, that is, when the suspension is composed of approximately the same concentration of drug at any point throughout the suspension.
  • Preferred embodiments are those that provide concentrations essentially the same (within 15%) when measured at various points in a drug aqueous oral formulation after shaking.
  • aqueous suspensions and dispersions which maintain homogeneity (up to 15% variation) when measured 2 hours after shaking. The homogeneity should be determined by a sampling method consistent with regard to determining homogeneity of the entire composition.
  • an aqueous suspension can be re-suspended into a homogenous suspension by physical agitation lasting less than 1 minute.
  • an aqueous suspension can be re-suspended into a homogenous suspension by physical agitation lasting less than 45 seconds. In yet another embodiment, an aqueous suspension can be re-suspended into a homogenous suspension by physical agitation lasting less than 30 seconds. In still another embodiment, no agitation is necessary to maintain a homogeneous aqueous dispersion.
  • the drug powders for aqueous dispersion described herein comprise size stabilized drug particles having an effective particle size by weight of less than 500 nm formulated with drug particles having an effective particle size by weight of greater than 500 nm.
  • the formulations have a particle size distribution wherein about 10% to about 100% of the drug particles by weight are between about 75 nm and about 500 nm, about 0% to about 90% of the drug particles by weight are between about 150 nm and about 400 nm, and about 0% to about 30% of the drug particles by weight are greater than about 600 nm.
  • the drug particles described herein can be amorphous, semi-amorphous, crystalline, semi-crystalline, or mixture thereof.
  • the aqueous suspensions or dispersions described herein comprise drug particles or drug complex at a concentration of about 20 mg/ml to about 150 mg/ml of suspension. In another embodiment, the aqueous oral dispersions described herein comprise drug particles or drug complex particles at a concentration of about 25 mg/ml to about 75 mg/ml of solution. In yet another embodiment, the aqueous oral dispersions described herein comprise drug particles or drug complex at a concentration of about 50 mg/ml of suspension.
  • the aqueous dispersions described herein are especially beneficial for the administration of drug to infants (less than 2 years old), children under 10 years of age and any patient group that is unable to swallow or ingest solid oral dosage forms.
  • Liquid drug formulation dosage forms for oral administration can be aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2 nd Ed., pp. 754-757 (2002).
  • the liquid dosage forms may comprise additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, (g) at least one flavoring agent, and (h) a complexing agent.
  • the aqueous dispersions can further comprise a crystalline inhibitor.
  • Dispersing/suspending agents and/or viscosity modulating agents include materials that control the diffusion and homogeneity of a drug through liquid media or a granulation method or blend method. In some embodiments, these agents also facilitate the effectiveness of a coating or eroding matrix. Viscosity enhancing agents are agents which are typically added to a particulate dispersion to increase the viscosity and prevent or slow settling of the particles. Viscosity enhancing agents in solid dosage forms are used on occasion to form a gel matrix as water permeates the solid dosage form and can delay the release of the pharmaceutically active ingredient(s).
  • the dispersing agents suitable for the aqueous suspensions and dispersions described herein are known in the art and include, for example, hydrophilic polymers, electrolytes, Tween® 60 or 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and the carbohydrate-based dispersing agents such as, for example, hydroxypropylcellulose and hydroxypropylcellulose ethers (e.g., HPC, HPC-SL, and HPC-L), hydroxypropylmethylcellulose and hydroxypropylmethylcellulose ethers (e.g.
  • HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone/vinyl acetate copolymer (Plasdone®, e.g., S-630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, F88®, and F108®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer
  • the dispersing agent is selected from a group comprising one of the following agents: hydrophilic polymers; electrolytes; Tween® 60 or 80; PEG; polyvinylpyrrolidone (PVP); hydroxypropylcellulose and hydroxypropyl cellulose ethers (e.g., HPC, HPC-SL, and HPC-L); hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers (e.g.
  • Pluronics F68®, F88®, and F108® which are block copolymers of ethylene oxide and propylene oxide
  • poloxamines e.g
  • wetting agents suitable for the aqueous suspensions and dispersions described herein are known in the art and include, but are not limited to, acetyl alcohol, glycerol monostearate, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Specialty Chemicals)), and polyethylene glycols (e.g., Carbowaxs 3350® and 1450®, and Carpool 934® (Union Carbide)), oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, vitamin E TPGS, sodium taurocholate, si
  • preservatives for the aqueous suspensions or dispersions described herein include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben) and their salts, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride.
  • parabens e.g., methylparaben and propylparaben
  • benzoic acid and its salts include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben) and their salts, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or
  • the aqueous liquid dispersion can comprise methylparaben and propylparaben in a concentration ranging from about 0.01% to about 0.3% methylparaben by weight to the weight of the aqueous dispersion and 0.005% to 0.03% propylparaben by weight to the total aqueous dispersion weight.
  • the aqueous liquid dispersion can comprise methylparaben 0.05 to about 0.1 weight % and propylparaben from 0.01-0.02 weight % of the aqueous dispersion.
  • the aqueous liquid dispersion can comprise sodium benzoate 0.05 to about 0.1 weight % of the aqueous dispersion and pH adjusted from 3.5 to 5.0.
  • Suspensions or dispersions described herein include, but are not limited to, methyl cellulose, xanthan gum, carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, Plasdone® S-630, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof.
  • concentration of the viscosity enhancing agent will depend upon the agent selected and the viscosity desired.
  • natural and artificial sweetening agents suitable for the aqueous suspensions or dispersions described herein include, for example, acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana, Bavarian cream, berry, black currant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dextrose, eucalyptus, eugenol, fructose, fruit punch, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glyrrhizinate (MagnaSweet®), maltol, mannitol, maple, marshmallow, menthol, mint cream,
  • the aqueous liquid dispersion can comprise a sweetening agent or flavoring agent in a concentration ranging from about 0.0001% to about 10.0% the weight of the aqueous dispersion.
  • the aqueous liquid dispersion can comprise a sweetening agent or flavoring agent in a concentration ranging from about 0.0005% to about 5.0 wt % of the aqueous dispersion.
  • the aqueous liquid dispersion can comprise a sweetening agent or flavoring agent in a concentration ranging from about 0.0001% to 0.1 wt %, from about 0.001% to about 0.01 weight %, or from 0.0005% to 0.004% of the aqueous dispersion.
  • liquid drug formulations can also comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
  • the invention is directed to an oral liquid dosage form comprising from about 2.5% to about 5% size stabilized drug complex particles, from about 2% to about 5% hydroxypropylmethyl cellulose, about 0.5% to about 1.5% polyvinyl alcohol, from about 0.1% to about 0.3% sodium lauryl sulfate, from about 0.005% to about 0.02% simethicone, from about 0.01% to about 0.03% sucralose, from about 0.05% to about 0.1% methylparaben, from about 0.01% to about 0.02% propylparaben, from about 0.05 to about 0.1% sodium benzoate, from about 0.05% to about 0.15% citric acid, from about 0.005 to about 0.1% sodium citrate and from about 0.002% to about 0.004% flavoring, the liquid having a pH of about 3.8 to about 4.2, wherein all percentages are weight percent to the total liquid formulation weight.
  • the invention is directed to an oral liquid dosage form comprising size stabilized complexed drug particles and at least one pharmaceutically acceptable excipient, the particles suspended in a pharmaceutically acceptable liquid vehicle, wherein the volume weighted median diameter (D50) after a suitable curing time does not change by more than about 15% after 10 days storage at room temperature, by more than about 12% after 10 days storage at room temperature, by more than about 10% after 10 days storage at room temperature, by more than about 8% after 10 days storage at room temperature, by more than about 15% after 20 days of storage at room temperature, by more than about 15% after 40 days of storage at room temperature, by more than about 15% after 60 days of storage at room temperature, or by more than about 15% after 80 days of storage at room temperature.
  • the volume weighted median diameter (D50) of the size stabilized drug complex particles prior to storage is from about 100 nm to about 500 nm, or from about 100 nm to about 350 nm.
  • the invention is directed to an oral liquid dosage form wherein the volume weighted median diameter (D50) of the size stabilized drug complex particles do not change by more than about 15% when placed in a glass vial and heated in a 100° C. oil bath for 20 minutes, does not change by more than about 15% when placed in a glass vial and heated in a 100° C. oil bath for 4 hours, does not change by more than about 10% when placed in a glass vial and heated in a 100° C. oil bath for 20 minutes, does not change by more than about 5% when placed in a glass vial and heated in a 100° C. oil bath for 20 minutes, or does not change when placed in a glass vial and heated in a 100° C. oil bath for 20 minutes (within the accuracy of the particle size measurement procedure).
  • D50 volume weighted median diameter
  • the invention is directed to an oral liquid dosage form the volume weighted median diameter (D50) of the size stabilized drug complex particles does not change by more than about 25% when placed in a HDPE container and frozen and thawed three or more times with the time frozen for each cycle being at least 12 hours.
  • the frozen temperature can be any suitable freezing temperature, e.g., from about ⁇ 80° C. to about ⁇ 20° C.
  • the oral liquid dosage form is prepared by contacting drug particles with a complexing agent, wherein the size of the particles exhibits an increase in volume weighted median diameter (D50) of from about 20% to about 300% and reaching an endpoint such that the particles are size stabilized.
  • D50 volume weighted median diameter
  • the size stabilized drug complex particles are dispersed in a liquid to form a suspension and the suspension is spray coated onto the plurality of substrates, or spray granulated with the plurality of substrates.
  • the drug particles are dispersed in a liquid to form a suspension and the suspension is spray dried to form a powder which is then granulated and added to a capsule or granulated and compressed into a tablet.
  • the suspension can be, e.g., about 5% to about 35%, or about 15% to about 25% total solids.
  • the drug concentration in the solids can be, e.g., from about 20% to about 80%.
  • the liquid dosage form can include at least one excipient selected from hydroxypropylmethylcellulose, sodium lauryl sulfate, methyl anthranilate, sodium benzoate, citric acid, sodium citrate, simethicone, sucralose and flavoring.
  • the liquid dosage form can comprise about 5% drug, about 5% hydroxypropylmethylcellulose (2910), about 0.1% sodium lauryl sulfate, about 0.4% methylanthranilate about 0.1% sodium benzoate, about 0.12% citric acid, about 0.06% sodium citrate, about 0.01% simethicone, and 0.02% sucralose.
  • these ingredients and % amounts are not meant to be limiting.
  • the pharmaceutical drug formulations described herein can be self-emulsifying drug delivery systems (SEDDS).
  • SEDDS self-emulsifying drug delivery systems
  • Emulsions are dispersions of one immiscible phase in another, usually in the form of droplets.
  • emulsions are created by vigorous mechanical dispersion.
  • SEDDS as opposed to emulsions or microemulsions, spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation.
  • An advantage of SEDDS is that only gentle mixing is required to distribute the droplets throughout the solution. Additionally, water or the aqueous phase can be added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient.
  • the SEDDS provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients.
  • SEDDS may provide improvements in the bioavailability of hydrophobic active ingredients.
  • Methods of producing self-emulsifying dosage forms are known in the art include, but are not limited to, for example, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563, each of which is specifically incorporated by reference.
  • Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, sodium lauryl sulfate, sodium doccusate, cholesterol, cholesterol esters, taurocholic acid, phosphotidylcholine, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • Intranasal formulations are known in the art and are described in, for example, U.S. Pat. Nos. 4,476,116, 5,116,817 and 6,391,452, each of which is specifically incorporated by reference.
  • Drug formulations prepared according to these and other techniques well-known in the art are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, for example, Ansel, H. C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995).
  • these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients.
  • nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, complexing agents or buffering and other stabilizing and solubilizing agents may also be present.
  • the nasal dosage form should be isotonic with nasal secretions.
  • buccal formulations comprising the drug formulations described herein may be administered using a variety of formulations known in the art.
  • formulations include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136, each of which is specifically incorporated by reference.
  • the buccal dosage forms described herein can further comprise a bioerodible (hydrolyzable) polymeric carrier that may also serves to adhere the dosage form to the buccal mucosa.
  • the buccal dosage form is fabricated so as to erode gradually over a predetermined time period, wherein drug delivery is provided essentially throughout.
  • buccal drug delivery avoids the disadvantages encountered with oral drug administration, e.g., slow drug absorption, degradation of the active agent by fluids present in the gastrointestinal tract and/or first-pass inactivation in the liver.
  • bioerodible (hydrolysable) polymeric carrier it will be appreciated that virtually any such carrier can be used, so long as the desired drug release profile is not comprised, and the carrier is compatible with drug and any other components that may be present in the buccal dosage unit.
  • the polymeric carrier comprises hydrophilic (water-soluble and water-swellable) polymers that adhere to the wet surface of the buccal mucosa.
  • polymeric carriers useful herein include acrylic acid polymers e.g., those known as “carbomers” (Carbopol®, which may be obtained from B.F. Goodrich, is one such polymer).
  • Carbopol® which may be obtained from B.F. Goodrich, is one such polymer.
  • Other components may also be incorporated into the buccal dosage forms described herein include, but are not limited to, disintegrants, diluents, binders, lubricants, flavoring, colorants, preservatives, and the like.
  • Transdermal formulations described herein may be administered using a variety of devices which have been described in the art.
  • such devices include, but are not limited to, U.S. Pat. Nos. 3,598,122, 3,598,123, 3,710,795, 3,731,683, 3,742,951, 3,814,097, 3,921,636, 3,972,995, 3,993,072, 3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,069,307, 4,077,407, 4,201,211, 4,230,105, 4,292,299, 4,292,303, 5,336,168, 5,665,378, 5,837,280, 5,869,090, 6,923,983, 6,929,801 and 6,946,144, each of which is specifically incorporated by reference in its entirety.
  • the transdermal delivery device used with the drug formulations described herein can comprise a power source, radio frequency, or a brief electrical current to micro-electrodes in the skin creating “channels” or “pores” in the stratum corneum to facilitate the delivery of the drug formulation, such methods are known in the art and are described in, for example U.S. Pat. Nos. 6,611,706, 6,708,060, and 6,711,435, each of which is specifically incorporated by reference in its entirety.
  • the transdermal delivery device can comprise a means for porating the stratum corneum, e.g., micro-lancing, application of sonic energy, or hydraulic puncturing, to facilitate the delivery of the drug formulation, such methods are known in the art and are described in, for example, U.S. Pat. Nos. 6,142,939 and 6,527,716, each of which is specifically incorporated by reference in its entirety.
  • the pores described by the methods herein are typically about 20-50 microns in depth and do not extend into areas of innervation or vascularization.
  • transdermal dosage forms described herein may incorporate certain pharmaceutically acceptable excipients which are conventional in the art.
  • the transdermal formulations described herein comprise at least three components: (1) a drug complex formulation; (2) a penetration enhancer; and (3) an aqueous adjuvant.
  • transdermal formulations can include additional components such as, but not limited to, gelling agents, creams and ointment bases, and the like.
  • the transdermal formulation can further comprise a woven or non-woven backing material to enhance drug absorption and prevent the removal of the transdermal formulation from the skin.
  • the transdermal formulations described herein can maintain a saturated or supersaturated state to promote diffusion into the skin.
  • Size stabilized drug complex formulations suitable for intramuscular, subcutaneous, or intravenous injection may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propylene glycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • Drug formulations suitable for subcutaneous injection may also contain additives such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, benzoic acid, benzyl alcohol, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like.
  • Prolonged drug absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
  • Drug suspension formulations designed for extended release via subcutaneous or intramuscular injection can avoid first pass metabolism and lower dosages of drug will be necessary to maintain plasma levels in therapeutic range.
  • the particle size of the drug particles and the range of the particle sizes of the drug particles can be used to control the release of the drug by controlling the rate of dissolution in fat or muscle.
  • Some of the drug formulations described herein can be sterile filtered. This property obviates the need for heat sterilization, which can harm or degrade drug, as well as result effective particle size growth.
  • Sterile filtration can be difficult because of the required small particle size of the composition.
  • this method is suitable and commonly used for dispersions comprising nanoparticles.
  • Filtration is an effective method for sterilizing homogeneous solutions when the membrane filter pore size is less than or equal to about 0.2 microns (200 nm) because a 0.2 micron filter is sufficient to remove essentially all bacteria.
  • Sterile filtration is normally not used to sterilize conventional suspensions of micron-sized drug because the drug particles are too large to pass through the membrane pores.
  • a sterile drug formulation is particularly useful in treating immunocompromised patients, infants or juvenile patients, patients with head trauma and the elderly.
  • compositions and methods described herein may also be used in conjunction with other well known therapeutic reagents that are selected for their particular usefulness against the condition that is being treated.
  • the compositions described herein and, in embodiments where combinational therapy is employed, other agents do not have to be administered in the same pharmaceutical composition, and may, because of different physical and chemical characteristics, have to be administered by different routes.
  • the determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition is well within the knowledge of the skilled clinician.
  • the initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.
  • the particular choice of compounds used will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol.
  • the compounds may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the proliferative disease, the condition of the patient, and the actual choice of compounds used.
  • the determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is well within the knowledge of the skilled physician after evaluation of the disease being treated and the condition of the patient.
  • the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought can be modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, the dosage regimen actually employed can vary widely and therefore can deviate from the dosage regimens set forth herein.
  • the pharmaceutical agents which make up the combination therapy disclosed herein may be a combined dosage form or in separate dosage forms intended for substantially simultaneous administration.
  • the pharmaceutical agents that make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step administration.
  • the two-step administration regimen may call for sequential administration of the active agents or spaced-apart administration of the separate active agents.
  • the time period between the multiple administration steps may range from, a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent. Circadian variation of the target molecule concentration may also determine the optimal dose interval.
  • the drug formulation is administered with at least one other agent, e.g., an anti-convulsant agent, an anti-anxiety agent or an anti-depression agent.
  • at least one other agent e.g., an anti-convulsant agent, an anti-anxiety agent or an anti-depression agent.
  • about 40% of the drug is released from the dosage form within about 3 hours and about 95% of the drug is released from the dosage form within about 10 hours after administration.
  • about 30% of the drug is released from the dosage form within about 3 hours and about 90% of the drug is released from the dosage form within about 10 hours after administration.
  • about 80% of the drug is released from the dosage form within about 2 hours and about 90% of the drug is released from the dosage form within about 10 hours after administration.
  • Conventional formulations of drug display large fed/fasted effects in a manner that is not limited to dose dependency.
  • the drug formulations described herein are less effected by the fed or fasted state of the subject being administered the formulation.
  • the systemic exposure of the drug formulations described herein is less sensitive to the type of meal ingested than conventional drug formulations. This means that there is a reduced difference in the AUC (0- ⁇ ) values of drug when the drug formulations are administered in the fed versus the fasted state at therapeutically effective doses.
  • described herein are drug formulations that can substantially reduce the effect of food on the pharmacokinetics of drug.
  • the drug formulation is an aqueous dispersion that when administered to a child under 12 yeas old or adult not capable of swallowing a solid formulation, provides a ratio of the AUC (0- ⁇ ) or AUC (0- ⁇ ) values of drug, when administered in the fed versus the fasted state, of less than about 4.
  • the drug formulation is a solid oral dosage form that when administered to a human over twelve years old provides a the ratio of the AUC (0- ⁇ ) values of drug, when administered in the fed versus the fasted state, of less than about 3.
  • the drug formulation is a solid oral dosage form that when administered to a human over twelve years old provides a ratio of the AUC (0- ⁇ ) values of drug, when administered in the fed versus the fasted state, of less than about 2.
  • the drug formulation is a solid oral dosage form that when administered to a human over twelve years old provides a ratio of the AUC (0- ⁇ ) values of drug, when administered in the fed versus the fasted state, of less than about 1.5.
  • the drug formulation is a solid oral dosage form that when administered to a human over twelve years old provides a ratio of the AUC (0- ⁇ ) values of drug, when administered in the fed versus the fasted state, ranging from about 3 to about 1.5.
  • the drug formulation is a solid oral dosage form that when administered to a human over twelve years old provides a ratio of the AUC (0- ⁇ ) values of drug, when administered in the fed versus the fasted state, of about 2.
  • the drug formulations described herein are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, and other factors known to medical practitioners.
  • the dosage forms described herein preferably deliver drug formulations that maintain a therapeutically effective amount of drug at steady state while reducing the side effects associated with an elevated C max blood plasma level of drug.
  • the amount of drug administered to a subject via a solid dosage form is the amount known in the art to achieve a therapeutically effective concentration of drug in the bloodstream of a human or animal in need thereof.
  • the amount of drug may range from about 0.01 micrograms to about 6 g. In other embodiments, the amount of drug may range from about 0.1 mg to about 1000 mg. In other embodiments, the amount of drug may range from about 1 mg to about 500 mg, from about 50 mg to about 800 mg or from about 300 mg to about 700 mg.
  • a drug formulation is administered in a solid dosage form at a concentration of about 250 mg to about 650 mg. In another embodiment, the drug formulation is administered in a solid dosage form at concentration of about 300-400 mg.
  • the solid oral dosage form can be administered twice a day (b.i.d).
  • the solid oral dosage form is a controlled release dosage form administered b.i.d. providing a pulsatile release of drug such that the C max of blood plasma drug is reduced to avoid adverse effects while simultaneously reducing fed/fasted effects and maintaining total exposure (AUC (0- ⁇ ) ).
  • a therapeutically effective concentration of an oral aqueous suspension or dispersion comprising a drug formulation described herein, administered according to the methods described herein, is typically in the range of about 20 mg/ml to about 150 mg/ml final concentration.
  • a drug formulation is administered as an aqueous oral suspension at a concentration of about 25 mg/ml to about 100 mg/ml final concentration.
  • a drug formulation is administered as an aqueous oral suspension at a concentration of about 50 mg/ml final concentration.
  • the aqueous oral suspensions comprising a drug formulation described herein can be administered both as a single dose per day or given multiple times within a 24 hour period.
  • the aqueous oral suspension can be administered three times a day (t.i.d).
  • the aqueous oral suspension can be administered twice a day (b.i.d.).
  • Contemplated compositions of the present invention provide a therapeutically effective amount of drug over an interval of about 30 minutes to about 8 hours after administration, enabling, for example, once-a-day, twice-a-day, three times a day, and etc. administration if desired.
  • greater than about 95%; or greater than about 90%; or greater than about 80%; or greater than about 70% of the drug dosed by weight is absorbed into the bloodstream within 8 hours after administration.
  • the pharmaceutical formulations provide a release profile for an immediate release dosage form of the drug, whereby using methods described in Example 29, whereby about 80% (or about 70% or about 90%) of the drug is released from the dosage form within about 1 hours in SGF and for a delayed release drug dosage form about 60% of the (or preferably 70% or 80%) is released from the composition within about 3 hours in SIF.
  • Plasma concentrations of drug referenced herein are intended to mean total drug concentrations including both free and bound drug. Any formulation giving the desired pharmacokinetic profile is suitable for administration according to the present methods. Exemplary types of formulations giving such profiles are liquid dispersions and solid dose forms of the drug formulation described herein. Aqueous dispersions of drug are size stable at temperatures from 4° C. to 40° C. for at least 4 months.
  • Certain drug compositions and formulations described herein display enhanced pharmacokinetic (PK) and pharmacodynamic (PD) profiles and/or minimized side effects as compared to conventional drug formulations known in the art.
  • PK pharmacokinetic
  • PD pharmacodynamic
  • Certain formulations described herein reduce the risk of drug side effects (e.g., ataxia, sedation and somnolence) relative to conventional drug formulations. In certain embodiments improved performance compared to conventional drug formulations can be seen on acute doses. In other embodiments, maximal benefit of the drug formulations described herein can be seen at steady state.
  • drug side effects e.g., ataxia, sedation and somnolence
  • the particle size data for examples in which a ganaxolone or phenyloin particle size is reported, were obtained using a Horiba LA-910 Laser Light Scattering Particle Size analyzer (Horiba Instruments, Irvine, Calif.) and reported as volume weighted median (D50).
  • 200 mg of a ganaxolone suspension formulation containing 5 wt % of ganaxolone and appropriate levels of HPMC, PVA, SLS, and complexing agents was dispersed into 20 mL of SGF or SIF in a vial for measurement.
  • the vial is immersed in an oil bath kept at 36 to 38° C. for 3 h.
  • the sample is assessed visually for signs of flocculation and particle size is measured on a Horiba LA-910 to obtain D50 values.
  • compositions/formulations are expressed weight percent (% wt) of the total composition for liquid suspensions and as weight percent (% wt) to the drug (API) for solid compositions unless specified otherwise.
  • Monobasic potassium phosphate (6.8 g) and sodium hydroxide (0.616 g) are added into 250 ml of distilled water in a 1000 ml volumetric flask and swirled until dissolved. 700 ml distilled water is added and the pH checked. The pH is adjusted to pH 6.8+/ ⁇ 0.1 by adding either 0.2N sodium hydroxide or 0.2N hydrochloric acid and the volume is brought to 1000 ml.
  • Sodium chloride (2 g), 750 ml distilled water, and 7.0 ml of concentrated hydrochloric acid are added into a 1000 ml volumetric flask. The flask is swirled to mix and the volume brought to 1000 ml with distilled water. The pH should be approx. 1.2.
  • Particle size measurement using Horiba laser scattering particle size distribution analyzer is generally well known for those skilled in the art. It is important that the parameters be kept constant when measuring different samples if they are used for comparison purposes.
  • instrument settings and sample preparation method are described below:
  • the sonication power is set to low and the sonication time is 1 minute.
  • the solid or liquid nanoparticulate composition is placed in a 25 ml HDPE vial with HDPE cap and is diluted with 15-20 ml of simulated gastric or intestinal fluid to achieve a final API concentration of approx 0.5 mg/ml.
  • the vial is agitated manually for until completely dispersed (generally 15-30 seconds).
  • the vial is then placed in a heated oil bath at 36-38° C. unstirred unless specified otherwise until the desired test time.
  • the vial is removed from the bath and inspected visually for signs of flocculation. After shaking the contents of the vial for 15-30 seconds manually, the particle size is determined (D50) using a Horiba-LA-910 particle analyzer as described in Example 2.
  • D50 values e.g.
  • Initial D50 values before addition to the dispersion media is used as the initial for liquid compositions.
  • Initial D50 value for a solid composition is the D50 of the liquid composition prior to removal of liquid (e.g. a spray suspension of API prior to spray drying, spray granulation or spray layering).
  • the purpose of this example is to show that the complexing agent can be present during milling to obtain complexed ganaxolone nanoparticles.
  • Ganaxolone was wet milled in a 600 ml chamber using a DYNO-Mill KDL equipped with four 64 mm polyurethane agitator discs. The mill was operated at 3000 RPM or a tip speed of 10 m/sec. The mill was loaded with 88 vol % of 0.4 mm yttrium stabilized zirconium oxide beads.
  • the milling slurry (1200 g) contained 25 wt % ganaxolone (Marinus Pharmaceuticals Inc., Connecticut, USA), 5 wt % hydroxypropyl methylcellulose (Pharmacoat 603), 0.0333 wt % 30% simethicone emulsion, 0.3 wt % sodium lauryl sulfate and 0.2 wt % methylparaben.
  • This slurry was circulated through the mill via a peristaltic pump and returned to a cooled reservoir where it was re-circulated through the mill.
  • the mill was operated in this recirculation mode, keeping the slurry temperature at 35-40° C., for a total of 410 minutes (90 minutes residence time).
  • the product slurry was filtered through a 20 micron polypropylene cartridge filter.
  • the mill was flushed with 300 mL of the milling media (milling slurry minus ganaxolone).
  • the total weight of the milled slurry was 1185 g.
  • the concentration of ganaxolone was determined to be 20.5% by HPLC.
  • the particle size (D50) measured on a Horiba LA 910 was 0.164 ⁇ m unsonicated/0.153 ⁇ m after 1 minute sonication. After 7 days at room temperature, the particle size increased to 0.320 ⁇ m (unsonicated)/0.309 ⁇ m (after 1 minute sonication).
  • This formulation was then used in different studies as described in other examples.
  • the D50 did not change by more than 10% after this curing period for the duration of all other studies conducted with this formulation.
  • the purpose of this example is to demonstrate preparation of an aqueous ganaxolone dispersion without a complexing agent.
  • Ganaxolone milling slurry (1200 g) having the same composition as described in Example 4 without methylparaben was milled as in Example 4 for 75 minutes of residence time. After filtration through a 20 micron polypropylene cartridge filter and the mill was flushed with 300 mL of milling media, milled ganaxolone slurry (1271 g) was obtained. The concentration of ganaxolone was 21.25% by HPLC.
  • the particle size (D50) measured on a Horiba LA 910 was 0.103 ⁇ m (unsonicated)/0.102 ⁇ m (after 1 min sonication). D50 increased slightly after storage under refrigerated conditions. This formulation was used in other examples.
  • Powdered ganaxolone aqueous dispersion (1200 g) comprising a mixture of 30 wt % ganaxolone and 5 wt % HPMC, 0.2 wt % sodium lauryl sulfate and 100 ppm simethicone was milled in a DYNO Mill KDL as described for Example 5A. After 24.0 minutes of residence time, D50 was 163 nm.
  • Powdered ganaxolone aqueous dispersion (1200 g) comprising a mixture of 15 wt % ganaxolone and 3 wt % HPMC was milled in a DYNO Mill KDL as described for Example 5A. During milling, 2 portions of 0.05% w/w sodium lauryl sulfate were added to keep the milling slurry fluid. After 50.8 minutes of residence time, D50 was 116 nm.
  • Powdered ganaxolone aqueous dispersion (1500 g) comprising a mixture of 25 wt % ganaxolone, 5 wt % HPMC, 0.1 wt % sodium lauryl sulfate and 0.028 wt % simethicone 30% emulsion (all based on total weight of the dispersion in deionized water) was milled in a DYNO Mill KDL as described in Example 5. After 43 minutes of residence time, the D50 was 0.113 ⁇ m (unsonicated)/0.112 (after 1 minute sonication). The final ganaxolone concentration was 22.6% by HPLC. This formulation was used in Example 12.
  • Powdered ganaxolone in deionized water 180 g containing a 30 wt % ganaxolone (Marinus Pharmaceuticals Inc., Connecticut, USA), 3 wt % HPMC, and 0.1% wt sodium lauryl sulfate (all based on total weight of suspension) was milled in a DYNO Mill KDL (Willy A. Bachofen A. G., Maschinenfabrik, Basel, Switzerland) with a 300 mL glass batch chamber and utilizing 0.1 mm zirconium oxide beads (260 mL, 85% of the chamber volume). The milling was conducted for 120 min at a tip speed of 22.5 m/s.
  • the particle size (D50) after milling was 0.106 ⁇ m unsonicated.
  • the milled slurry (105 g) was diluted with 150 g of deionized water containing 7 wt % HPMC and 0.1 wt % SLS to give a 15 wt % gnx suspension.
  • a sample of this 15 wt % slurry was further diluted using 100 g of the slurry and 500 g of deionized water containing 5% HPMC and 0.1% SLS to give a final concentration of 2.5% ganaxolone in 5% HPMC, 0.1% SLS and water.
  • the particle size (D50) remained unchanged at room temperature (25° C.) after 4 months.
  • This ganaxolone nanoparticle suspension underwent flocculation upon incubation in SGF and SIF (shown below) using the method as described in Example 3.
  • This material was used in one oral dog pharmacokinetics study (Example 27, formulation 27A) to show pharmacokinetics of an uncomplexed ganaxolone suspension (D50 of 110 nm) which demonstrated good storage stability but aggregation in simulated gastric and intestinal fluids.
  • a milling slurry (164 g) containing by weight percent 20 wt % Phenyloin 5% wt HPMC, 0.1 wt % SLS, 0.03 wt % simethicone 30% emulsion and 74.87% deionized water was milled in the same manner as described in Example 7 for 35 minutes using 0.3 mm zirconium oxide balls (260 ml, 85% of chamber volume).
  • the particle size (D50) after milling was 0.150 ⁇ m unsonicated/0.127 ⁇ m after 1 min sonication.
  • the purpose of this example was to create complexed and uncomplexed phenyloin nanoparticulate suspensions to further exemplify the benefits of a complexing agent and an ionic dispersion modulator in forming more stable solid nanoparticulate compositions.
  • a milling slurry (1500 g) comprising a mixture of 20% wt phenyloin, 5 wt % HPMC (Pharmacoat 603), 0.1 wt % SLS and 0.028 wt % simethicone 30% emulsion was milled in a DYNO Mill KDL as described in Example 6 for a residence time of 26 minutes (total milling time of 145 minutes) to obtain 1419.6 g of milled suspension after filtration.
  • the D50 after milling was 0.141 ⁇ m unsonicated and 0.128 ⁇ m after 1 minute sonication.
  • the uncomplexed composition after 5 days at room temperature had a D50 of 0.169 ⁇ m unsonicated/0.144 ⁇ m after 1 minute sonication.
  • Example 9A To a portion of the milled phenyloin suspension (496.1 g) of Example 9A was added methyl anthranilate (2 g, 0.4%) as a complexing agent. The milled material with the complexing agent was allowed to cure for 5 days. The D50 for the complexed material after 5 days of curing time was 0.206 ⁇ m unsonicated/177 ⁇ m after 1 minute sonication.
  • the complexed and uncomplexed suspensions were used to create solid dose nanoparticulate phenyloin compositions described in Examples 18 and 24.
  • Example 8 A sample of the uncomplexed phenyloin nanoparticle suspension (17 g) prepared in Example 8 was added methyl anthranilate (71.4 mg, 0.42%) and the suspension was allowed to cure for 5 days at room temperature (25° C.).
  • the initial D50 value for the uncomplexed suspensions at the time of study were 0.162 ⁇ m unsonicated/0.123 ⁇ m after 1 minute sonication, whereas the initial D50 value for the complexed suspensions were 0.169 ⁇ m unsonicated/0.159 ⁇ m after 1 min sonication.
  • the uncomplexed and complexed suspensions were incubated side by side in SGF and SIF using the method described in Example 3.
  • the uncomplexed composition visibly flocculated and settled to the bottom of the vials after 1 hour whereas the complexed composition remained dispersed in both conditions for the 3 hour period.
  • the complexed composition in both SGF and SIF showed less particle size changes when examining both unsonicated and sonicated D50 values to initial values as well as demonstrating less loose aggregation (difference between D50 unsonicated and sonicated for 1 minute). The results are shown in Table 1.
  • This example demonstrates the enhanced stability of ganaxolone nanoparticulates complexed with methylparaben compared with uncomplexed ganaxolone nanoparticulates after incubation in SGF, SIF, heating to 100° C. and conducting several freeze/thaw cycles.
  • the complexed ganaxolone nanosuspension of Example 4 and uncomplexed ganaxolone nanosuspension of Example 5A after a curing time (for complexed preparations) of at least 7 days of storage at room temperature (20-25° C.) were incubated side by side in SGF and SIF using the method described in Example 3.
  • the D50 of the complexed formulation (Entry 1, Table 2) increased only slightly ( ⁇ 23% unsonicated and 9% after 1 minute sonication) from its initial values.
  • the D50 of the uncomplexed formulation (Entry 2, Table 2) increased at least 560% unsonicated and 153% after 1 minute sonication from its initial values.
  • Example 4 complexed
  • Example 5A uncomplexed
  • the milled compositions of Example 4 (complexed) and Example 5A (uncomplexed) were placed in 25 mL glass vials and sealed with a plastic cap.
  • the vials were heated in a 100° C. oil bath.
  • the D50 of the complexed formulation did not change after heating for 4 h (both unsonicated and 1 minute sonication) (Table 3).
  • D50 of the uncomplexed suspension continued to grow over the 4 hour period and doubled in size from initial values as shown in Table 3.
  • Example 6 Aliquots of the uncomplexed ganaxolone suspension from Example 6 were diluted with either diluent A or diluent B (diluent composition listed in tabular form below) in 1:2 ratio (Example 6 Suspension/Diluent) to provide two 75 mg/ml ganaxolone nanoparticle suspension; One with 0.1 wt % methylparaben and 0.02 wt % propylparaben as complexing agents (Diluent A) and the other with 0.09 wt % sodium benzoate as the complexing agent with pH adjusted to 4 by the sodium citrate buffer (Diluent B).
  • both formulations contained the following: 5 wt % HPMC, 1 wt % PVA, 0.1 wt % SLS.
  • the two formulations were allowed to cure for at least 5-7 days (paraben complexed formulation) and 20 days (sodium benzoate complexed formulation) to reach a stable particle size (D50) of 0.314 ⁇ m (unsonicated)/0.311 ⁇ m (after 1 minute sonication) for the paraben complexed formulation and 0.321 ⁇ m (unsonicated)/0.314 ⁇ m (after 1 minute sonication) for the sodium benzoate complexed formulation at a pH of 4.
  • D50 stable particle size
  • Diluent A Diluent B Ingredients % wt % wt Hypromellose (Pharmacoat 603) 5.00 5.00 Polyvinyl Alcohol 1.50 1.50 Sodium Lauryl Sulfate 0.10 0.10 Methylparaben 0.15 0.00 Propylparaben 0.03 0.00 sodium benzoate 0.00 0.14 citric acid anhydrous 0.00 0.18 Sodium citrate 0.00 0.014 Deionized water 93.22 93.07 Total: 100.00 100.00
  • Example 6 To the uncomplexed ganaxolone nanoparticulate suspension prepared as in Example 6 was added 0.1 wt % or 0.4 wt % methyl anthranilate. All suspensions (with and without methyl anthranilate as the complexing agent) were kept at room temperature to allow sufficient curing time to obtain complexed particles. The complexed suspensions were tested in SGF with the uncomplexed control as per Example 3. The results are shown in Table 6 below. The complexed formulation showed virtually no change from initial after incubation in SGF. In contrast, the uncomplexed control showed 3-fold increase in D50 unsonicated and 1.6-fold after 1 min sonication.
  • This example illustrates the dilution to 50 mg/mL ganaxolone nanoparticulate suspension formulations.
  • An uncomplexed ganaxolone nanoparticulate suspension of known ganaxolone concentration prepared as described in Example 5A is diluted with appropriate amount of diluent containing appropriate levels of excipients and other necessary components such as preservatives, complexing agents, flavoring, sweetener and antifoaming agent to achieve 50 mg/mL drug concentration.
  • An uncomplexed ganaxolone nanoparticulate suspension prepared as described in Example 5A is first diluted to an intermediate drug concentration (ca. 80 mg/mL) with appropriate amount of diluent containing appropriate levels of surface stabilizers excipients and all necessary components such as preservatives, complexing agents, antifoaming agents, flavoring and sweeteners.
  • an intermediate drug concentration ca. 80 mg/mL
  • diluent containing appropriate levels of surface stabilizers excipients and all necessary components such as preservatives, complexing agents, antifoaming agents, flavoring and sweeteners.
  • ganaxolone concentration 25 wt % is diluted by mixing one part of the milled suspension with two parts of the diluent to obtain an intermediate concentration of complexed ganaxolone nanoparticulate suspension of about 8 wt %.
  • the precise ganaxolone concentration is then determined by appropriate assay (e.g. HPLC).
  • the final dilution to 50 mg/mL ganaxolone is performed with an appropriate amount of diluent containing the correct levels of all excipients and other components.
  • This method was applied for ganaxolone nanoparticulate composition optimization.
  • the method described below can be generally applied to other water insoluble nanoparticulate compositions.
  • a general method for drying small samples of complexed and uncomplexed nanoparticulate compositions for solid dose optimization studies is as follows: One gram of complexed or uncomplexed nanoparticulate suspension was placed in a 25 ml glass scintillation vial then fitted onto a Buchi rotary evaporator R-124. The vial was rotated at 150-175 rpm and the water bath temperature set at 70°-90° C. Full vacuum was applied (2 to 4 mbar) over a 2 minute period and continued for 20 to 25 minutes until all visible signs of moisture were gone. This method yields vials containing solids which are used for incubation studies.
  • additional components were added to the nanoparticulate suspensions prior to drying as follows: The components were weighed into the vial first and 0.5 g of deionized water was added to dissolve or disperse the component(s). To this solution/suspension was added 1.0 g of the nanoparticulate suspension. The contents of the vial were swirled manually for 15-30 seconds followed by evaporation of water as described above.
  • D50 changes from the initial values with and without sonication are listed in Table 7.
  • Incubation in SGF and SIF were conducted using the method described in Example 3.
  • Complexed Ganaxolone nanoparticles showed 2-4 fold increase in unsonicated D50 values versus initial values. No change in sonicated D50 values was observed.
  • Uncomplexed ganaxolone nanoparticles showed a 27-fold increase in unsonicated D50 values versus initial values and still showed a 7-9-fold increase in sonicated D50 values versus initial values.
  • This example shows the effect of various amounts of an ionic dispersion modulator (e.g., sodium chloride) on stabilizing and reducing the amount of sucrose needed to reduce changes in D50 values (from initial) when dispersed in SGF and SIF.
  • an ionic dispersion modulator e.g., sodium chloride
  • Example 4 The complexed ganaxolone suspension (1 g) of Example 4 containing 20.5 wt % ganaxolone, 5.0 wt % HPMC, 0.3 wt % sodium lauryl sulfate, 0.2 wt % methylparaben 0.03 wt % simethicone (30% emulsion in water) was then added to the vial and the mixture was swirled to mix well. The contents in the vial were then dried per Example 15. This produced the composition listed in Table 8, Entry 7.
  • Table 9 shows the degree of aggregation of solid nanoparticulate complexed and uncomplexed ganaxolone compositions incubated in SGF and SIF.
  • the Entry number in Table 9 corresponds to the compositions given in Table 8.
  • Sodium chloride as an ionic dispersion modulator is very effective in preventing aggregation in SGF and SIF when used with a complexed nanoparticle formulation. Addition of an ionic dispersion modulator also allows the complexed solid nanoparticulate formulation to have a higher drug concentration by requiring less of a water soluble spacer (e.g. sucrose) to achieve minimal aggregation. This ability to create more stable and concentrated solid formulation is needed in preparing commercially viable compositions of drugs requiring a high dose.
  • a water soluble spacer e.g. sucrose
  • the complexed and uncomplexed phenyloin nanoparticulate suspensions of Example 9, were diluted (1:1 by weight, 5 g of each) with deionized water containing 6.25 wt % HPMC and 0.125 wt % SLS to obtain phenyloin nanoparticulate suspensions containing 10 wt % phenyloin, 5.625 wt % HPMC, 0.1125 wt % SLS for rotary evaporated drying.
  • the suspensions (0.5 g) containing appropriate amount of urea and/or sodium chloride were dried on a Buchi rotary evaporator using the method described in Example 15 to obtain dried phenyloin nanoparticulate powders.
  • the dried phenyloin nanoparticulate powders were incubated in SGF per Example 3. The results are shown in Table 10 below:
  • Examples 19-20 below demonstrate that certain complexed ganaxolone spray dried and spray layered compositions containing an ionic dispersion modulator have less aggregation in SGF and SIF (unsonicated) by a factor of greater than 10-fold. Additionally the examples below show less aggregation for certain complexed phenyloin nanoparticulate formulations than for uncomplexed.
  • Complexed ganaxolone nanoparticulate suspensions for spray layering and spray drying were prepared by milling a slurry (7000 g) containing 28.3 wt % ganaxolone, 3 wt % HPMC, 0.15 wt % SLS and 0.033 wt % simethicone (as a 30% emulsion) as described in Example 6. After milling, a complexing agent (methylparaben sodium, 12.60 g), SLS (11.52 g), citric acid anhydrous (13.91 g) and deionized water (3972.93 g) were added and stirred for 20 minutes.
  • a complexing agent methylparaben sodium, 12.60 g
  • SLS 11.52 g
  • citric acid anhydrous 13.91 g
  • deionized water 3972.93 g
  • the suspension was packaged in a HDPE container and kept at room temperature (25° C.) to cure. After a curing time of 2 weeks, additional components (e.g. sucrose, PEG, salt) were added and diluted with water to desired concentration for spray layering or spray drying. D50 values were 0.336 ⁇ m (unsonicated)/0.332 ⁇ m (after 1 min sonication).
  • additional components e.g. sucrose, PEG, salt
  • a Mini Glatt 8560 (Glatt Air Techniques, Ramsey, N.J.) was configured for fluid bed coating using a 0.5 mm Schlick nozzle with a Wurster column (3.5 cm ⁇ 9.5 cm) set 10 mm above the bottom of the chamber floor. The temperature of the bed was monitored with an internal probe. A peristaltic pump was used to introduce the spray solutions through the nozzle. The unit was first pre-heated for one hour at 56° C. The bed chamber was opened and 40 g of MCC beads (Celphere, CP-305) was introduced and a pressure of 0.36 bar was used to fluidize the bed. To minimize electrostatic charges, water was immediately sprayed (atomization pressure 0.26 bar). After 1-2 minutes of spraying, the feed line was switched to a stirred vessel containing the ganaxolone spray slurry.
  • Examples 20A and 20B demonstrate optimization of SGF dispersion testing results of a complexed ganaxolone spray layered composition (immediate release) for dog pharmacokinetics described below in Example 27.
  • Example 20C describes spray layering of an uncomplexed ganaxolone nanoparticulate composition.
  • a total of 80 g of slurry was sprayed onto 40 g of MCC beads (Celphere CP-305) over a period of 105 minutes to obtain 63 g of spray layered beads (57.5% loading).
  • the bed temperature was maintained at 43-47° C. and inlet air temperature was 54° C.
  • This spray formulation was prepared by adding PEG 4000 (3 wt % of total formulation) to the uncomplexed ganaxolone nanoparticulate suspension of Example 5A. A total of 93 g of slurry was sprayed onto 40 g of MCC beads (Celphere CP-305) over a period of 110 minutes to obtain 58 g of spray layered beads (45% loading). The bed temperature was maintained at 36-44° C. and inlet air temperature was 48° C.
  • Example 19 To the complexed ganaxolone nanoparticle suspension of Example 19 was added sucrose, and sodium chloride. The mixture was diluted with deionized water to obtain the following composition suitable for spray drying: 14.47 wt % Ganaxolone, 1.91 wt % HPMC, 0.96 wt % SLS, 2.15 wt % sucrose, 1.43 wt % NaCl, 0.04 wt % methylparaben and 0.006 wt % simethicone 30% emulsion. This slurry (478 g) was spray dried on a Buchi B-191 Mini Spray Drier to obtain 63.4 g of dry ganaxolone nanoparticle powder.
  • the process parameters were as the following: average spray rate: 5.3 g/min; outlet temperature: 64-66° C.; inlet temperature: 108-114° C.; airflow: 85% aspiration.
  • D50 values for the ganaxolone nanoparticles were 0.329 ⁇ m unsonicated/0.318 ⁇ m after 1 minute sonication upon re-dispersion in water.
  • D50 values in SGF were 0.317 ⁇ m unsonicated/0.306 ⁇ m 1 minute sonication.
  • D50 of the ganaxolone nanoparticles was 0.249 ⁇ m unsonicated/0.220 ⁇ m after 1 minute sonication upon re-dispersion in water.
  • D50 in SGF was 4.71 ⁇ m unsonicated/2.54 ⁇ m after 1 minute sonication.
  • Example 20B The complexed spray layered beads prepared as described in Example 20B is spray coated with an enteric coating formulation having the following composition:
  • the coating process is carried out as follows:
  • Eudragit enteric coating formulation is introduced to the mini Glatt via a peristaltic pump that is positioned in close proximity.
  • the coating formulation is well stirred during the coating.
  • the Eudragit slurry is added at 2.5 ml/min with an atomization pressure of 0.92 bar.
  • the bed temperature is maintained between 26 and 28° C.
  • the coated beads are allowed to cool for 5 minutes. After cooling, one hundred and thirty grams (130 g) of the Eudragit slurry is coated onto the beads. This amounts to 18.4% of coating solids. The weight of the coated beads isolated is 166 g.
  • a Mini Glatt (Glatt Air Techniques, Ramsey, N.J.) is configured for top spray with a fluid bed.
  • a 0.5 mm Schlick-type nozzle is inserted above the fluid bed.
  • 50 g of lactose monohydrate (Kerry) is added and fluidized with 0.27 bar pressure.
  • the apparatus is heated to 50° C. for approximately 30 min with bed fluidization pressure of 0.20-0.25 bar.
  • a ganaxolone slurry comprising 14 wt % ganaxolone, 3.5 wt % HPMC, 8 wt % sucrose, 0.08 wt % methylparaben, 0.07 wt % sodium benzoate, 0.14% citric acid, 0.9 wt % PEG 4000, 0.4 wt % sodium chloride is introduced by a peristaltic pump through the top-mounted nozzle.
  • the spray pressure ranges from 0.27 to 0.35 bar and the bed temperature is held at 40-45° C. while spraying at 1 to 2 ml/min.
  • the fine powered lactose becomes granular during the spraying.
  • a total of 36 g of 21% solids is sprayed, for a solids loading of 20%.
  • a Mini Glatt 8560 was configured for spray layering as described in Examples 20 A-C.
  • the unit was pre-heated at 60° C.
  • the bed chamber was opened and 75 g of MCC beads (Celphere, CP-305) was introduced and a pressure of 0.30-0.32 bar was used to fluidize the bed.
  • MCC beads Chemical Chemical Company, Inc.
  • atomization pressure 1 bar water was immediately sprayed (atomization pressure 1 bar).
  • the feed line was switched to a stirred vessel containing the phenyloin spray slurry.
  • the bed temperature was maintained at 36-41° C. during spraying.
  • the spray layered beads were incubated in SGF per Example 3 and the testing results are shown in Table 12.
  • This formulation was prepared by adding sucrose (5.4 g), sodium chloride (0.2 g), SLS (0.06 g) and deionized water to the uncomplexed phenyloin nanoparticulate suspension of Example 9 (100.0 g). It was sprayed at 2.5 ml/min. After completion of the spray layering, 96.8 g of spray layered beads were obtained. The loading was 29%.
  • This formulation was prepared and spray layered as described for the above formulation 24A except using the complexed phenyloin nanoparticulate of Example 9. After completion of spraying, 101.1 g of spray layered beads was obtained. The loading was 34.8%.
  • This formulation was prepared by adding a solution of urea (0.8 g), sodium chloride (0.5 g) in deionized water (2 g) to the uncomplexed phenyloin nanoparticulate suspension of Example 9 (50.0 g).
  • the resultant suspension was diluted with deionized water (50 g) containing 6.25 wt % HPMC, 0.125 wt % SLS and 0.08 wt % simethicone 30% emulsion.
  • This suspension was spray layered onto 75 g of the MCC beads (Celphere CP-305) as described for spray formulation 24A. After completion, phenyloin spray layered beads (87.2 g) was obtained. The loading of phenyloin on the beads was 16.2%.
  • This formulation was prepared and spray layered onto 75 g of MCC cores as described above for Formulation 24C except using the complexed phenytion nanoparticulate suspension of Example 9. After completion of the spray layering, 86.8 g of spray layered beads was obtained. The loading was 15.7%.
  • Purpose-bred Beagle dogs are obtained and housed in a USDA-approved facility in accordance with AAALAC guidelines. Expected dog weights are from 8 to 12.0 kg at the beginning of the evaluation, and are weighed prior to each period of the study. Animals are block randomized into groups of 3 per treatment. Each study will test a complexed drug composition. Fasted animals are fasted overnight with water prior to each study day. Designated fed dogs are fed a can (about 400 g) of Alpo “Chunky Beef for Dogs,” which has 55% of total calories from fat, approximately 45 minutes prior to dosing. If the liquid suspension is to be administered without dilution, the dose is given via oral gavage followed by a 7.5 to 10 ml/kg water flush.
  • the uncomplexed ganaxolone formulation 26A from Example 7 (final composition of 2.5 wt % ganaxolone, 5 wt % HPMC, 0.1 wt % SLS,) showed an approx. 3 and 2-fold increase in Cmax and AUC in the Fed and fasted state respectively.
  • the uncomplexed ganaxolone formulation 26B prepared from a concentrated slurry as in Example 6 (final composition of 5 wt % ganaxolone, 5 wt % HPMC, 0.2 wt % SLS and 1 wt % Polyvinyl alcohol (PVA) (all based on total weight of formulation).
  • Uncomplexed formulation 26B gave a decrease in Cmax levels and AUC by about 50% as compared to uncomplexed formulation 26A.
  • Administering the complexed ganaxolone formulation prepared from a concentrated slurry as in Example 6 (final composition of 5 wt % ganaxolone, 5 wt % HPMC, 0.1 wt % SLS, 1 wt % PVA, 0.1 wt % methylparaben, 0.02 wt % propyl paraben, 0.09 wt % sodium benzoate, 0.12 wt % citric acid and 0.0093 wt % sodium citrate) gave the most desirable pharmacokinetic performance by achieving optimal bioavailability and reduced variability and Cmax.
  • the solid ganaxolone formulations from Example 20A and 20B were placed into gelatin capsules to deliver a 5 mg/kg dose of ganaxolone to beagle dogs in the fasted state.
  • the fasted state was chosen as this condition tends to show more pharmacokinetic differences in nanoparticulate formulations of water insoluble drugs.
  • These formulations were chosen as they were part of the solid dose optimization process and exhibited different degrees of loose aggregation.
  • AUC bioavailability
  • Suspensions (1200 grams) in water containing 25 wt % ganaxolone, 5.0 wt % hydroxypropyl methylcellulose (Pharmacoat 603), 0.0333 wt % of 30% simethicone emulsion, and 0.2 wt % sodium lauryl sulfate, either with 0.05 wt % methylparaben (capsule Ex. 1) or with no methylparaben (capsule Ex. 2, 5.2 wt % of HPMC instead of 5 wt %) are prepared. Each wt % is based on the total weight of the suspension.
  • the ganaxolone particles are milled using conditions as described in Example 4.
  • complexing agent Capsule Form 1
  • ganaxolone nanoparticles having a particle size (D50) of about 120 nm as measured by Horiba LA 910 particle size analyzer are obtained immediately after milling.
  • This volume-weighted-median particle size grows to about 220 nm after 7 days of curing at ambient temperature, indicating that ganaxolone complex is formed.
  • the D50 does not change after this curing period for the duration of the study.
  • Capsule Form 2 without complexing agent
  • ganaxolone nanoparticles having the same particle size (D50) about 120 nm
  • Capsule Form 1 and 2 For each of Capsule Form 1 and 2, 100 grams of microcrystalline cellulose (MCC) beads (e.g. Celphere, 30/35 mesh) are added to a Glatt GPCG-3 fluidized bed with Wurster column insert (4 inch), inlet temperature of about 55° C. and air temp of about 40° C. (total air volume approx. 175 cubic cm/hr). About 2000 grams of each spray mixture are sprayed (bottom spray) through 1.2 mm nozzles at 11 ml/min and 1.5 bar of pressure until a layering of about 400 wt % is achieved as compared to initial beads weight.
  • the theoretical compositions of the spray layered complexed ganaxolone particles (Capsule Form 1) and ganaxolone particles (Capsule Form 2) are shown in Table 16.
  • Capsule Form 1 The spray layered ganaxolone complexed particles (Capsule Form 1) or ganaxolone particles (Capsule Form 2) are then filled into gelatin capsules with a fill weight of 518-520 mg coated beads to achieve a 300 mg dose.
  • Drug complexed particles e.g., prepared as set forth for the ganaxolone nanoparticles in the above examples
  • spray-layered onto inert beads 500 g
  • the rotating particle bed is sprayed with a coating solution containing 50 wt % Eudragit® L 30-D55, 2.5 wt % talc, 1.5 wt % dibutyl sebecate, 20 wt % ethanol, 23.5 wt % isopropyl alcohol, and 2.5 wt % water.
  • a coating level of about 8 wt % is achieved.
  • the ganaxolone content in each coated bead is about 53.4 wt % based on the total weight of the coated beads.
  • a suitable amount of the coated beads are hand-filled into gelatin capsule shells, respectively, to form modified release capsules. These particulates are substantially insoluble in the stomach due to the enteric coating but substantially soluble in the intestine.
  • Prosolv 90, and Dipotassium Phosphate Powder are added sequentially into a Bohle Bin Blender (BL07C, Warminster, Pa., USA) and blended for 10 ⁇ 0.1 minutes at 11 ⁇ 1 rpm. Additional Prosolv 90 and Sodium Starch Glycolate are added and blended for 10 ⁇ 0.1 minutes at 11 ⁇ 1 rpm. The material is then milled and then passed through a 0.5 mm screen (35 Mesh).
  • the drug blend is loaded into a tablet compressing machine, such as a Fette 1200 B Tool Tablet Press (TP06) or equivalent, and tablets are formed using oval upper and lower punches.
  • a tablet compressing machine such as a Fette 1200 B Tool Tablet Press (TP06) or equivalent
  • an enteric coat is applied to the tablet cores as follows: The enteric coating comprising Opadry® Enteric from Colorcon® and the over coat comprising Opadry® clear applied sequentially as aqueous coating suspensions using a coating pan.
  • the tablet cores are preheated to 46° C. (Exhaust air temperature).
  • the pan speed is adjusted to provide adequate tablet flow and the coating suspensions are sprayed onto the tablets at an atomizing air pressure of 18-30 psi; an inlet air temperature of 60-70° C. for over coat, and of 42-50° C. for the enteric coat; an exhaust air temperature of 40 to 50° C. for the over coat and 30 to 35° C.
  • the enteric coating should be applied so that a tablet core weight gain of 8-15 w %/tablet core weight is achieved.
  • Cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, a methacrylic acid copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, or a combination comprising one or more of the foregoing enteric polymers may be used in place of the Opadry Enteric coating.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US11/998,362 2006-11-28 2007-11-28 Nanoparticulate formulations and methods for the making and use therof Abandoned US20090004262A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/998,362 US20090004262A1 (en) 2006-11-28 2007-11-28 Nanoparticulate formulations and methods for the making and use therof
US12/777,920 US8455002B2 (en) 2006-11-28 2010-05-11 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
US13/887,673 US9017728B2 (en) 2006-11-28 2013-05-06 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86161606P 2006-11-28 2006-11-28
US11/998,362 US20090004262A1 (en) 2006-11-28 2007-11-28 Nanoparticulate formulations and methods for the making and use therof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/777,920 Continuation-In-Part US8455002B2 (en) 2006-11-28 2010-05-11 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
US12/777,920 Continuation US8455002B2 (en) 2006-11-28 2010-05-11 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof

Publications (1)

Publication Number Publication Date
US20090004262A1 true US20090004262A1 (en) 2009-01-01

Family

ID=39468517

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/998,362 Abandoned US20090004262A1 (en) 2006-11-28 2007-11-28 Nanoparticulate formulations and methods for the making and use therof
US12/777,920 Active 2028-04-03 US8455002B2 (en) 2006-11-28 2010-05-11 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
US13/887,673 Active US9017728B2 (en) 2006-11-28 2013-05-06 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/777,920 Active 2028-04-03 US8455002B2 (en) 2006-11-28 2010-05-11 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
US13/887,673 Active US9017728B2 (en) 2006-11-28 2013-05-06 Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof

Country Status (9)

Country Link
US (3) US20090004262A1 (fr)
EP (1) EP2101735A2 (fr)
JP (1) JP2010510988A (fr)
KR (1) KR20090091321A (fr)
AU (1) AU2007325628A1 (fr)
BR (1) BRPI0717721A2 (fr)
CA (1) CA2669815A1 (fr)
IL (1) IL199006A0 (fr)
WO (1) WO2008066899A2 (fr)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148252A1 (en) * 2005-11-28 2007-06-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
US20080047160A1 (en) * 2004-09-21 2008-02-28 Iglesias Vives Joan Method and machine for the sintering and/or drying of powder materials using infrared radiation
US20100010059A1 (en) * 2008-07-11 2010-01-14 National Health Research Institutes Anticancer oral formulation
WO2012109216A1 (fr) * 2011-02-11 2012-08-16 Zx Pharma, Llc Formulations de l-menthol multiparticulaires et procédés associés
US20130089575A1 (en) * 2011-10-05 2013-04-11 Douglas Pharmaceuticals Ltd. Pharmaceutical methods and topical compositions containing acitretin
US20130101644A1 (en) * 2011-10-21 2013-04-25 Sami Mahmoud Nazzal Tocotrienol compositions
US8455002B2 (en) 2006-11-28 2013-06-04 Marinus Pharmaceuticals Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
WO2012051426A3 (fr) * 2010-10-15 2013-10-17 Glaxo Group Limited Formulations de médicament sous forme d'agrégats de nanoparticules, leur fabrication et leur utilisation
US20140004194A1 (en) * 2012-05-21 2014-01-02 University Of Maryland Highly stable colloid from aqueous solutions of small organic molecules
WO2014122077A1 (fr) * 2013-02-08 2014-08-14 Basf Se Fabrication de matériaux composites inorganiques-organiques par séchage réactif par pulvérisation
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8895086B2 (en) 2013-04-23 2014-11-25 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US9138381B2 (en) 2013-02-08 2015-09-22 Basf Se Production of inorganic-organic composite materials by reactive spray-drying
WO2015153762A1 (fr) * 2014-04-01 2015-10-08 Arbor Pharmaceuticals, Llc Compositions de sotalol et utilisations associées
US20150320036A1 (en) * 2013-01-25 2015-11-12 Fundação Universidade Federal De São Carlos Process for obtaining biopolymeric nanoparticles containing azadirachta indica a. juss. (neem.) oil and extracts, biopolymeric nanoparticles, and powder microparticles
US9186351B2 (en) 2011-01-28 2015-11-17 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20160081965A1 (en) * 2014-06-02 2016-03-24 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
US9474292B1 (en) * 2010-09-16 2016-10-25 EvoSci Biotech LLC Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals
US20160328839A1 (en) * 2013-12-24 2016-11-10 Sony Corporation Image processing apparatus and image processing method
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
CN106998758A (zh) * 2014-12-22 2017-08-01 三得利食品饮料株式会社 含柠檬果汁饮料
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US10384372B2 (en) * 2013-04-09 2019-08-20 Fondazione Istituto Italiano Di Tecnologia Method for producing shaped polymeric microparticles
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
US10881663B2 (en) 2018-03-08 2021-01-05 Baudax Bio, Inc. Method of treating pain in elderly patients with mild renal impairment
US11253478B2 (en) * 2009-05-27 2022-02-22 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN114224834A (zh) * 2021-12-24 2022-03-25 沈阳伟嘉生物技术有限公司 一种具有较高生物利用度的阿苯达唑纳米混悬剂及其制备方法
CN114605922A (zh) * 2022-03-18 2022-06-10 北京通美晶体技术股份有限公司 一种快速抛光的化学抛光液及其制备方法
US20220233411A1 (en) * 2021-01-23 2022-07-28 Godrej Consumer Products Ltd. Reconstitutable sanitiser
WO2022232371A1 (fr) * 2021-04-29 2022-11-03 Protara Therapeutics, Inc. Compositions aqueuses stériles de sels de choline
US20230085008A1 (en) * 2021-09-06 2023-03-16 Slayback Pharma Llc Pharmaceutical compositions of mifepristone
WO2023060067A1 (fr) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Formulation de ganaxolone à dispersion solide amorphe
US11679117B2 (en) 2019-08-05 2023-06-20 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
US11701367B2 (en) 2019-12-06 2023-07-18 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
US11752095B2 (en) * 2018-09-07 2023-09-12 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US11806336B2 (en) 2016-08-11 2023-11-07 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN117462491A (zh) * 2023-11-26 2024-01-30 江西省保灵动物保健品有限公司 一种阿苯达唑混悬液及其制备方法
US11911500B2 (en) 2016-03-02 2024-02-27 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073774A1 (es) 2008-10-07 2010-12-01 Actelion Pharmaceuticals Ltd Compuestos antibioticos oxazolidinona triciclicos
WO2010092260A2 (fr) * 2009-02-13 2010-08-19 Ipsen Pharma S.A.S. Compositions pharmaceutiques du 6-oxo-6.7.8,9.10.11-hexahydrocyclohepta mchromen-3-yl sulfamate
JP2012528889A (ja) * 2009-06-05 2012-11-15 アーシエックス セラピューティックス， インコーポレイテッド フルチカゾンの眼科処方物および使用方法
MY174552A (en) * 2010-08-24 2020-04-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
BR112015001838B1 (pt) * 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
CN104968332B (zh) * 2012-11-12 2020-10-20 新泽西理工学院 药用芯-壳复合粉末及其制备方法
CN105050585A (zh) * 2013-03-04 2015-11-11 Vtv治疗有限责任公司 稳定的葡萄糖激酶活化剂组合物
US9235010B2 (en) 2013-06-28 2016-01-12 Commscope Technologies Llc Robust optical crimp connector
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
ES2925656T3 (es) * 2016-04-29 2022-10-19 Rousselot B V Excipiente basado en proteínas para principios farmacéuticos activos
AU2017342521A1 (en) * 2016-10-14 2019-04-18 Marinus Pharmaceuticals, Inc Method of administering a neurosteroid to effect electroencephalographic (EEG) burst suppression
KR20190137839A (ko) * 2017-04-18 2019-12-11 마리누스 파마슈티컬스 인코포레이티드 지속 방출 주사용 뉴로스테로이드 제제
WO2019036483A1 (fr) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Composition de nébulisation aqueuse
KR102036144B1 (ko) * 2017-10-12 2019-10-24 주식회사 엘지생활건강 미온수로 세정이 쉬운 화장료 조성물
GB2571937B (en) * 2018-03-12 2021-07-14 Syri Ltd Stable liquid suspension composition of fludrocortisone
EP4015086A4 (fr) 2019-08-16 2023-09-13 Hiroshima Metal & Machinery Co., Ltd. Procédé de production de nanoparticules organiques et nanoparticules organiques
DK3928772T3 (da) 2020-06-26 2024-08-19 Algiax Pharmaceuticals Gmbh Nanopartikulær sammensætning
KR102461071B1 (ko) * 2020-07-30 2022-11-01 가천대학교 산학협력단 신규 염증성 질환 치료제
CN117881411A (zh) * 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
WO2024091462A1 (fr) * 2022-10-24 2024-05-02 Lyondellbasell Advanced Polymers Inc. Particule de pontage et agent de régulation de perte de fluide

Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671750A (en) * 1950-09-19 1954-03-09 Merck & Co Inc Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US4540602A (en) * 1979-04-13 1985-09-10 Freund Industry Company, Limited Process for the preparation of activated pharmaceutical compositions
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5299131A (en) * 1987-11-17 1994-03-29 Robert Bosch Gmbh Method of correcting the rotating speed of vehicle wheels sensed by wheel sensors
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5312390A (en) * 1992-01-10 1994-05-17 Alza Corporation Osmotic device with delayed activation of drug delivery
US5318588A (en) * 1990-06-20 1994-06-07 Danforth Biomedical, Inc. Radially-expandable tubular elements for use in the construction of medical devices
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5445829A (en) * 1989-05-05 1995-08-29 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5470583A (en) * 1992-12-11 1995-11-28 Eastman Kodak Company Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation
US5472700A (en) * 1993-10-20 1995-12-05 Fmc Corporation Combinations of neem seed extract and bifenthrin for control of ectoparasites on animals
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5518187A (en) * 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5660932A (en) * 1993-05-17 1997-08-26 Raychem Limited Polymer composition and electrical wire insulation
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5741522A (en) * 1991-07-05 1998-04-21 University Of Rochester Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US5865331A (en) * 1994-02-10 1999-02-02 The Procter & Gamble Company Package with a lighweighted closure system
US5980508A (en) * 1994-06-22 1999-11-09 Controlled Release Technologies Pty Ltd Controlled release device and method
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6214379B1 (en) * 1998-04-02 2001-04-10 Kv Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US6228398B1 (en) * 1998-11-02 2001-05-08 Elan Corporation, Plc Multiparticulate modified release composition
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020012675A1 (en) * 1998-10-01 2002-01-31 Rajeev A. Jain Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6432381B2 (en) * 1994-12-30 2002-08-13 Elan Pharma International Limited Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract
US20020150616A1 (en) * 1997-06-05 2002-10-17 Roger Petrus Gerebern Vandecruys Pharmaceutical compositions comprising cyclodextrins
US6514518B2 (en) * 1993-10-18 2003-02-04 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6689378B1 (en) * 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US20040067251A1 (en) * 2000-11-03 2004-04-08 Dow Chemical Company Preparation of drug particles using evaporation precipitation into aqueous solutions
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20040214746A1 (en) * 2001-12-10 2004-10-28 Bosch H. William Pharmaceutical composition of a tachykinin receptor antagonist
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
US20060003005A1 (en) * 2004-07-02 2006-01-05 Bruce Cao Tablet for pulsed delivery
US20060216353A1 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US20070141161A1 (en) * 2005-11-28 2007-06-21 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393072A (en) 1964-04-23 1968-07-16 Fuji Photo Film Co Ltd Dioximes as antifoggants in silver halide emulsions
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
CA1282405C (fr) 1984-05-21 1991-04-02 Michael R. Violante Methode pour produire des particules dimensionnellement uniformes a partir des composes organiques insolubles dans l'eau
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
DE69510190T2 (de) 1994-03-30 2000-01-27 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5629277A (en) * 1995-10-04 1997-05-13 William L. Brown Paint removing composition
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998057648A1 (fr) 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose
WO1999017754A1 (fr) * 1997-10-08 1999-04-15 Sepracor Inc. Forme posologique pour administration d'aerosol
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6708060B1 (en) 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
US6423746B1 (en) 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
EP1239844B1 (fr) 1999-12-20 2005-06-08 Nicholas J. Kerkhof Procede de production de particules d'echelle nanometrique par sechage par atomisation en lit fluidise
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
JP4865990B2 (ja) * 2002-04-12 2012-02-01 エラン ファーマ インターナショナル，リミティド ナノ粒子メゲストロール製剤
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003231234A1 (en) * 2002-05-03 2003-11-17 Children's Hospital Medical Center Simulated vernix compositions for skin cleansing and other applications
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
KR20070112164A (ko) * 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
JP2010510988A (ja) * 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用

Patent Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671750A (en) * 1950-09-19 1954-03-09 Merck & Co Inc Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US4540602A (en) * 1979-04-13 1985-09-10 Freund Industry Company, Limited Process for the preparation of activated pharmaceutical compositions
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4997454A (en) * 1984-05-21 1991-03-05 The University Of Rochester Method for making uniformly-sized particles from insoluble compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5299131A (en) * 1987-11-17 1994-03-29 Robert Bosch Gmbh Method of correcting the rotating speed of vehicle wheels sensed by wheel sensors
US5445829A (en) * 1989-05-05 1995-08-29 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
US5318588A (en) * 1990-06-20 1994-06-07 Danforth Biomedical, Inc. Radially-expandable tubular elements for use in the construction of medical devices
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5741522A (en) * 1991-07-05 1998-04-21 University Of Rochester Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods
US5776496A (en) * 1991-07-05 1998-07-07 University Of Rochester Ultrasmall porous particles for enhancing ultrasound back scatter
US5312390A (en) * 1992-01-10 1994-05-17 Alza Corporation Osmotic device with delayed activation of drug delivery
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5508040A (en) * 1992-05-04 1996-04-16 Andrx Pharmaceuticals, Inc. Multiparticulate pulsatile drug delivery system
US5518187A (en) * 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5470583A (en) * 1992-12-11 1995-11-28 Eastman Kodak Company Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5660932A (en) * 1993-05-17 1997-08-26 Raychem Limited Polymer composition and electrical wire insulation
US6514518B2 (en) * 1993-10-18 2003-02-04 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US5472700A (en) * 1993-10-20 1995-12-05 Fmc Corporation Combinations of neem seed extract and bifenthrin for control of ectoparasites on animals
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US5865331A (en) * 1994-02-10 1999-02-02 The Procter & Gamble Company Package with a lighweighted closure system
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5980508A (en) * 1994-06-22 1999-11-09 Controlled Release Technologies Pty Ltd Controlled release device and method
US6432381B2 (en) * 1994-12-30 2002-08-13 Elan Pharma International Limited Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US20020150616A1 (en) * 1997-06-05 2002-10-17 Roger Petrus Gerebern Vandecruys Pharmaceutical compositions comprising cyclodextrins
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6214379B1 (en) * 1998-04-02 2001-04-10 Kv Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US20020012675A1 (en) * 1998-10-01 2002-01-31 Rajeev A. Jain Controlled-release nanoparticulate compositions
US6793936B2 (en) * 1998-11-02 2004-09-21 Elan Corporation, Plc Multiparticulate modified release composition
US6902742B2 (en) * 1998-11-02 2005-06-07 Elan Corporation, Plc Multiparticulate modified release composition
US6228398B1 (en) * 1998-11-02 2001-05-08 Elan Corporation, Plc Multiparticulate modified release composition
US6730325B2 (en) * 1998-11-02 2004-05-04 Elan Corporation, Plc Multiparticulate modified release composition
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6923988B2 (en) * 1999-11-23 2005-08-02 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6569463B2 (en) * 1999-11-23 2003-05-27 Lipocine, Inc. Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6689378B1 (en) * 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US20050118268A1 (en) * 2000-02-11 2005-06-02 Percel Phillip J. Timed pulsatile drug delivery systems
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6592903B2 (en) * 2000-09-21 2003-07-15 Elan Pharma International Ltd. Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20040067251A1 (en) * 2000-11-03 2004-04-08 Dow Chemical Company Preparation of drug particles using evaporation precipitation into aqueous solutions
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US20040214746A1 (en) * 2001-12-10 2004-10-28 Bosch H. William Pharmaceutical composition of a tachykinin receptor antagonist
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20060003005A1 (en) * 2004-07-02 2006-01-05 Bruce Cao Tablet for pulsed delivery
US20060216353A1 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US20070141161A1 (en) * 2005-11-28 2007-06-21 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US20070148252A1 (en) * 2005-11-28 2007-06-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8015725B2 (en) * 2004-09-21 2011-09-13 Dos-I Solutions, S.L. Method and machine for the sintering and/or drying of powder materials using infrared radiation
US20080047160A1 (en) * 2004-09-21 2008-02-28 Iglesias Vives Joan Method and machine for the sintering and/or drying of powder materials using infrared radiation
US8367651B2 (en) 2005-11-28 2013-02-05 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
US11071740B2 (en) 2005-11-28 2021-07-27 Marinus Pharmaceuticals, Inc. Method of treatment using nanoparticulate ganaxolone formulations
US7858609B2 (en) 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US9056116B2 (en) 2005-11-28 2015-06-16 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US20070148252A1 (en) * 2005-11-28 2007-06-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
US8455002B2 (en) 2006-11-28 2013-06-04 Marinus Pharmaceuticals Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
US9017728B2 (en) 2006-11-28 2015-04-28 Marinus Pharmaceuticals Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
US20100010059A1 (en) * 2008-07-11 2010-01-14 National Health Research Institutes Anticancer oral formulation
US11717481B2 (en) 2009-05-27 2023-08-08 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US11253478B2 (en) * 2009-05-27 2022-02-22 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US9474292B1 (en) * 2010-09-16 2016-10-25 EvoSci Biotech LLC Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals
WO2012051426A3 (fr) * 2010-10-15 2013-10-17 Glaxo Group Limited Formulations de médicament sous forme d'agrégats de nanoparticules, leur fabrication et leur utilisation
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US9241926B2 (en) 2011-01-28 2016-01-26 Zx Pharma, Llc Melatonin treatment methods
US9186351B2 (en) 2011-01-28 2015-11-17 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US10226447B2 (en) 2011-01-28 2019-03-12 Physician's Seal, LLC Controlled-release melatonin compositions and related methods
US10143654B2 (en) 2011-01-28 2018-12-04 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US11389428B2 (en) 2011-01-28 2022-07-19 Société des Produits Nestlé S.A. Controlled-release melatonin compositions and related methods
US9549900B2 (en) 2011-01-28 2017-01-24 Physician's Seal, LLC Controlled-release melatonin compositions and related methods
US9220686B2 (en) 2011-02-11 2015-12-29 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US9393279B2 (en) 2011-02-11 2016-07-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US9132095B2 (en) 2011-02-11 2015-09-15 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
WO2012109216A1 (fr) * 2011-02-11 2012-08-16 Zx Pharma, Llc Formulations de l-menthol multiparticulaires et procédés associés
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US11779547B2 (en) 2011-02-11 2023-10-10 Société des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
US11207276B2 (en) 2011-02-11 2021-12-28 Société des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
US9668982B2 (en) 2011-02-11 2017-06-06 Zx Pharma, Llc Preventing whisker growth from an L-menthol composition
AU2012214553B2 (en) * 2011-02-11 2015-07-09 Sociétés des Produits Nestlé S.A. Multiparticulate L-menthol formulations and related methods
US9707260B2 (en) 2011-02-11 2017-07-18 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8568776B2 (en) 2011-02-11 2013-10-29 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
CN103442727A (zh) * 2011-02-11 2013-12-11 Zx制药有限责任公司 多微粒l-薄荷醇制剂及相关方法
WO2013050874A1 (fr) * 2011-10-05 2013-04-11 Douglas Pharmaceuticals Ltd. Procédés pharmaceutiques et compositions topiques contenant de l'acitrétine
US20130089575A1 (en) * 2011-10-05 2013-04-11 Douglas Pharmaceuticals Ltd. Pharmaceutical methods and topical compositions containing acitretin
CN103945836A (zh) * 2011-10-05 2014-07-23 道格拉斯制药有限公司 包含阿曲汀的药物方法和局部用组合物
US20130101644A1 (en) * 2011-10-21 2013-04-25 Sami Mahmoud Nazzal Tocotrienol compositions
US10874635B2 (en) * 2011-10-21 2020-12-29 First Tech International Limited Tocotrienol compositions
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US20140004194A1 (en) * 2012-05-21 2014-01-02 University Of Maryland Highly stable colloid from aqueous solutions of small organic molecules
US11406595B2 (en) * 2012-05-21 2022-08-09 University Of Maryland, College Park Highly stable colloid from aqueous solutions of small organic molecules
US9668473B2 (en) * 2013-01-25 2017-06-06 Fundacao Universidade Federal De Sao Carlos Process for obtaining biopolymeric nanoparticles containing Azadirachta indica A. Juss. (neem.) oil and extracts, biopolymeric nanoparticles, and powder microparticles
US20150320036A1 (en) * 2013-01-25 2015-11-12 Fundação Universidade Federal De São Carlos Process for obtaining biopolymeric nanoparticles containing azadirachta indica a. juss. (neem.) oil and extracts, biopolymeric nanoparticles, and powder microparticles
CN105121559A (zh) * 2013-02-08 2015-12-02 巴斯夫欧洲公司 通过反应喷雾干燥的无机/有机复合材料的制备
US9138381B2 (en) 2013-02-08 2015-09-22 Basf Se Production of inorganic-organic composite materials by reactive spray-drying
WO2014122077A1 (fr) * 2013-02-08 2014-08-14 Basf Se Fabrication de matériaux composites inorganiques-organiques par séchage réactif par pulvérisation
US10384372B2 (en) * 2013-04-09 2019-08-20 Fondazione Istituto Italiano Di Tecnologia Method for producing shaped polymeric microparticles
US9192583B2 (en) 2013-04-23 2015-11-24 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
US11207273B2 (en) 2013-04-23 2021-12-28 Société des Produits Nestlé S.A. Method of making an L-menthol dosage form
US8895086B2 (en) 2013-04-23 2014-11-25 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
US9717696B2 (en) 2013-04-23 2017-08-01 ZxPharma, LLC Enteric coated multiparticulate composition with proteinaceous coating for improved storage stability
US10420730B2 (en) 2013-04-23 2019-09-24 Zx Pharma, Llc L-menthol dosage forms having a proteinaceous coating for enhanced storage stability
CN105142726A (zh) * 2013-04-23 2015-12-09 Zx制药有限责任公司 具有蛋白类底包衣的肠溶包衣多颗粒组合物
US9572782B2 (en) 2013-04-23 2017-02-21 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
US11826475B2 (en) 2013-04-23 2023-11-28 Société des Produits Nestlé S.A. Enteric coated multiparticulate compositions with a proteinaceous subcoat
US20160328839A1 (en) * 2013-12-24 2016-11-10 Sony Corporation Image processing apparatus and image processing method
US11850222B2 (en) 2014-04-01 2023-12-26 Arbor Pharmaceuticals, Llc Sotalol compositions and uses of the same
US9724297B2 (en) 2014-04-01 2017-08-08 Arbor Pharmaceuticals, Inc. Sotalol compositions and uses of the same
WO2015153762A1 (fr) * 2014-04-01 2015-10-08 Arbor Pharmaceuticals, Llc Compositions de sotalol et utilisations associées
US20160081965A1 (en) * 2014-06-02 2016-03-24 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
CN106998758A (zh) * 2014-12-22 2017-08-01 三得利食品饮料株式会社 含柠檬果汁饮料
US20170332671A1 (en) * 2014-12-22 2017-11-23 Suntory Beverage & Food Limited Beverage containing lemon juice
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
US11911500B2 (en) 2016-03-02 2024-02-27 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US11903930B2 (en) 2016-08-11 2024-02-20 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US11918563B1 (en) 2016-08-11 2024-03-05 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US12109201B2 (en) 2016-08-11 2024-10-08 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US11806336B2 (en) 2016-08-11 2023-11-07 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10639317B2 (en) 2016-09-09 2020-05-05 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US11304961B2 (en) 2017-12-18 2022-04-19 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11458145B2 (en) 2018-03-08 2022-10-04 Baudax Bio, Inc. Methods of administering intravenous meloxicam in a bolus dose
US10881663B2 (en) 2018-03-08 2021-01-05 Baudax Bio, Inc. Method of treating pain in elderly patients with mild renal impairment
US11752095B2 (en) * 2018-09-07 2023-09-12 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
US11679117B2 (en) 2019-08-05 2023-06-20 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
US11980625B2 (en) 2019-12-06 2024-05-14 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
US11701367B2 (en) 2019-12-06 2023-07-18 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
US20220233411A1 (en) * 2021-01-23 2022-07-28 Godrej Consumer Products Ltd. Reconstitutable sanitiser
WO2022232371A1 (fr) * 2021-04-29 2022-11-03 Protara Therapeutics, Inc. Compositions aqueuses stériles de sels de choline
US12083081B2 (en) 2021-04-29 2024-09-10 Protara Therapeutics, Inc. Sterile aqueous choline salt compositions
US20230085008A1 (en) * 2021-09-06 2023-03-16 Slayback Pharma Llc Pharmaceutical compositions of mifepristone
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone
WO2023060067A1 (fr) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Formulation de ganaxolone à dispersion solide amorphe
CN114224834A (zh) * 2021-12-24 2022-03-25 沈阳伟嘉生物技术有限公司 一种具有较高生物利用度的阿苯达唑纳米混悬剂及其制备方法
CN114605922A (zh) * 2022-03-18 2022-06-10 北京通美晶体技术股份有限公司 一种快速抛光的化学抛光液及其制备方法
CN117462491A (zh) * 2023-11-26 2024-01-30 江西省保灵动物保健品有限公司 一种阿苯达唑混悬液及其制备方法

Also Published As

Publication number Publication date
US9017728B2 (en) 2015-04-28
US20110008453A1 (en) 2011-01-13
EP2101735A2 (fr) 2009-09-23
JP2010510988A (ja) 2010-04-08
WO2008066899A2 (fr) 2008-06-05
WO2008066899A3 (fr) 2009-04-16
CA2669815A1 (fr) 2008-06-05
AU2007325628A1 (en) 2008-06-05
KR20090091321A (ko) 2009-08-27
US20130243830A1 (en) 2013-09-19
IL199006A0 (en) 2010-02-17
BRPI0717721A2 (pt) 2013-10-29
US8455002B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
US20090004262A1 (en) Nanoparticulate formulations and methods for the making and use therof
US11071740B2 (en) Method of treatment using nanoparticulate ganaxolone formulations
JP4776233B2 (ja) 摩損しにくくかつプルランを含む速崩壊性固形製剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: MARINUS PHARMACEUTICALS, CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHAW, KENNETH;ZHANG, MINGBAO;REEL/FRAME:022754/0182

Effective date: 20071126

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION